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palavras-chave 
 
Nanopartículas multifuncionais, core-shell/corona, sílica, Fe2O3, lantanídeos, 
agentes de contraste para IRM, agentes de contraste ópticos, relaxometria, 
RMND, fotoluminescência 
resumo 
 
Nos últimos anos, surgiu uma nova geração de nanopartículas (NPs) 
multifuncionais destinada a aplicações biomédicas, mais concretamente para 
uso em técnicas de diagnóstico, reconstrução celular e em diversas aplicações 
terapêuticas. Em relação às suas antecessoras, estas novas nanopartículas 
apresentam uma estrutura mais elaborada, integrando vários componentes 
ativos com diferentes funcionalidades que, em princípio, permitem realizar 
diversas tarefas em simultâneo (como o direcionamento ativo para 
determinadas células ou compartimentos celulares, imagem e libertação de 
fármacos). Estas nanopartículas são designadas, por isso, de nanopartículas 
multifuncionais. 
A presente dissertação relata o desenvolvimento de dois tipos de sondas 
bimodais e as propriedades físico-químicas destas, nomeadamente a sua 
textura, estrutura e relaxometria e dinâmica de 
1
H , com o objectivo de avaliar 
o seu potencial como agentes de contraste para Imagem por Ressonância 
Magnética Nuclear (IRM). São, também, apresentados estudos de 
fotoluminescência que permitem avaliar o potencial daquelas sondas para 
serem usadas como agentes de contraste óptico. Estes materiais combinam as 
propriedades dos complexos de lantanídeos trivalentes (Ln
3+
) e das NPs 
funcionando, assim, como agentes bimodais. 
Foram desenvolvidos os seguintes sistemas fotoluminescentes e com 
contraste T1 em IRM em que os iões Ln
3+
 magnetica (Gd
3+
) e opticamente 
(Eu
3+
, Tb
3+
) activos se encontram à superfície das NPs de sílica: 
SiO2@APS/DTPA:Gd:Ln e SiO2@APS/Pyd-DTPA:Gd:Ln (Ln = Eu ou Tb). No 
que respeita às propriedades de  relaxometria, na presença destas NPs 
observa-se um aumento moderado de r1 e considerável de r2, especialmente a 
campos magnéticos altos (devido aos efeitos de susceptibilidade para r2). Os 
iões Eu
3+
 apresentam um único ambiente local de baixa simetria, sendo que a 
emissão de fotoluminescência não é influenciada pela presença simultânea de 
Gd
3+
 e Eu
3+
. Verificou-se que a presença de Tb
3+
 (em lugar do ião Eu
3+
) 
aumenta ainda mais o valor r1, diminuindo r2. A internalização das NPs em 
células vivas é rápida e resulta num aumento de intensidade nas imagens 
ponderadas em T1. Foram estudadas as características ópticas de pastilhas de 
células (“cellular pellets”) contendo NPs, tendo-se confirmado o interesse das 
novas sondas propostas enquanto agentes para imagem bimodal. 
Esta dissertação relata, ainda, agentes com contraste em T2 para IRM, que 
consistem em um sistema núcleo-coroa (“core-shell”) em que é ajustável a 
espessura da coroa de sílica envolvendo o núcleo de óxido de ferro. A 
espessura do revestimento de sílica tem um efeito significativo sobre a 
relaxividade r2 e r2* , sendo aqui proposto um modelo para explicar este 
comportamento. A viabilidade celular e a expressão da desidrogenase 
mitocondrial das células da microglia foram também avaliadas. 
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abstract 
 
In the past few years a new generation of multifunctional nanoparticles 
(NPs) has been proposed for biomedical applications, whose structure is 
more complex than the structure of their predecessor monofunctional 
counterparts. The development of these novel NPs aims at enabling or 
improving the performance in imaging, diagnosis and therapeutic 
applications. The structure of such NPs comprises several components 
exhibiting various functionalities that enable the nanoparticles to perform 
multiple tasks simultaneously, such as active targeting of certain cells or 
compartmentalization, imaging and delivery of active drugs. 
This thesis presents two types of bimodal bio-imaging probes and 
describes their physical and chemical properties, namely their texture, 
structure, and 
1
H dynamics and relaxometry, in order to evaluate their 
potential as MRI contrast agents. The photoluminescence properties of 
these probes are studied, aiming at assessing their interest as optical 
contrast agents. These materials combine the properties of the trivalent 
lanthanide (Ln
3+
) complexes and nanoparticles, offering an excellent 
solution for bimodal imaging. 
The designed T1- type contrast agent are SiO2@APS/DTPA:Gd:Ln or 
SiO2@APS/PMN:Gd:Ln (Ln= Eu or Tb) systems, bearing the active 
magnetic center (Gd
3+
) and the optically-active ions (Eu
3+
 and Tb
3+
) on 
the surface of silica NPs. Concerning the relaxometry properties, 
moderate r1 increases and significant r2 increases are observed in the 
NPs presence, especially at high magnetic fields, due to susceptibility 
effects on r2. The Eu
3+
 ions reside in a single low-symmetry site, and the 
photoluminescence emission is not influenced by the simultaneous 
presence of Gd
3+
 and Eu
3+
. The presence of Tb
3+
, rather than Eu
3+
 ion, 
further increases r1 but decreases r2. The uptake of these NPs by living 
cells is fast and results in an intensity increase in the T1-weighted MRI 
images. The optical features of the NPs in cellular pellets are also studied 
and confirm the potential of these new nanoprobes as bimodal imaging 
agents. 
This thesis further reports on a T2 contrast agent consisting of core-shell 
NPs with a silica shell surrounding an iron oxide core. The thickness of 
this silica shell has a significant impact on the r2 and r2* relaxivities, and a 
tentative model is proposed to explain this finding. The cell viability and 
the mitochondrial dehydrogenase expression given by the microglial cells 
are also evaluated. 
 
 
  
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
  
Mots clés 
 
Nanoparticules multifonctionnelles, coeur-écorce/couronne, silice, Fe2O3,  
lanthanides, agents de contraste IRM, agents de contraste optiques, 
relaxométrie, RMRD, photoluminescence 
resumée 
 
Cette thèse décrit une stratégie de synthèse de nouvelles générations 
des nanoparticules (NPs) pour applications biomédicales, visant à une 
amélioration de leurs performances pour l’imagerie, le diagnostic 
thérapeutique. Ces NPs présentent plusieurs fonctionnalités leur 
permettant de réaliser des tâches multiples. Deux types de sondes 
bimodales ont été développés et étudiés afin d'évaluer leur potentiel 
comme agents (1) de contraste en IRM et (2) luminescents. Ces objets 
combinent les propriétés des complexes de lanthanide (Ln
3+
) et celles 
des NPs de silice ou de type coeur-écorce Fe2O3@SiO2 pour une 
imagerie bimodale. Ces NPs testées sur des cellules vivantes ont permis 
d’illustrer la preuve du concept aussi bien en IRM avec une augmentation 
d'intensité des images et un impact significatif sur les relaxivities r1, r2 et 
r2* qu’en photoluminescence. L’étude du système coeur-écorce a montré 
que l’influence du contrôle fin de l’écorce autour du noyau d'oxyde de fer 
a pu être modélisée. 
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Nomenclature, symbols and 
acronyms  
B0: The static, homogeneous magnetic field used to polarize spins, 
creating magnetization. This can refer to both the direction and the 
magnitude of the field. The direction of B0 defines the longitudinal axis.  
B1: Magnetic component of a radio-frequency field applied perpendicular 
to the longitudinal axis (B0) to perturb the magnetization in some manner 
(e.g., excitation pulses, inversion pulses, etc).  
BOLD, or blood oxygenation level dependent: The BOLD effect is the 
source of contrast in FMRI. The presence of deoxygenated blood leads to 
signal loss due to a reduction in T2*.  
BPA: Blood pool agents. 
Contrast Agent (CA): A substance that enhances contrast, i.e., shortens 
the relaxation time of water molecules, making them appear ‘brighter’ in 
T1 or T2 weighted MR images. 
Dephasing: In an ensemble of spins, each has a phase angle in the 
transverse plane. The ensemble can either be coherent (have the same 
angle) or incoherent (varying angle). Loss of coherence is referred to as 
"dephasing", which leads to net signal loss. BOLD and diffusion contrast 
are both based on dephasing.  
DNP: Dynamic nuclear polarization. 
Echo time (TE): The time between the excitation of magnetization and the 
acquisition of signal. For long acquisition windows, the TE is usually 
defined as the point at which the acquisition is closest to the center of k-
space. 
ED: Electric-dipole. 
Emission quantum efficiency (η): the fraction of emission processes in 
which emission of light is involved: 
NRADRAD
RAD
RAD
EXP
AA
A




 . 
 
Emission quantum yield (ϕ): the ratio of the number of photons emitted 
and the absorbed: 
photonsabsorvedofnumber
photonsemittedofnumber


 . 
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Nomenclature, symbols and 
acronyms (cont.) 
Extracellular fluid agents (ECF): are the contrast agents that have been in 
clinical use for the longest period of time in contrast-enhanced MR 
imaging of the liver. 
Frequency encode (FE) direction: The direction along which individual 
lines are acquired in k-space. Note that one may also refer to the 
frequency encode direction in the image (i.e., if the FE direction is along 
kx, one may also refer to the x direction in image space as the FE 
direction). See also phase encode (PE) direction.  
Gradient: Spatially varying magnetic field used to manipulate the 
resonance frequency across an object. MRI scanners incorporate three 
linearly-varying gradient fields across x, y and z. The strength of the 
gradient is controlled by the pulse sequence and can be rapidly 
manipulated (or "switched"). 
Gradient echo, or GRE/GE: Any MRI sequence that detects an un-
refocused signal (i.e., a non-spin-echo sequence). 
Inner Coordination Sphere. Used to describe any water molecules that 
are directly coordinated to the metal ion of a contrast agent. 
Inversion: Rotation of magnetization from alignment with B0 (along +z) to 
anti-alignment (along -z), caused by a RF pulse with 180º flip angle.  
Inversion time (IT): The time between inversion of magnetization and its 
excitation (often to acquire signal that has been "prepared" with an 
inversion pulse). 
k-space: The conceptual space in which MRI images are acquired. Data 
in k-space provides a map of the amount of structure in the image that 
can be attributed to each spatial frequency. The image and k-space are 
related by the mathematical operation called the Fourier transform (FT). 
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Nomenclature, symbols and 
acronyms (cont.) 
Larmor frequency: See resonance frequency. 
LLBs: Lanthanide luminescent bioprobes. 
LMCT: ligand to-metal charge-transfer. 
Longitudinal axis (z): The direction parallel to the main magnetic field (B0), 
which represents the direction along which magnetization is in 
equilibrium. After an RF pulse, the magnetization recovers to this 
equilibrium according to the rate T1. The component of magnetization 
along z cannot be detected.  
MD: Magnetic dipole. 
Magnetization: The net nuclear magnetic moment induced in an object or 
tissue when exposed to an external magnetic field. The magnetization is 
at equilibrium when it is aligned parallel to the external field (along the 
longitudinal axis) and at its maximum magnitude. MRI experiments 
manipulate the magnetization away from this equilibrium, into the 
transverse plane to detect its signal. 
MRI: Magnetic Resonance Imaging, a non-invasive technique using 
strong magnetic fields and radiofrequency pulses to create images of 
internal anatomy. 
NIR: Near-infrared. 
NPs: Nanoparticles. 
NMR: Nuclear Magnetic Resonance, an analytical technique commonly 
employed in chemistry. 
NMRD. Nuclear Magnetic Resonance Dispersion profile. 
OCT: Optical coherence tomography. 
Outer Coordination Sphere: Used to describe any water molecules that 
are not in the inner- or second-coordination spheres.  
 
  
iv 
  
Nomenclature, symbols and 
acronyms (cont.) 
PARACEST: Paramagnetic chemical exchange saturation transfer. 
PHIP: Parahydrogen-induced polarization. 
PET: Positron-emission tomography. 
Phase: In MRI, phase most commonly refers to the angle of the 
magnetization in the transverse plane. 
Phase encode (PE) direction: The direction perpendicular to individual 
lines in k-space. Note that one may also refer to the phase encode 
direction in the image (i.e., if the PE direction is along ky, one may also 
refer to the y direction in image space as the PE direction). Image 
artefacts are often most severe along the PE direction. See also 
frequency encode (FE) direction. 
Polarization: The tendency for spins to align in the presence of an 
external magnetic field, creating a net magnetic moment (or, 
magnetization). 
Precession: Gyration of a spinning body, which traces out a cone about 
the axis of precession. In MRI, the magnetization that is out of alignment 
with the longitudinal axis precesses about this axis. 
Relaxation Time: The time it takes nuclear spins to return to their 
equilibrium state after excitation by an RF pulse.  
Relaxivity: The ability of a contrast agent to shorten the relaxation time of 
nearby water protons. The higher the relaxivity, the shorter the relaxation 
time. 
Pulse sequence: The series of RF pulses, gradient field amplitudes and 
acquisition periods applied to acquire a spectrum or an image. Also used 
to refer to sets of sequences with common properties (e.g., the family of 
spin echo pulse sequences include structural and diffusion variants). 
QDs: Quantum dots. 
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Nomenclature, symbols and 
acronyms (cont.) 
R1: The expression of time constant T1 as a rate: R1=1/T1.  
R2: The expression of time constant T2 as a rate: R2=1/T2.  
Relaxation: The process by which the magnetization slowly returns to 
equilibrium following the rotation of the magnetization away from the 
longitudinal axis with an RF pulse. Relaxation (decay) in the transverse 
plane has the characteristic time T2; relaxation (recovery) along the 
longitudinal axis has characteristic time T1. 
Refocusing: The rotation of magnetization in the transverse plane by 
180º, usually with the intention of removing the effect of field 
inhomogeneities on signal.  
Repetition time (TR): The time between repeated excitations of a given 
component of the magnetization. For multi-slice sequences that 
sequentially excite different imaging slices, the TR is the time between 
repeated excitations of the same slice. For volume-excite (3D) sequences 
that repeated excite the entire imaging volume, the TR is the time 
between repeated excitations of the volume. 
Resonance frequency (ω0): The frequency at which the magnetization 
can be excited and detected. The frequency varies directly with magnetic 
field strength, and is normally in the radio frequency (RF) range. Also 
called Larmor frequency. 
RF pulse: A brief transmission of energy in the RF range. In MRI, RF 
pulses are used to manipulate the direction of the magnetization (e.g., to 
excite or invert). 
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Nomenclature, symbols and 
acronyms (cont.) 
Saturation: Removal or reduction of a component of the magnetization 
using excitation into the transverse plane. Most commonly used to in the 
context of "T1 saturation", where repeated excitations of magnetization 
result in incomplete T1 recovery, and therefore signal reduction. Can also 
refer to an excitation followed by a "spoiling" mechanism, which 
deliberately removes signal. 
Second Coordination Sphere. Used to describe any water molecules that 
are coordinated to only the contrast agent ligand, not to the metal ion 
inside a contrast agent. For example, a water molecule that is hydrogen 
bound to a polar group on the ligand. 
Shimming: The process of improving field homogeneity by compensating 
for imbalances in the main magnetic field of an MRI system. 
Accomplished by a combination of constant ("passive") shims and 
controllable ("active") shim coils. 
Spin: The property exhibited by atomic nuclei that contain an odd number 
of protons and/or neutrons. The property spin causes nuclei to behave as 
though they are spinning charges. These nuclei are often referred to 
colloquially as "spins". 
Spin echo, or SE: Any MRI pulse sequence characterized by the use of a 
refocusing pulse to reverse the effect of off-resonance precession. The 
signal is said to form a spin echo when the off-resonance precession of all 
spins is reversed, such that the spins re-align to form a signal peak (or 
"echo"). 
T1: The time constant defining the rate of recovery of magnetization along 
the longitudinal (z) axis following an RF pulse. Also called the spin-lattice 
relaxation time.  
T2: The time constant defining the irreversible loss of magnetization (and 
therefore signal) in the transverse (xy) plane following excitation. Also 
called the spin-spin relaxation time. In tissue, T2 is shorter than T1 (often 
by an order of magnitude). This signal loss cannot be recovered by a spin 
echo.  
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Nomenclature, symbols and 
acronyms (cont.) 
T2*: The time constant defining the loss of signal following excitation. Two 
components contribute to T2*. First, some signal loss occurs due to T2 
relaxation (i.e., loss of magnetization). Second, some signal loss is 
caused by variation in precession angles for different spins within a voxel. 
This does not represent loss of magnetization, and this component can be 
recovered wiwth a spin echo. 
T1M and T2M: The longitudinal and transverse proton relaxation 
enhancement experienced by the inner-sphere water molecules, 
respectively. 
TRL: Time-resolved luminescent. 
Transverse plane: The plane orthogonal to the longitudinal axis, denoted 
as the xy plane. It is defined by the direction of the main (B0) field, and the 
plane in which the magnetization is observable (i.e., where signal can be 
detected). 
Voxel: A resolution element in a 3D imaging experiment (coming from the 
term "volume element"); the 3D extension of a pixel (a "picture element"). 
C: the molar concentration of the paramagnetic complex. 
q: the number of water molecules in the inner-coordination sphere directly 
coordinated to the paramagnetic centre. 
ΔωM:  the chemical shift difference between the free and the bound water 
molecules. 
γ: the proton gyromagnetic ratio. 
τM: the mean residence lifetime of the coordinated water protons within 
the inner-sphere coordination sphere. 
τR: The rotational correlation time of a contrast agent. This is related to 
how fast the contrast is physically tumbling in solution. 
τRAD: Radiative lifetime. 
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 3 
 
1.1. CONTEXT OF THE THESIS 
 
Nanomedicine is defined as the medical application technology in the nanometer 
range (ranging from biomedical imaging to drug delivery and therapeutics.1 This is a new, 
fast expanding and growing medical field. The overall goals of traditional medicine and 
nanomedicine are the same: early and accurate diagnosis, effective treatments, free from 
side effects and non–invasive evaluation of the efficacy of the treatment. Nanotechnology 
used in nanomedicine brings not only improvements to the existing techniques but also 
provides completely new tools and capabilities.2,3 
 
Nanotechnology is the study, understanding and control of matter at dimensions in 
the range of 1 to ~100 nanometres, where unique phenomena enable novel applications.4 
It is a very broad interdisciplinary research field that involves various areas of science, 
such as chemistry, physics, engineering, biology and medicine, while eroding the 
traditional boundaries between them.5 
 
Indeed, there is a radical change in the physical and chemical properties of 
materials as their size is scaled down to small clusters of atoms. When the size decreases 
the surface-area-to-volume ratio increases, since there is a larger percentage of surface 
atoms compared with bulk materials.6 As nanodevices in the same range of dimension as 
antibodies, membrane receptors, nucleic acids and proteins, among other biomolecules 
the can possess biomimetic features.7 
 
Given all these outstanding features nanoparticles are powerful tools for imaging, 
diagnosis and therapy. Over the last few years, a new generation of nanoparticles has 
arisen with improved performances for the same type of applications and with a more 
complex structure compared to the simpler monofunctional nanoparticles. These complex 
nanoparticles comprise different components that can carry out various functions, which 
enable these nanoparticles to perform multiple tasks simultaneously (active targeting a 
given type of cells or compartment, imaging them and delivering an active compound). For 
example, a core particle may be linked to a specific targeting functional group that 
recognises the unique surface signatures of the target cells. The same particle can be 
modified with an imaging functional group to monitor the drug transport process, a 
molecular entity to evaluate the therapeutic efficacy of a drug, a specific cellular 
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penetration moiety and a therapeutic agent.7 Therefore, these complex nanoparticles are 
termed multifunctional nanoparticles.8 A schematic representation of these systems is 
given in Figure 1.1. 
 
 
 
 
 
Figure 1.1. Schematic representation of a multifunctional nanoparticle
7 
 
 
 
A large variety of therapeutic entities can be incorporated or attached on the surface 
of the multifunctional nanoparticles while other components can be used for targeting 
and/or imaging. Nanoparticles are prepared with organic polymers (organic nanoparticles) 
and/or inorganic elements (inorganic nanoparticles).7 Figure 1.2 depicts examples of 
nanomaterials and nanocarrier systems. There are three major categories in which the 
multifunctional nanoparticles may be classified: liposomes and micelles, polymeric 
carriers, and core-shell/corona structures. 
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Table 1.1. Strategies for constructing multifunctional nanoparticles.6 
 
Properties Benefits Functional group Refs 
Stability, 
biocompatibility  
 
 
Specific targeting 
 
 
 
 
 
Intracellular 
penetration  
 
 
 
 
 
 
 
Imaging  
 
 
Stimulus-sensitive 
drug release 
Maintain drug levels in the blood, 
thereby improving specificity  
 
 
Increase efficiency, reduce toxicity 
 
 
 
 
 
Modify nanoparticle pharmacokinetics 
and biodistribution, increasing drug 
efficacy 
 
 
 
 
 
 
Report real-time nanoparticle 
biodistribution  
 
Control bioavailability, reduces toxicity 
Polyethylene glycol 
Modified acrylic acid polymers 
Phospholipid micelles 
Polypeptides 
Antibodies  
Peptides 
Aptamers 
Carbohydrate 
Folic acid  
 
Peptides 
Trans-activating 
transcriptional activator (TAT) 
Ligands 
Transferrin 
Positively charged moieties 
Cationic lipids 
Cationic polymers 
 
Quantum dots 
Magnetic nanoparticles 
 
pH-labile 
Photosensitive 
Thermosensitive  
Magnetic sensitive 
Photothermal sensitive 
Redox sensitive 
[9] 
[10] 
[11]  
[12] 
[13] 
[14] 
[15] 
[16] 
[17] 
 
 
[18] 
 
 
[19] 
 
[20] 
[21] 
 
[22] 
[23] 
 
[18] 
[24] 
[25] 
[26] 
[27] 
[28] 
 
 
Liposomes and micelles 
 
One of the earliest forms of nanomedicine was the development of liposomes as 
drug delivery vesicles. As their sizes vary from 100 nm up to a few micrometers they can 
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carry within their phospholipid bilayered membrane different types of vesicles (e.g. small 
molecules to proteins, peptides, DNA, magnetic nanoparticles).29,30,31  
Liposomes are generally considered non-toxic, biodegradable and non-
immunogenic, although recently some adverse effects have been described..32 Although 
the underlying mechanism has not yet been fully elucidated, it appears that the choice of 
liposome characteristics plays an important role and that choosing the appropriate lipids 
and their size helps to overcome these unexpected effects.33,34 
PEGylation is the process of covalent attachment of polyethylene glycol polymer 
chains to another molecule, normally a drug or therapeutic protein. By employing 
PEGylation the circulation time is increased and by combining the liposomes with a 
therapeutic agent the multifunctionality of the vesicles is increased.35 
Micelles (lipid vesicles of 20 to 100 nm) present similar features as liposomes (long 
circulating behaviour, high biocompatibility and the possibility of increasing the 
functionality number). They also offer a better method of delivering hydrophobic drugs. In 
this system, the hydrophobic parts form the core to minimize their exposure to aqueous 
surroundings, whereas the hydrophilic blocks form the corona-like shell that stabilizes the 
core through direct contact with water.36 The hydrophobic core is capable of carrying 
pharmaceuticals (poorly water soluble drugs), with high loading capacity (5–25% weight), 
while its hydrophilic shell provides not only a steric protection for the micelle (with 
increased stability in blood) but also functional groups suitable for further micelle 
modification.37 
 
 
Polymeric carriers (polymeric or dendrimers) 
 
The polymeric carriers are formed by a hydrophobic core that is capable of carrying 
pharmaceuticals (poorly water soluble drugs) with high loading capacity (5–25% weight) 
and a hydrophilic shell that provides not only a steric protection for the micelle (with 
increased stability in blood) but also functional groups suitable for further micelle 
modification (repeated relative to previous phrase, reword)38,39, such as starch,40 
poly(ethylene glycol) –PEG,41,42 poly(lactic-coglycolic acid) -PLGA43,44). 
Dendrimers are a relatively novel class of synthetic polymers with highly ordered 
structure. They are highly branched (<15 nm) and have layered architectures consisting of 
a central core, an internal region and numerous terminal groups that determine dendrimer 
characteristics.7 They present a highly interbranched cavity density, therefore a high 
 7 
density of functional groups on the surface. Their functionalisation possibilities, symmetry 
perfection, diameters in the range of 10 to 100 nm and internal cavities provide many 
potential applications in biochemistry, gene therapy and nanomedicine. Nanoparticles 
coated with dendrimers can alter the charge, functionality, reactivity and enhance their 
both stability and dispersibility.45,46,47 
 
 
Core – shell/corona structures (Inorganic or magnetic nanoparticles, 
quantum dots or carbon nanotubes)  
 
The core – shell/corona architecture is another attractive alternative approach for 
developing multifunctional nanoparticles. These structures normally comprise optical, 
targeting and delivery functions. Nanoparticles visualisation is normally achieved through 
the core’s functionality. The shell/corona protects the core and acts as the scaffold for 
adding further functions, such as drug delivery (drugs are incorporated and released in a 
controlled manner, either via diffusion or active delivery via pH), temperature modulation, 
active targeting (through surface modification with specific ligands), or even a tool for an 
alternative way of visualisation through the incorporation of a different imaging agent. A 
large variety of combinations of materials that are assembled in core-shell/corona 
architecture can be found in the literature as the core quantum dots48,49,50, fluorophores51 
or magnetic nanoparticles52,53 are the most researched moieties. The most commonly 
used coating layers are either organic layers (polymethyl methacrylate) (PMMA),54 
polylactic acid (PLA),55,56 poly(lactic-co-glycolic acid) (PLGA), 26,43 polyvinyl alcohol 
(PVA)25,57) or inorganic materials as silica (amorphous,58 mesoporous59), apatite,60 or have 
a metallic layer of gold61 or silver.62 
 
 
Extensive in vivo application of nanoparticles will require a more exhaustive 
exploration of the physicochemical and physiological processes occurring in the biological 
environments. The smallest capillaries in the human body are 4-6 μm in diameter. When 
considering possible medical applications (both in-vivo or in-vitro) the nanoparticles have 
to possess some basic properties. Specifically they must have a size of less than 20 nm 
(especially for intraveneous (i.v.) administration), high surface area with a larger platform 
for surface functionalisation, high colloidal stability (with minimum agglomeration and 
aggregation) and the ability to overcome biological barriers.63 For the particular case of in-
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vivo applications the particles should adhere to more strict requirements: non-toxicity, 
non-immunogenicity, long term retention during blood circulation and the ability to reach, 
and pass through, the endothelial capillary membranes without causing an embolism of 
the bigger vessels.64,65  
The three major applications of nanoparticles in medicine are imaging (diagnosis), 
drug delivery (therapeutics) and cell reconstruction. In this thesis I report the design and 
synthesis of nanoparticles for bi-modal imaging with potential to be further developed in 
the future with the addition of cell-targeting agents and drug delivery molecules. 
 
 
 
1.2. SCOPE AND OBJECTIVES OF THIS THESIS 
 
Nanoparticles have to meet several specifications in order to be applied in-vivo and 
in-vitro. Important features these particles should have are a small overall size, high 
surface area for surface functionalisation, high colloidal stability and the ability to pass the 
biological barriers. 
To achieve the proposed objective two sets of contrast agents were designed, 
synthesized and characterized: 
 
 T1 contrast agent with an optical Ln
3+ probe 
 
The nanoparticles we will consider are hybrid inorganic-organic SiO2@APS 
core-corona. Lanthanide chelates are linked onto these particles, for their 
relaxometry (Gd3+) and luminescence (Eu3+ or Tb3+) properties. Subsequently, 
these nanoparticles are internalised in living cells in the form of cellular pellets 
in order to confirm their potential as new probes for bimodal imaging. 
  
 T2 contrast agent  
 
These are core-shell nanoparticles, Fe2O3@SiO2. The influence of the silica 
shell on the relaxometry and cytotoxicity properties was studied. 
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1.3. OUTLINE OF THIS THESIS 
 
This thesis is organised in six chapters, as follows. 
 
Chapter 1 provides an overview of different multifunctional nanoparticles for 
applications in medicine. 
Chapter 2 presents a general introduction of magnetic resonance imaging and MRI 
contrast agents, as well as the parameters governing the relaxivity of the latter, presenting 
a summary of the various classes of contrast agents, classified according to their 
applications. 
Chapter 3 gives a brief introduction to optical imaging and its main applications are 
presented. A short overview is provided of the photoluminescence phenomenon, in 
particular of trivalent lanthanides. The optical properties of tissues are succinctly 
described as well as the different techniques available for optical imaging. A summary of 
the various types of optical contrast agents is also presented. 
Chapter 4 describes the synthesis of T1 contrast agents, with an optical Ln
3+ probe 
attached. In order to optimise the nanoparticles emission, two types of chelating agents, 
with and without an aromatic ring, were used. The physical and chemical properties were 
studied by several different techniques. The uptake of these nanoparticles by living RAW 
cells was evaluated using cellular pellets. The optical and magnetic features of these 
probes in the cellular pellet were assessed in order to confirm their potential as bimodal 
imaging agents. 
Chapter 5 reports the synthesis both, the core of the magnetic iron oxide 
nanoparticles, with a well-defined size, and the silica shellI shall show that the silica-shell 
thickness determines the relaxometry properties, and I shall propose a tentative 
theoretical to explain this fact. The effect of these nanoparticles on the viability and the 
mitochondrial dehydrogenase expression of microglial cells were also evaluated. The 
magnetic properties of these nanoparticles and their T1 relaxivities as a function of the 
external magnetic field (Nuclear Magnetic Relaxation Dispersion (NMRD) plots) were also 
studied in detail and rationalized on the basis of current theory.  
Finally, chapter 6 presents the concluding remarks of this thesis and an outlook for 
the future. 
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2.1. MAGNETIC RESONANCE IMAGING 
 
Magnetic Resonance Imaging (MRI) is a non-invasive diagnostic tool providing high-
resolution ( m scale) anatomical images of soft tissue and allowing the quantitative 
assessment of disease pathogenesis by measuring up-regulated biomarkers. MRI is 
based on the principles of Nuclear Magnetic Resonance (NMR), a spectroscopic 
technique applied by scientists to obtain microscopic chemical and physical information 
about molecules. 
Felix Bloch and Edward Purcell independently discovered the phenomenon of 
magnetic resonance in 1946 and for this they were awarded the Nobel Prize in 1952. Until 
the 1970s the NMR technique was used only for chemical and physical analysis. The first 
step towards the discovery of the magnetic resonance was taken in 1971 by Raymond 
Damadian who showed that the nuclear magnetic relaxation times of healthy and 
pathogenic tissues are different.1 It was only in 1973, however, that imaging moved from 
the single dimension of NMR spectroscopy to the second dimension of spatial orientation 
with the discovery of NMR-zero field gradients by Paul Lauterbur. He published this new 
imaging technique in a short and concise paper in Nature entitled "Image formation by 
induced local interaction; examples employing magnetic resonance".2 
MRI is an extension of nuclear magnetic resonance spectroscopy used in chemistry. 
The nuclei of certain atoms have an inherent magnetic dipole moment resulting from their 
electrical charge and spin. If these nuclei are placed in a strong, static magnetic field, 0B , 
they precess around it at the Larmor frequency, I . The energy levels of the spins are 
determined by their orientation along the axis parallel to 0B  (either with or against 0B ). 
There are more spins aligned with the field (parallel - low energy state) than spins aligned 
against the field (anti-parallel- high energy state). Due to this slight excess of parallel 
spins, the net equilibrium magnetization (macroscopic magnetization) is parallel to 
0B (figure 2.1a). The difference in energy between the two spin states increases as the 
magnetic field strength increases. 
 
Besides the static 0B  field applied along z, we apply a time varying field 1B , 
perpendicularly to 0B  and oscillating at 0 , which perturbs the populations of the spin-up 
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and spin-down states and gives phase coherence to the spins. A 90º pulse ( 1B  along the x 
axis) brings the magnetisation vector to the xy plane (figure 2.2b). In this case, the 
magnetisation precesses about 0B  at 0  and 1B  at 1 . At this point, it is appropriate to 
introduce a new frame of reference for viewing the evolution of the magnetisation vector, 
the rotating frame (x',y',z) rotating about the z-axis at frequency 0 . In the rotating frame 
the magnetisation precesses about the x' axis with frequency 11 B   (figure 2.3c). 
 
 
Figure 2.1. a) Precession of the spins in a static the external magnetic field 
and equilibrium magnitisation b) Precession of the net magnitisation in the 
laboratory frame under the influence of the static 0B  field and the RF field 1B , 
c) Net magnitisation viewed in the rotating frame after a on-resonance 90º (x) 
pulse.3,4 
 
 
In MRI the unpaired nuclear spins (mainly from hydrogen atoms in water - 70% to 
90% of most tissues - and organic compounds) align themselves when exposed to a 
magnetic field. A temporary radiofrequency pulse at the Larmor frequency changes the 
alignment of the spins, and their return to thermal equilibrium (relaxation) is detected in a 
coil. Protons from different tissues react differently giving a picture of anatomical 
structures.5 
c)c)
B0
a)
b
B0
B1
,
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In order to create a MRI image of a patient it is necessary to create different voxels 
(volume picture elements) of its volume. This is accomplished by applying perpendicular 
magnetic gradients. MRI allows a complete and flexible image orientation; although 
normally in clinical use the reference employed for the magnetic gradient is the principal 
axis of the patient (patient’s images are obtained in the x and y axis while the z axis is the 
head to toe direction). These gradients are small perturbations superimposed on the main 
magnetic field 0B , with a typical imaging gradient producing a total field variation of less 
than 1%. Therefore, in the presence of a field gradient, each proton will resonate at a 
unique frequency that depends on its exact position within the gradient field. The spatial 
encoding is obtained by applying magnetic field gradients which encode the position within 
the phase of the signal. 
In the case of one dimension, a linear relationship of phase with respect to position 
can be obtained via collection of data in the presence of a magnetic field gradient. In the 
case of three dimensions (3D), a plane can be defined by "slice selection" where a RF 
pulse of defined bandwidth is applied in the presence of a magnetic field gradient (Figure 
2.2). This procedure is applied in order to reduce spatial encoding to two dimensions (2D). 
Figure 2.2 is an illustration of slice selection during the RF excitation phase using a 
longitudinal magnetic field gradient. The typical medical resolution is about 1 3mm , while 
research models can exceed 1
3m .6 
 
 
Figure 2.2. Illustration of slice selection during the RF excitation phase using 
a longitudinal magnetic field gradient5 
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Although the most common sequence is a spin-echo sequence, there are numerous 
pulse sequence types. The spin-echo sequence (Figure 2.3) consists on the application of 
a 90º pulse to the spin system. This 90º pulse rotates the magnetization to the x’y’ plane, 
where the transverse magnetization begins to diphase. Following the 90º pulse a 180º 
rephasing pulse at TE/2 is applied. This pulse rotates the magnetization by 180º about the 
x’ axis, forcing the magnetization to at least partially rephase and generating a signal 
called a spin echo. In terms of time this is an echo time (TE). 
This pulse sequence is repeated at each time interval TR (Repetition Time). With 
each repetition a k-space line acquisition (often refers to the temporary image space, 
usually a matrix, in which data from digitized MR signals are stored during data acquisiton) 
is filled due to a different phase encoding. Three types of gradients are applied: slice 
selection (GS), phase encoding (GP) and frequency encoding (GF). 
 
One of the advantages of using a spin-echo sequence is that it introduces 2T  (see 
2.2.1 for definition) dependence to the signal intensity, since some tissues and 
pathologies have similar 1T  values but different 2T  values. It is, thus, of interest to have an 
imaging sequence that can produce images with 2T  dependence (since the 180º 
rephasing pulse compensates for the constant field heterogeneities to obtain an echo that 
is weighted in 2T  and not in 
*
2T ). The pulse sequence timing can be adjusted to give 1T -
weighted proton or spin density and 2T -weighted images. This sequence also provides a 
high signal-to-noise ratio.  
 
A spin-echo sequence has two essential parameters: repetition time (TR) and echo 
time (TE), in which TR is defined as the time between repetitions of the sequence and TE 
is the time between the 90º pulse and the maximum amplitude in the echo, respectively. 
This sequence has a clear contrast mechanism for a 1T -weighted image, where a short 
TR (450 – 850 ms) and TE (10 – 30 ms) are used. In the case of a 2T -weighted image a 
long TR (>2000 ms) and TE (>60 ms) are used. In the case of 1H images a long TR with a 
short TE are used.  
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Figure 2.3. Spin-echo pulse sequence used in MRI.7 
 
 
 
The signal intensity (SI) is given by Eq. 2.1, where k is a proportionality constant 
dependent on flow, perfusion and diffusion, and ρ is the density of spins in the sample. 
 
  2/1/1 TTETTR eekSI    (2.1) 
 
Three types of spin echo sequences are commonly used: standard single echo, 
standard multi-echo, and echo-train spin echo. Standard single-echo sequences are 
generally used to produce 1T -weighted images when acquired with relatively short TR and 
TE (less than 700 ms and 30 ms, respectively). A multi-slice loop structure is used with a 
single pair of excitation and refocusing pulses applied per slice loop. The pixel intensity is 
proportional to the number of protons contained within the voxel weighted by the 1T  and 
2T  relaxation times for the tissues within the voxel. The echo-train spin echo sequence is 
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similar to the multi-echo sequences, except that each spin echo is acquired with a 
different phase encoding as well as its own TE. The echo-train length (or turbo factor) is 
the number of echoes acquired in each TR period. Here, k-space is filled segmentally with 
one echo from each echo-train filling each segment of k-space and, as such, is an efficient 
sequence. These sequences are typically used to create 2T -weighted images. 
Nevertheless, at times insufficient contrast is observed and the administration of 
Contrast Agents (CAs) or Contrast Media is necessary. MRI CAs are able to change the 
1H relaxation properties of the tissues, leading to MR images with improved contrast. In 
MRI the object or patient is exposed to a powerful magnetic field. The hydrogen protons of 
the water molecules in the object or body are excited by radio-frequency pulses. During 
the time they are “recovering” (or relaxing back) they transmit signals that are recorded 
and compiled into an image. The faster the atomic nuclei return from an excited to an 
unexcited state, the stronger the signal and thus also the contrast. Most approved MRI 
contrast agents are based on the rare earth element gadolinium, adding paramagnetic 
properties to the compound. This element causes the atomic nuclei to relax more quickly 
and thus to transmit stronger signals.  
 
 
 
2.2. MRI CONTRAST AGENTS  
 
One of the strengths of MRI is the significant amount of intrinsic contrast between 
tissues. This contrast is due to differences in the longitudinal ( 1T ) and/or transverse ( 2T ) 
proton relaxation times of the tissues under observation accentuated by the chosen TR 
and TE. Pathologic tissue may or may not exhibit significant differences in 1T  or 2T  
relatively to the surrounding normal tissue. For this reason, there may be little signal 
difference between normal and pathologic tissue in spite of the inherent high contrast in 
the images. An example of difference between a 1T  and 2T -weighted image is given in 
Figure 2.4a and b. 
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Figure 2.4. Brain MRI images with a) wT1 , b) wT2 , c) wT1  without the administration 
of a commercial CA and d) 
wT1 with the administration of a commercial CA
8
  
 
 
A MRI Contrast Agent (CA) is a chemical substance introduced to the anatomical or 
functional region being imaged in order to increase the differences between different 
tissues, or between normal and abnormal tissue, by altering the relaxation times. 
Therefore, the aim of using CAs in MRI is to accelerate the relaxation of water proton 
spins with their surrounding. This can be achieved by using paramagnetic substances. 
Examples of these achievements are the experiments of Bloch et al.9 and Lauterbur et 
al.10 
The MRI contrast mechanism can be affected by many intrinsic and extrinsic factors 
such as proton density and MRI pulse sequences. Based on their relaxation processes the 
contrast agents can be classified as 1T  or 2T  contrast agents. The commercially approved 
1T  contrast agents are usually paramagnetic complexes, while the 2T  contrast agents are 
based on iron oxide nanoparticles, which are the most representative nanoparticulate 
agents. 
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The most common paramagnetic complexes are the paramagnetic chelates 
containing a lanthanide ion. Currently, gadolinium (III) complexes are by far the most 
widely used CAs in clinical practice because it has seven unpaired electrons making it the 
most paramagnetic (highest spin density) stable metal ion. Gadolinium (III) also has 
another significant feature due to the symmetrical 8S ground state: its electron spin 
relaxation is relatively slow, which is relevant to its efficiency as an MRI CA. There are a 
number of excellent reviews11-18 covering the development and properties of first and 
second-generation contrast agents, particularly focusing on gadolinium complexes.       
11,12,13,14,15,16,17,18 
 
 
2.2.1. RELAXATION 
 
Relaxation is a fundamental precess in MR and presents the main mechanism for 
the image contrast. The RF pulse turns the macroscopic magnetization away from the z-
axis. Once the 1B -field has been turned off the magnetization rotate around the main 
magnetic field ( 0B ) at the Lamor frequency. Due to relaxation processes, the 
magnetization will eventually return to its equilibrium position along the z-axis and the 
NMR signal will as a result fade away. There are two different relaxation pathways 
possible: the spin-lattice relaxation and the spin-spin relaxation.  
 
 
2.2.1.1. SPIN-LATTICE RELAXATION 
 
The spin-lattice relaxation, or longitudinal relaxation, or 1T  relaxation, is responsible 
for the return of the z-magnetization component, ZM , to its equilibrium value. It provides 
the mechanism by which the protons give up their energy and return to the thermal 
equilibrium. Therefore, if a 90° pulse at the resonant frequency, 0 , is applied to a sample 
its magnetization, 0M , will rotate to the x’y’ plane as shown in Figure 2.4-a, and ZM  will 
be zero. With time, ZM  will increase, as the protons release their energy (Figure 2.4-b). 
This return of magnetization to equilibrium follows an exponential growth process, with a 
time constant 1T  describing the rate of growth (equation 2.2): 
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where   is the time following the RF pulse. After three 1T  time periods, M  will have 
returned to 95% of its value prior to the excitation pulse, 0M . The term spin-lattice refers 
to the fact that the excited proton (“spin”) transfers its energy to its surroundings (“lattice”) 
rather than to another spin, where the energy will no longer contribute to spin excitation. 
This energy transfer to the surroundings has some very important consequences. The key 
to this energy transfer is the presence of some type of molecular motion (e.g., vibration, 
rotation) in the vicinity of the excited proton with an intrinsic frequency, L , that matches 
the resonant frequency, 0 . The closer 0  
is to L , the more willingly the motion absorbs 
the energy and the more frequently this energy transfer occurs, allowing the protons to 
return to equilibrium. 
 
a) b)
Figure 2.4. a) Effect of a 90º RF pulse on the net magnetization, viewed in the 
rotating frame. b) Plot of the relative ZM  component as a function of time 
after the RF pulse, know as the 1T  relaxation curve. 
 
In general any mechanism which gives rise to fluctuating magnetic fields is a 
possible relaxation mechanism. Therefore all mechanisms contribute to the observable 
relaxation time according equation 2.3. 
 

m mTT 11
11
 (2.3) 
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where mT1  is the time constant of mechanism m . The magnitude of the contribution to the 
overall relaxation rate from a single mechanism may differ greatly among different 
chemical groups, the chemical environment and has a dependence regarding parameters 
such as temperature and field strength. 
 
 
2.2.1.2. SPIN-SPIN RELAXATION 
 
Spin–spin relaxation time or transverse relaxation time or the relaxation time 2T  is 
the time required for the transverse component of M  to decay to 37% of its initial value 
via irreversible processes. The net magnetization 0M  is initially along the z-axis ( 0B ). If a 
90° pulse is applied to a sample, 0M  will rotate as shown in Figure 2.5a-1. This causes 
0M  to rotate entirely into the x’y’ plane, so that the individual spin magnetic moments 
have phase coherence in the transverse plane at the end of the pulse. With time this 
phase coherence disappears and the value of M  in the x’y’ plane decreases toward 0. 2T  
or 
*
2T  relaxation is the process by which this transverse magnetization is lost. At the end 
of the 90° RF pulse, when the proton spins have absorbed energy and are oriented in the 
transverse plane, all spins precess at the same frequency 0  and are synchronized at the 
same point or phase of its precessional cycle. Given that a nearby proton of the same type 
will have the same molecular environment, and the same 0 , it can easily absorb the 
energy that is being released by its neighbour. Therefore the spin–spin relaxation refers to 
this energy transfer from an excited proton to another nearby proton and the absorbed 
energy remains as spin excitation rather than being transferred to the surroundings as in 
1T  relaxation. Figure 2.5a illustrates a rotating frame slower than 0  and the various steps 
of the net magnetization after a 90º RF pulse, where:  
1- Net magnetization M is oriented parallel to 0B ,  
2- following a 90° RF pulse the protons initially precess in phase in the transverse 
plane, 
3- due to inter- and intramolecular interactions the protons begin to precess at 
different frequencies and become asynchronous with each other 
4 and 5- as more time elapses the transverse coherence becomes smaller until,  
6- there is complete randomness of the transverse components and no coherence. 
 27 
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Figure 2.5. a) Illustration of the net magnetization M with regards to the x’y’ 
plane within a rotating frame slower than 0 .  b) Plot of the relative XYM  
component as a function of time, known as the 2T  relaxation curve. 
 
If the protons continue in close proximity and remain at the same 0  the proton–
proton energy transfer will occur many times. The local magnetic field of the protons can 
fluctuate due to intermolecular and intramolecular interactions such as vibrations or 
rotations. This fluctuation produces a gradual, irreversible loss of phase coherence of the 
spins as they exchange energy and reduce the magnitude of the transverse magnetization 
as well as reduce the generated signal (Figure 2.5b). With the increase in time this 
transverse coherence completely disappears, only to reform in the longitudinal direction as 
1T  relaxation occurs. 
There are two main causes for a loss of transverse coherence to M . The first cause 
is the movement of the adjacent spins due to molecular vibrations or rotations 
(responsible for spin–spin relaxation or the true 2T ). The second cause is due to the 
inhomogeneity of the magnetic field. As the proton spin precesses it experiences a 
fluctuating local magnetic field, causing a change in 0  and a loss in transverse phase 
coherence. 
 
 
The proper design of the pulse sequence can eliminate the imaging gradients as a 
source of dephasing. While, the other sources contribute to the total transverse relaxation 
time, 
*
2T  equation 2.4: 
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where MT2  is the dephasing time due to the main field inhomogeneity and MST2 is the 
dephasing time due to the magnetic susceptibility differences.  
The decay of the transverse magnetization following a 90° rf pulse follows an 
exponential process with the time constant of 
*
2T rather than just 2T  equation 2.5: 
 
)/( *2
max
)(
Tt
XYXY eMtM
  (2.5) 
 
where 
maxXY
M  is the transverse magnetization XYM  immediately following the 
excitation pulse. For most tissues or liquids, MT2  is the major factor in determining 
*
2T , 
whereas for tissue with significant iron deposits or air filled cavities, MST2  dominates 
*
2T  
( 2T  determined using the spin-echo experiment). 
 
 
2.2.2. RELAXIVITY 
 
Relaxivity is the ability of magnetic compounds in enhancing the relaxation rate of 
the surrounding water proton spins. Therefore, the longitudinal and transverse relaxivity 
values, 1r  and 2r , refer to the amount of increase in 11 T and 21 T , respectively, per 
millimolar concentration of agent (often given as per mM of Gd). 1T  agents usually have 
12 rr ratios of 1-2, whereas 2T  agents normally have 12 rr ratios ~10 or higher.
 19-23    
19,20,21,22,23 
Solomon, Bloembergen and Morgan developed the general theory of solvent nuclear 
relaxation in the presence of paramagnetic substances.19-23. The Gd (III) complexes 
induce an increase of both the longitudinal and transverse relaxation rates, 11 T and 21 T , 
respectively, of the solvent nuclei (normally water). Diamagnetic and paramagnetic 
relaxation rates are additive and given by equation 2.6: 
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where 
obsiT ,
1
 is the observed solvent relaxation rate, 
diT ,
1
the diamagnetic relaxation 
rate, and 1/Ti,p the paramagnetic relaxation rate that depends on the concentration of 
paramagnetic species expressed in millimolar for diluted samples. Relaxivity, r i, is defined 
as the slope of the concentration dependence, equation 2.7., and is normally expressed in 
mM-1 s-1; molal (mol/kg) concentrations should be used when dealing with nondilute 
systems. 
Within the Solomon, Bloembergen and Morgan’s (SBM) theory the paramagnetic 
relaxation process is described on the basis of a model that considers ‘inner sphere’ and 
‘outer-sphere’ contributions (equation 2.8). 
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where piT , , 
is
piT ,  and 
os
piT ,  are, respectively, the total paramagnetic, the inner- and outer-
sphere paramagnetic contributions to the longitudinal (i=1) or transverse (i=2) NMR 
relaxation times. The inner-sphere contribution is related to the exchange between the 
bound water molecules and bulk water, and the outer sphere-contribution is caused by 
water molecules diffusing near the paramagnetic centre during their translational 
diffusion.13,24 Often, a third contribution is also taken into account, the ‘second-sphere’, 
that is caused by the presence of mobile protons or water molecules in the second 
coordination sphere of the paramagnetic species (Figure 2.6).25 The relaxivity ( ir ) is 
defined in equation 2.9 (combination of eqs. 2.14, 2.15 and 2.16), if the second sphere 
contribution is not considered. 
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Figure 2.6. Schematic representation of the three types of water molecules 
surrounding the metal complex. 
 
 
2.2.2.1. INNER SPHERE RELAXIVITY 
 
The inner-sphere contribution to the overall relaxation rates is described in 
equations 2.10 and 2.11. The parameters involved in this inner-sphere mechanism are i) 
q , the number of water molecules in the inner-coordination sphere directly coordinated to 
the paramagnetic centre, ii) C , the molar concentration of the paramagnetic complex, iii) 
M , the mean residence lifetime of the coordinated water protons within the inner-sphere 
coordination sphere, iv) MT1  and MT2 , the longitudinal and transverse proton times 
enhancement experienced by the proton of the inner-sphere water molecules, 
respectively, and v) M , the chemical shift difference between the free and the bound 
water molecules. 
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In the case where the system is in the ‘fast exchange’ regime ( MMT 1 ) the inner-
sphere contribution becomes important and is transferred to the bulk water. When the 
coordinated water molecule is in the ‘slow exchange’ regime ( MMT 1 ), the water 
exchange rate becomes the limiting factor of the relaxivity.  
 
The Solomon-Bloembergen-Morgan theory18,20 provides a foundation to understand 
the basis of iMT  (Equations 2.12-18). The two components of the iMT  term (Equation 
2.12) are dipole-dipole (arising from random fluctuations of the through-space interaction 
of the nuclear dipole with the unpaired electron dipole) and scalar interactions (resulting 
from a through-bond delocalization of the unpaired spin density on the nucleus) that are 
noted by the “DD” and “SC” superscripts respectively. 
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where I  is the proton gyromagnetic ratio, g  is the electronic g-factor, B  is the 
Bohr magneton, S  is the number of unpaired electrons in the paramagnetic metal ion, 
GdHr  is the distance between the water protons and the unpaired electrons of the 
paramagnetic metal ion, 0 is the magnetic permeability of a vacuum, 






A
 
is the 
hyperfine coupling constant between the metal electrons and the water protons, I and 
S  are the nuclear and electron Larmor frequencies, respectively ( BSISI ,,   , where B  
is the magnetic field). For field strengths used in MRI the electronic contributions (the “7” 
term inside the square brackets in equation 2.13) may be conveniently ignored since, 
122
2 cs , reducing the electronic contributions to an insignificant amount. The nuclear 
contribution (the “3” term also inside the square brackets in equation 2.13) is determined 
by 
2
I , the proton Larmor frequency, and 1c , the local correlation time. The relaxation 
enhancement efficiency of the CA depends on how closely matched the proton frequency 
(i.e., the Larmor frequency, I ) is to the correlation frequency of the contrast agent 








cT ,1
1
. The nuclear contributions to relaxation are maximized when 








cT ,1
1
 approaches 
the Larmor frequency of the protons. 
 
The local correlation time ( ci ), defined by equations 2.17 and 2.18, has three 
components, eT ,1  
(the electronic relaxation time of the unpaired electrons, M ) the water 
residency lifetime, and RT – the rotational correlation lifetime. The high-field strengths 
used in MRI again simplify matters, eT ,1  is long enough to reasonably ignore the 
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contributions from the 

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 term. M  is the same term from equation 2.10. R  is the 
rotational correlation time and is related to the physical tumbling time of the CA in solution. 
 
Considering equations 2.13 and 2.15, 
dipR1  and 
dipR2  are roughly equal at the fast 
motion limit (in the case of small c ), while far from this limit (in the case of long c ) the 
dipole-dipole mechanism behaviour differs. In this case 
dipR1  decreases with c  and 
dipR2  
is constantly increasing due to the presence of the frequency independent term c4 . 
Regarding the contact contribution, SC, due to its nature the correlation time modulating 
this contribution is not affected by R (equations 2.14 and 2.16) and since 
22
eS  is 
extremely large, for Gd3+ complexes, 
SCR1 is usually negligible. In the case of R2, however, 
the contact contribution (
SCR2 ) is often the dominant mechanism, mainly from nuclei near 
the metal ion26. 
 
At high magnetic fields, especially if R  is much larger than eiT , , the Curie or 
susceptibility mechanism is another dipolar effect that must be considered (equations 2.19 
and 2.20).27 
 














2262
44222
1 1345
61
RI
ReffoIo
rkT
B
T 




.
)(
.
,  (2.19) 
 














2262
44222
2 1
3
4
345
11
RI
R
R
effoIo
rkT
B
T 






.
)(
.
,  (2.20) 
 
where 0B  is the magnetic field strength, T  is the absolute temperature, eff  is the 
effective magnetic moment of the metal ion, k  is the Boltzmann constant, r  is the 
distance between the nuclear spin and the metal ion. 
 
The Curie mechanism describes the dipolar interaction between the nuclear spins 
and the magnetic moment generated by the thermally averaged excess of electron 
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population in the electronic spins levels. The contribution of the Curie mechanism to the 
total longitudinal relaxation is only relevant for slowly rotating macromolecules (long R ).  
The electronic relaxation rates ( ieT1 ) described by Bloembergen and Morgan
20 and 
McLachlan28 depend on the magnetic field. For Gd3+ complexes, these are normally 
interpreted in terms of a modulation of the zero field splitting (ZFS)29(only once) These 
relaxation rates are described by Equations. 2.21 and 2.22, referred to as the 
Bloembergen-Morgan theory of paramagnetic electron spin relaxation:  
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where 
2  is the mean squared ZFS energy and V  is the correlation time for the 
modulation of the ZFS interaction. This modulation results from the transient distortions of 
the complex “metal coordination cage”. A transient ZFS of the spin levels can be induced 
by vibration, intramolecular rearrangement and collisions between solvent molecules and 
the metal complexes, allowing the coupling of rotation with spin transitions. The validation 
of equations 2.21 and 2.22 is restricted to certain conditions where 10 V  is fulfilled. 
 
At low magnetic field ( 1.00 B  T) the relaxivity of the Gd
3+ complexes depends 
mainly on the electronic relaxation (Equation. 2.23). At high magnetic field ( 5.10 B  T) the 
electronic relaxation rate decreases and becomes slower than the rotational rate of the 
complex (Equation. 2.24). 
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A reported temperature and magnetic field dependence EPR study30 demonstrated 
that 





eT1
1
 of various aqueous solutions of a series of Gd3+ complexes is described to a 
good approximation by the previously developed equations. The major contribution to the 
observed EPR line widths is due to electronic relaxation. 
A more recent description of electron spin relaxation requires EPR measurements 
over a very wide range of temperatures and magnetic fields.31 This theoretical model 
shows that the electronic relaxation mechanisms at the origin of the EPR line shape arise 
from the combined effects of the modulation of the static crystal field by the random 
Brownian rotation of the complex and of the transient zero-field splitting. 
 
 
2.2.2.2. SECOND AND OUTER SPHERE RELAXIVITY 
 
 
Water molecules not directly coordinated to the metal ion also experience relaxation 
enhancement in the presence of the CA. These water molecules may be organized into a 
second- and outer-coordination sphere as shown in Figure 2.6. The Solomon-
Bloembergen-Morgan theory may also be applied to second-sphere water molecules, thus 
SST1  may be modelled from equations 2.10, 2.14 and 2.15.  
 
The outer-sphere relaxation enhancement may be modelled using theories 
developed by Hwang and Freed32,33,34 that take into account the electronic relaxation and 
diffusion. Essentially, 
OST1  is determined by jeT , the electronic relaxation time,  jei TJ ;  is 
a non-Lorentzian spectral density function, NA is the Avogadro’s number, S  is electron 
gyromagnetic ratio, GdHa  is the distance of closest approach of the solvent protons to the 
paramagnetic centre, GdHD  is the sum of the diffusion coefficients of the water proton and 
of the Gd3+ complex and GdH  is the diffusion correlation time. The symbols not mentioned 
here maintain the meaning given before. 
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In the case of small-sized Gd3+ complexes the outer sphere contribution is 
responsible for about 50% of the total relaxivity. For macromolecular systems, the outer 
sphere contribution may be considered less important. Complexes of similar shape and 
size have similar diffusion coefficients and outer sphere contribution to the relaxivity. 
 
The second sphere water molecules should be considered as bound via hydrogen 
bonds to the functional group in the ligand molecule. The second-sphere contribution is 
difficult to evaluate due to the number of second-sphere water molecules and their 
exchange rates, which are unknown. Usually, the second sphere effect is included in the 
outer-sphere contribution. The explanation of unexpected high relaxivity of some Gd3+ 
complexes, such as [Gd(DOTP)]7 where no water molecules can be found in the inner-
sphere, is given by a very strong second-sphere contribution.35 
 
It is problematic to separate the inner-, second- and outer-sphere components of 
CAT1 . An approach often used to approximate 
IST1  of a CA is to simply remove 
CAT1  of a 
second sphere component, related CA that has 0q . In the case of the second CA, IST1  
is zero (since 0q ) and the observed relaxation enhancement is attributed solely to SST1  
and 
OST1 , therefore providing a reasonable estimate of 
SST1  and 
OST1  for the first CA 
because these parameters are not expected to differ significantly among structurally 
related CAs. Nevertheless, there are noteworthy exceptions to this assumption and this 
approach must be carefully applied. Presently there is no satisfactory experimental 
method to partition the second- and outer sphere components of 
CAT1 . 
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2.2.2.3. PARAMAGNETIC RELAXATION PARAMETERS 
 
In order to better understand the potential of the different parameters to affect 
CAT1 , 
equations 2.6-2.25 are condensed and presented into equation 2.26. Two reasonable 
assumptions are made in simplifying the equations, 
SCT1
1
is omitted because 0

A
 for 
water proton metal interactions in CA’s and 
 222
2
1
7
cS
c



 because 0B  is sufficiently strong. 
 
   
      
  
    
ioneContributOuterSpher
SH
OS
tionreContribuSecondSphe
M
cI
c
SS
ioneContributInnerSpher
M
cI
c
ISCA
jjCSS
k
SSr
Cq
k
SS
Cq
k
T







73)1(
1
'
'1
'
)1('
1
'
1
)1(
1
1
2
1
2
16
2
1
2
1
1






















 (2.26) 
 
 
The development of more effective contrast agents involves the optimization of 
various parameters governing the relaxivity. The relation between the molecular structure 
and electronic relaxation is still not well established. This task is focused on the 
optimization of three parameters, which are the number of water molecules coordinated to 
the metal ion ( q ), the exchange lifetime ( M ) and the reorientation correlation time ( R ). 
An example of the variation of 
CAT1  with respect to these three parameters is given in 
Figure 2.7. Figure 2.7, which represents the inner-sphere proton relaxivity ( 1r ) calculated 
at two magnetic fields as a function of M and R for two electronic relaxation time values, 
q = 1 and r = 3.1 Å. Several important conclusions may be drawn from these simulated 
curves: i) the optimal relaxivities are obtained by slowing down the rotation of the complex 
and optimizing the exchange lifetime (for the later, an extreme exchange lifetime has a 
negative influence on the relaxivity); ii) the optimal relaxivity decreases with increasing 
magnetic field strength; iii) when one parameter begins to be optimized the other 
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parameters become more critical and, therefore a compromise has to be reached; and iv) 
eT1  increases as the magnetic field strength increases and at 0.5 T, eT1  may be a limiting 
factor, while at 1.5 T it may reach a point where it does not influence 1r .  
 
 
 
Figure 2.7. Inner-sphere relaxivities calculated as a function of M and R for 
values of eT1  at 0.5T (~21MHz) and 1.5T (~64MHz).
11 
 
The relaxation induced by superparamagnetic particles36, briefly outlined in the next 
section, is explained by the classical outer-sphere relaxation theory, reformulated by the 
Curie relaxation theory,24 since the former considers the relaxation rates of water protons 
diffusing near the unpaired electrons responsible for the particle’s magnetization.37 These 
agents exhibit strong 1T  relaxation properties and due to susceptibility differences to their 
surroundings, also produce a strongly varying local magnetic field, which enhances 2T  
relaxation. An important result from the outer-sphere theory is that the 12 rr  ratio 
increases with increasing particle size and, thus, smaller particles are much better 1T -
shortening agents than larger ones.32,38,39  
 
 
 39 
2.2.3. NUCLEAR MAGNETIC RESONANCE DISPERSION 
 
The nuclear magnetic relaxation properties of a compound are ideally acquired 
by a magnetic field dependence study. This is performed by measuring the proton 
longitudinal and transverse relaxation over a range of magnetic fields with a Fast-Field-
Cycling (FFC) spectrometer that switches the magnetic field strength over a range of 
proton Larmor frequencies. The data acquired represents the Nuclear Magnetic 
Resonance Dispersion (NMRD) profile, which can be fitted by eqs 2.10-2.18, eqs 2.21-
2.22 and eqs 2.23-2.24, in order to obtain the values of the relaxation parameters. The 
underlying complexity is a major drawback to this technique, since there are too many 
influencing parameters inducing possible errors in the fitting of the NMRD profile. For this 
reason,40 an accurate interpretation of NMRD profiles may only be made by reference to 
independent information from other techniques, such as 17O NMR, 2H or 13C NMR and 
Electron Paramagnetic Resonance (EPR). The 17O NMR relaxation rates and chemical 
shifts, over a range of magnetic fields and as function of temperature and pressure, allow 
estimates of the number of inner-sphere water molecules (q ), the rotational correlation 
time ( R ), the water exchange rate ( M ), and the longitudinal electronic relaxation rate. 
With 2H or 13C NMR it is also possible to determine the rotational correlation time ( R ), 
while the EPR line widths give direct access to transverse electronic relaxation rates.30 
With these techniques a more reliable determination of the set of parameters 
governing proton relaxivity provide a more stringent test of the relaxation theories applied 
to the techniques and allow a validation of current models for the dynamics in 
paramagnetic solutions. 
Within a NMRD profile, despite possible inaccuracies, it is viable to draw some 
valuable conclusions concerning the relaxation processes: i) at the high magnetic field 
region (10-100 MHz) the inner-sphere relaxation is governed by the reorientational 
correlation ( R ) time, which is dependent on the molecular weight of the complexes; ii) at 
the low magnetic field, this region is mainly determined by the zero-field electronic 
relaxation time ( 0s ), where 
v
s


20 12
1

   and is dependent on the symmetry of the 
complex and on the chemical nature of the coordinating groups. 
An example of a typical NMRD profile of low-molecular-weight Gd(III) complexes 
with one inner-sphere water molecule such as [Gd(DTPA-BMA)(H2O)], [Gd(DTPA)(H2O)]
2-
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, or Gd(DOTA)(H2O)]
- (three clinically approved CAs) have the general forms shown in 
Figure 2.8. 
 
 
Figure 2.8. NMRD profile of three commercially-available CAs [Gd(DTPA-
BMA)(H2O)], [Gd(DTPA)(H2O)]2-, or Gd(DOTA)(H2O)]-.14 
 
The main feature of these profiles is that the relaxivity is limited by fast rotation, 
especially at high frequencies (>10 MHz). As a consequence, the high-field relaxivities of 
these three agents are practically the same, since their sizes and therefore their rotational 
correlation times ( R ) are very similar. The lower value for the water exchange rate (one-
order of magnitude) determined for [Gd(DTPA-BMA)(H2O)] has no influence on the high-
field relaxivities, since at these fields the relaxivity is exclusively limited by the rotation of 
the CA. In the low-field region the different relaxivities reflect the extremely slower 
electronic relaxation of the symmetric [Gd(DOTA)(H2O)]
- species, as compared to the 
linear chelates. The higher relaxivity is a consequence of its much longer zero-field 
electronic relaxation time ( 0s ). The determined 0s  values are 650ps for 
[Gd(DOTA)(H2O)]
- 41 and 72 and 81ps for [Gd(DTPA)(H2O)]
2- and [Gd(DTPA-BMA)(H2O)], 
respectively.41 
 
In the case of superparamagnetic NPs the relaxation induced by these crystals is 
complicated by another feature. The ferromagnetic crystals are dispersed in a liquid media 
 41 
to form a colloid suspension. As their size is much smaller than the size of one magnetic 
domain, they are completely magnetized, constituting a nanomagnet made of a fully 
magnetized single domain. In addition to the value of its magnetization, each single mono-
domain is also characterized by its anisotropy energy. The magnetic energy of each nano-
magnet depends upon the direction of its magnetization vector with respect to the 
crystallographic directions, increasing with the tilt angle between the magnetization vector 
and the anisotropy directions (or easy axes) which minimize this magnetic energy. The 
difference between the maximum and minimum energy is called the anisotropy energy, Ea, 
which is proportional to the crystal volume (V), Ea = Ka V, where Ka is the anisotropy 
constant.  
In these conditions, the return of the magnetization to equilibrium is determined 
by two different processes. The first one is the Néel relaxation, which is determined by the 
anisotropy energy, and is characterized by a relaxation time constant N, which defines the 
fluctuations that arise from the jumps of the magnetic moment between different easy 
directions causing the return of the magnetization to equilibrium after a perturbation 
(Figure 2.9). The second process is the Brownian relaxation, which characterizes the 
viscous rotation of the entire particle, is characterized by a (Figure 2.9).36 Therefore, the 
global magnetic relaxation rate of the colloid (1/, where  is the global magnetic relaxation 
time) is the sum of the Néel relaxation rate (1/N) and the Brownian relaxation rate (B). 
The Brownian relaxation time is proportional to the crystal volume while the Néel 
relaxation time is an exponential function of the volume. Then, in the case of larger 
particles, B is shorter then N, so the viscous rotation of the particle becomes the 
dominant process determining the global relaxation. In these conditions, the magnetization 
curve is perfectly reversible because the fast magnetic relaxation allows the system to be 
always at thermodynamic equilibrium. This behavior has been named 
“superparamagnetism” by Bean and Livingston.36 
 
 
Magnetic Resonance Imaging Background Concepts 
 
 
42 
 
Figure 2.9. Illustration of the two components of the magnetic relaxation of a 
magnetic fluid.36 
 
Therefore, the influence of the electron magnetic moment is modulated by the 
Néel relaxation, which depends upon the crystal anisotropy. In the case of large 
superparamagnetic crystals or crystals with a very high anisotropy constant42 the 
anisotropy energy is larger than the thermal energy, maintaining the direction of the crystal 
magnetic moment very close to that of the anisotropy axes. This characteristic simplifies 
the models, enabling the precession of the electron magnetization. Considering small 
crystals, the anisotropy energy is of the same order of magnitude as the thermal energy, 
therefore it is possible for the magnetic moment to point in a different direction from the 
anisotropy axes, allowing some electron precession.  
In both these cases the explanation of the longitudinal relaxation rate 
dependence with the magnetic field (NMRD profile) is based on the so-called Curie 
relaxation.27 This relaxation arises from considering separately two contributions to 
relaxation: i) diffusion into the inhomogeneous non-fluctuating magnetic field created by 
the mean crystal moment, aligned onto 0B  (the accurately termed Curie relaxation) and ii) 
the fluctuations of the electronic magnetic moment or the Néel relaxation. 
The different contributions to proton relaxation, in the simplified model for crystals 
with large anisotropy, are given in Figure 2.10. As shown at low field, the proton 
longitudinal relaxation rate is obtained by introducing into the Freed equations the 
precession prohibition mentioned above (the electron Larmor precession frequency is set 
to zero).43 Figure 2.10 shows the dispersion of this density spectral function, called Freed 
function, centred around 
C
I


1
 . At high field strength the magnetic vector is locked 
 43 
along the 0B  direction and the Curie relaxation dominates and the corresponding 
relaxation rates are given by Ayant’s model.44 In the case of intermediate field strength, 
the proton relaxation rates ( 1R  and 2R ) are combinations of the high- and low-field 
strength contributions, weighed by factors depending upon the Langevin function.45 
 
 
Figure 2.10. Different contributions to proton relaxation in the simplified model 
for crystals with large anisotropy. 
 
In the case of superparamagnetic nanoparticles, the fitting of the NMRD profiles 
by adequate theories provides information on: their average radius ( r ), their specific 
magnetization ( sM ),anisotropy energy ( AE ), and Néel relaxation time ( N ).
46 Figure 2.11 
illustrates a standard NMRD profile of magnetite particles in colloidal suspension. The 
average radius ( r ) may be determined since at high magnetic fields the relaxation rate 
only depends upon D  as the inflection point corresponds to the condition 1~DI  (see 
Figure 2.11) and given that 
D
r
D
2
 , the determination of D  gives the crystal size r . 
Regarding the specific magnetization ( sM ), also at high fields, sM  can be obtained from 
the equation: 
2/1
max~ 





D
s
C
R
M

, where C  is a constant and maxR  is the maximal relaxation 
rate. The absence or presence of dispersion at low fields provides information about the 
magnitude of the anisotropy energy. In the case of crystals characterized by a high 
 
Magnetic Resonance Imaging Background Concepts 
 
 
44 
anisotropy energy ( AE ) value as compared to the thermal agitation the low field 
dispersion disappears. These conclusions have also been confirmed in previous work with 
cobalt ferrites,39 which are known to have high anisotropy energy. The relaxation rate at 
very low fields 0R  is governed by a “zero magnetic field” correlation time 0C , which is 
equal to N  if DN   . Often this situation is not met; therefore, N  is often reported as 
qualitative information in addition to the crystal size and the specific magnetization. 
 
Figure 2.11. NMRD profile of magnetite particles in colloidal suspension.39 
 
 
 
 
2.3. CLASSIFICATION OF CAs 
 
According to their various features, the currently available MR CAs may be 
classified in different ways, based on the: i) presence and nature of the metal centre, ii) 
their magnetic properties, iii) effect on the magnetic resonance image (MRI), iv) chemical 
structure and ligands present, and v) biodistribution and applications. A simplification of 
the above classification may be made, since several of these characteristics are closely 
related: on one side the chemical composition (metal and ligands), the magnetic 
properties and the effects on the MRI image and, on the other side, their applications 
resulting from their in vivo bio-distribution. 
 45 
2.3.1. CHEMICAL COMPOSITION, MAGNETIC PROPERTIES AND EFFECTS 
ON THE MRI IMAGE 
 
The chemical nature of MRI CAs varies widely. They can be i) small 
mononuclear or polynuclear paramagnetic chelates, ii) metalloporphyins, iii) polymeric or 
macromolecular carriers (covalently or noncovalently labelled with paramagnetic chelates, 
such as dendrimers or proteins), iv) particulate CAs, v) paramagnetic or 
superparamagnetic particles, vi) diamagnetic or paramagnetic chemical exchange 
saturation transfer (PARACEST) polymers or chelates, vii) diamagnetic hyperpolarization 
probes, such as 13C labelled compounds or ions.47 
The most common and simplest paramagnetic chelates use Gd3+ or Mn2+ (due to 
their properties already described) as metal centres with linear or macrocyclic 
polyaminocarboxylate/phosphonate derivative ligands. In the case of particulate CAs, Gd3+ 
ions are also used in various forms, for example: bound to amphiphylic chelates in 
paramagnetic micelles, in the bilayer of liposomes, as small chelates in their aqueous 
internal compartment, or bound to porous materials like zeolites.47 When considering 
paramagnetic or superparamagnetic particles, gadolinium oxide nanoparticles and iron 
oxide particles with different sizes and coatings are considered, respectively. 47  
Other paramagnetic chelates containing different Ln3+ ions, such as Dy3+ or Tm3+, 
are used as MRI CAs with different variations. Examples of these variations are as 
susceptibility agents, when they are in a compartment, affecting T2 or T2
* relaxation,48 or 
as PARACEST and LIPOCEST agents, where the paramagnetic shift effect of the ion on 
the proton nuclei of the CA facilitates the irradiation of their shifted resonances and 
consequent saturation transfer by chemical exchange (CEST effect), thus decreasing the 
water proton signal intensity and leading to a negative image contrast.49 
Less conventional MRI CAs do not contain any metal centre. Examples include 
the oral agents or the CEST agents. 
Recently a new class of MRI CAs has been developed, dynamic nuclear 
polarization (DNP) agents, such as hyperpolarized noble gases (3He, 129Xe) and 13C-
labeled organic compounds or ions like 6Li+. The probe’s nuclei (with long T1 values) 
exhibit a strong signal enhancement allowing the direct imaging of the probe’s molecular 
distribution. 47 
 
CAs may also be classified according to their magnetic properties as 
paramagnetic or superparamagnetic agents. Metal ions with one or more unpaired 
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electrons are paramagnetic and consequently possess a permanent magnetic moment. 
Organic free radicals are also paramagnetic due to their unpaired valence electron. Within 
an aqueous suspension a dipolar magnetic interaction between the electronic magnetic 
moment of the paramagnetic atom and the much smaller magnetic moments of the 
protons of the nearby water molecules is formed. Random fluctuations in this dipolar 
magnetic interaction can be caused by the molecular motions, therefore reducing both the 
longitudinal ( 1T ) and the transverse ( 2T ) relaxation times of the water protons. As already 
mentioned, Gd3+ and Mn2+ are examples of paramagnetic ions used as MR CAs, because 
their physical properties are suitable for efficiently reducing the 1T  and 2T  proton 
relaxation times. 47 
Unfortunately, paramagnetic metal ions, like Gd3+, can not be used as CAs in 
their ionic form due to their undesirable biodistribution (accumulating in bones, liver or 
spleen) and relatively high toxicity. Therefore, metal ion complexes (chelates) with high 
thermodynamic and kinetic stabilities are required in order to use these paramagnetic 
metal ions in vivo. Small Gd3+ or Mn2+-based paramagnetic chelates are nonspecific CAs 
and have similar 1r  and 2r  effects in water. Currently these agents are used mainly for 
positive contrast 1T -weighed images. As already mentioned, the relaxivity effects of these 
agents result mostly from both inner- and outer-sphere mechanisms. 
The superparamagnetic agents consist of materials, such as iron oxides, in the 
form of colloids made up of particles (typically 5 – 200nm in diameter) in suspension, 
which are composed of very small crystallites (1 – 10 nm) containing several thousand 
magnetic ions. These agents exhibit a behaviour similar to paramagnetism except that, 
instead of each individual atom being independently influenced by an external magnetic 
field, the magnetic moment of the entire crystallite tends to align with that magnetic field. 47 
Therefore the magnetic moments of the individual ions do not cancel out but are mutually 
aligned, inducing a much higher permanent magnetic moment within the crystallites when 
in the presence of a magnetic field compared to a single molecule of a Gd chelate. 47 
These particles are embedded in a coating such as dextrans (in ferumoxide) or 
siloxanes (in ferumoxsil), which prevents agglomeration. There are three kinds of 
particulate superparamagnetic iron oxides, according to the overall size of the particles: i) 
if they have a diameter d<50 nm , they are known as ultra-small superparamagnetic iron 
oxide (USPIO) particles; ii) if 1 m >d>50 nm , they are called small superparamagnetic 
iron oxide (SPIO) particles; and iii) micron-sized particles of iron oxide (MPIO) are large 
particles, with a diameter of several microns. Intravenous administration is only possible 
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for the former two, while the large particles can only be administered orally to explore the 
gastrointestinal tract, otherwise they would be trapped in the lung alveoli. Yet more 
nomenclatures exist, such as monocrystalline iron oxide particles (MION) and cross-linked 
iron oxides (CLIO). 
 
As a consequence of their larger size and magnetic moment SPIOs were initially 
developed as 2T -agents, producing a dark area on MRI images resulting from their 
negative contrast effect.50 A new generation of USPIOs with sizes less than 10 nm has 
also been reported to have excellent 1T -enhancing properties.
39,51,52,53 As already 
mentioned, the relaxation induced by superparamagnetic particles is explained by the 
classical outer-sphere relaxation theory, reformulated by the Curie relaxation theory.48 
The susceptibility agents induce long-range interactions which can dominate the 
2T  or 
*
2T  relaxation. This relaxation mechanism, known as susceptibility-induced 
relaxation, 47 is related to the magnetization of the CA, which results from the partial 
alignment of the individual magnetic moments in the direction of the magnetic field. 
 
An example of this type of agent is when a CA becomes compartmentalized, like 
when superparamagnetic particles are taken up by Kupffer cells, or in a vessel, the 
compartment containing these CA functions as a secondary CA. In this case the water 
protons on the outside of the compartment are affected by the overall magnetization of the 
magnetic bulk material inside that compartment and are, therefore, relaxed by an outer-
sphere mechanism. 47 The blood oxygen level dependent (BOLD) effect is due to this long-
range 
*
22 TT relaxation effect, where the paramagnetic hemoglobin is compartmentalized 
within blood erythrocytes. This phenomenon is the basis of functional MRI 54 and can 
depend on several parameters such as the magnetic moment and local concentration of 
the CA, the dimensions and geometry of the compartment, the diffusion constant of water 
within the compartment and so on. 
As already mentioned, the classification of MR CAs as ‘ 1T  agents’ or ‘ 2T  agents’ 
is not always accurate, since any CA that reduces 1T  also reduces 2T . Nevertheless any 
agent that reduces 2T  does not necessarily reduce 1T , at least at MRI field strengths. 
Therefore the CA functions as a ‘ 1T  agent’ or ‘ 2T  agent’ depending on the imaging 
sequence used, the magnetic field strength, the size of the CA and how the CA is 
compartmentalized in the tissue. 47 
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2.3.2. BIODISTRIBUTION AND APPLICATIONS 
 
The biodistribution of CAs is very important because it is vital to know what 
happens to the CAs and where they go when they are intravenously administered. The 
main distribution sites and excretion pathways for soluble metal complexes are 
summarized in Figure 2.12.  
There are several types of possible classifications and divisions for CAs such as: 
i) non-specific agents, ii) specific or targeted agents, iii) non-injectable organ-specific 
agents, iv) responsive, smart or bio-activated agents and v) CEST and Hyperpolarized 
agents. 
 
 
 
Figure 2.12. Main distribution sites and excretion pathways for intravenously 
administered soluble metal complexes. 47 
 
 
 
2.3.2.1. NON-SPECIFIC AGENTS  
 
Nonspecific CAs (those that do not interact specifically with any type of cells) 
encompass the extracellular fluid (ECF) agents and the blood pool agents (BPA). The 
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former are low molecular weight extracellular complexes that equilibrate rapidly between 
the intravascular and interstitial space and are mainly excreted by the kidneys.55-58 BPA 
have high molecular weight, such as high generation dendrimers, which stay within the 
intravascular space and are slowly excreted via the kidneys and/or the liver.     55,56,57,58 
The ECF agents leak rapidly from the blood into the interstitium with a distribution 
half-life of about 5 minutes and are cleared by the kidney with an elimination half-life of 
about 80 minutes. ECF agents have been extensively used in extra-cranial applications. 
Since these agents rapidly clear out of the blood, the images are typically acquired in the 
early phase following a bolus injection, when used in conjunction with MRA. The most 
common ECF agents are Gd3+ chelates of linear or macrocyclic polyaminocarboxylate 
ligands and are the main commercially-available MRI CAs. These type of CAs can be 
divided into two groups: neutral and ionic agents (Figure 2.13, Table 2.1). In conclusion, 
Gd3+-based ECF agents are typically safe when used in clinically recommended doses, 
and adverse reactions and side effects, such as allergy, are very rare.  47 
 
 
Figure 2.13. Structures of commercial ECF contrast agents with intravasculsar 
and extracellular distribution.
 36 
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Table 2.1. Properties of commercial ECF contrast agents with intravascular 
and extracellular distribution. 
 
Short Name &   
Generic Name 
Trade Name 
Relaxivity (mM-1s-1) 
0B =1.0 T (37 ºC) 
MRI Enhancement & 
Physiochemical Properties 
Gd-DTPA - Gadopentetate 
dimeglumine 
Magnevist® 
Bayer Schering 
Pharma AG 
1r =3.4, 2r =3.8 positive – charged (ionic) – linear 
Gd-DOTA – Gadoterate 
meglumine 
Dotarem® 
Guerbet 1
r =3.4, 2r =4.8 
positive – charged (ionic) – 
macrocyclic 
Gd-DTPA-BMA - 
Gadodiamine 
Omniscan® GE 
Healthcare 1
r =3.9, 2r =4.3 positive – neutral (non-ionic) – linear 
Gd-HP-DO3A – Gadoteridol 
Prohance® 
Bracco SpA 1
r =3.7, 2r =4.8 
positive – charged (ionic) – 
macrocyclic 
Gd-BT-DO3A - Gadobutrol 
Gadovist® 
Bayer Schering 
Pharma AG 
1r =3.6, 2r =4.1 (at 0.47 T) 
positive – charged (ionic) – 
macrocyclic 
Gd-DTPA-BMEA – 
Gadoversetamide 
OptiMARK® 
Mallinckrodt 1
r =3.8, 2r =4.2 positive – neutral (non-ionic) – linear 
Gd-BOPTA – Gadobenate 
dimeglumine 
MultiHance® 
Bracco 
Diagnostics 
1r =4.6, 2r =6.2 positive – charged (ionic) – linear 
 
 
Blood-pool agents (BPA) or intravascular agents are compounds with larger 
‘sizes’ than the previous ECF agents and also have higher 1r  relaxivities. These two 
characteristics offer many advantages in MR angiography (MRA) when compared to ECF 
agents.14,59 Because their high molecular weight (>20 kDa) prevents leakage into the 
interstitium, they remain in the intravascular system longer than conventional ECF 
agents.60 These agents have been primarily developed for MRA and there main properties 
are to have a relatively long vascular half-life and the highest possible 1r -relaxivity. Their 
r2 relaxivity must be low enough to avoid excessive signal loss due to 
*
22 TT  relaxation.
 47 
 
The potential advantage of using a BPA in MRA is the prolonged imaging window 
given that a longer image acquisition time is granted. This translates into a higher image 
resolution and/or signal-to-noise ratio, therefore higher-quality angiograms may potentially 
be attained when compared to gadolinium-based ECF agents. In this respect, vascular 
abnormalities, associated with certain tumours or atherosclerosis, can be more easily 
detected. Additionally, tissue blood volume and perfusion can be measured.61 The 
disadvantage of this ‘steady-state’ approach is that arteries and veins are equally 
enhanced, thus making their differentiation more challenging. 
 51 
 
According to their action mechanism the BPA can be divided into several 
classes: i) the noncovalent binding of low molecular weight Gd3+ -based complexes to 
human serum albumin –HSA (the most abundant plasma protein) which prevents 
immediate leakage into the intersititial space; ii) systems based on polymers or liposomes 
(increases the size of the CA molecule); and iii) systems based on particles (involves a 
change in the route of elimination). Figure 2.14 and Table 2.2 display several examples of 
these different classes of BPA. 
 
 
 
 
 
Figure 2.14. Structures of some HSA-binding and polymeric Gd3+ complexes, 
as potential or approved blood pool CAs for MRA (simplified structure for 
Gadomer 17).47  
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Table 2.2. Properties of commercial BPA contrast agents. 
 
Short Name &   
Generic Name 
Trade Name 
Relaxivity (mM-1s-1) 
 (37 ºC) 
MRI Enhancement & 
Physiochemical Properties 
MS-325 – 
Diphenylcyclohexyl 
phosphodiester-Gd-DTPA 
Vasovist® 
Bayer Schering 
Pharma AG 
1r =19, 0B =1.5 T 
positive – Albumin binding 
molecules – MRA 
vascularisation, capillary 
permeability 
B-22956 or B-22956/1 – 
Gadocoletic acid 
Bracco SpA 1r =27, 0B =0.5 T 
positive – Reversible albumin 
binding – coronary MRA 
Gadomer-17 or Gd-DTPA-17 
Bayer Schering 
Pharma AG 1
r =11.9, 2r =16.5 0B =0.5 T 
positive – Polymeric Gd complex 
– MRA vascularisation and tumor 
differentiation 
P792 – Gadomelitol 
Vistarem® 
Guerbet 1
r =42, 2r =50 0B =0.47 T 
positive – Polymeric Gd complex) 
– MRA 
Gadofluorine-M _ 
1r =137, 0B =1.5 T 
positive – Polymeric Gd complex 
– MRA  
AMI-227 – Ferumoxtran-10 
Sinerem® 
Guerbet, 
Combidex® 
AMAG 
1r =22.7, 2r =53.1 0B =1.0 T 
Positive or negative – Coated 
USPIO particles – MRA 
SH U 555 C – Ferucarbotran 
Supravist® 
Bayer Schering 
Pharma AG 
1r =14, 0B =1.5 T 
Positive – Coated USPIO 
particles – MRA 
 
 
 
2.3.2.2. SPECIFIC OR TARGETED AGENTS  
 
Specific or targeted agents can also be divided into two main groups: those that 
are actively targeted to a molecularly specific site with an appropriate ligand and those 
that are passively directed to a particular type of cell. The first group includes agents that 
target pathologic processes or states, such as inflammation, angiogenesis, apoptosis, 
atherosclerosis and tumour. The cell labelling CAs function through recognition of specific 
molecular markers of those processes at the cell surface (such as cell-specific receptors 
or transport proteins) and accumulate at those molecular sites (usually in the intracellular 
space). 47 Therefore, these cell labelling CAs are essential for MRI molecular imaging. The 
second main group are the organ-specific agents for the liver (hepatobiliary), spleen, 
lymph nodes, bone marrow or brain, based mainly on the agent size and/or chemical 
structure. Nevertheless, all CAs can be considered organ-specific CAs to some extent, as 
they are excreted either by the liver or the kidneys.  
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Actively Targeted or cell labelling Contrast Agents 
 
The actively targeted or cell labelling CAs are able to recognize specific 
molecular sites (e.g. cell-specific receptors or transport proteins) at the cellular membrane 
and accumulate at those sites. Researchers involved in the synthesis of MRI contrast 
agents devote special attention to these types of agents. The development of agents 
enables the recognition and imaging of a specific ‘signature’ of a given disease (molecular 
imaging) that simplifies the task of diagnosis and therapy.62 One of the requirements for 
efficient molecular probes is the development of high affinity ligands and their conjugation 
to contrast agents Figure 2.15A. A major problem is the need to have a local 
concentration of CA of ca. 0.5 mM in order to have 50% enhancement of contrast. It is 
possible to increase the payload of reporter groups delivered at the target site by using 
manyreporters bound to a single carrier, as illustrated in Figure 2.15B. 
 
 
 
 
Figure 2.15. General structure of a targeted CA for cell labelling a) with a single 
reporter group, b) with a carrier of many reporter groups.47 
 
The main applied targeting strategies are cell-surface targeting and receptor 
targeting. In the former, specific epitopes easily available at the cell surface are targeted 
to which the CA stays bound. This strategy has been used together with the pretargeting 
approach in order to facilitate the detection and imaging of tumour cells (as tumour cells 
are known to have abnormally high negative charges on their cell surface). It is clear that 
A 
B 
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the use of low-molecular-weight targeting CAs that are able to accumulate quickly at 
specific cell surface sites have more advantages with regards to the use of 
macromolecular agents. 47 Another example of cell-surface targeting is the well-known 
non-specific binding of porphyrins to the interstitial space of tumours, e.g. Dy-TPPS 
(TPPS=tetraphenylporphyrin sulfonate). One expanded porphyrin (texaphyrin) complex, 
[Gd(Tex)]2+ (PCI-120), selectively accumulates in tumours, inducing a prolonged 
enhancement in MRI images and provides the possibility of being used as a radiation 
sensitizer for brain cancer.63 
 
The targeting of cell-surface receptors approach can be pursued using labelled 
antibodies or low-molecular-weight targeting complexes. In the first approach, due to the 
slow diffusion of the antibodies, the most accessible targets are those present on the 
endothelial vessels. 47 A typical example is the targeting of the endothelial integrin receptor 
3V , a specific angiogenesis marker whose concentration correlates to the tumour 
grade. An example of an imaging probe containing many reporter groups per carrier is a 
Gd3+-containing polymerized liposome. The pretargeting approach was used, where the 
target was bound first to a biotinylated monoclonal antibody against 3V , which is well 
recognized by an avidin moiety present on the liposome surface carrying the Gd3+ chelate 
reporter groups.64 The same 3V  target has also been grafted with lipidic nanoparticles 
containing Gd3+ chelates.65 The large molecular size and consequently the slow delivery of 
these systems can be considered the major limitation of this technique. 
 
A more efficient way to accumulate CAs at the target site is by cell internalization. 
For this process to be completely successful the concentration of the agent inside the cell 
must be higher than at the cell surface. The internalization processes may occur via 
phagocytosis and pinocytosis (or fluid phase endocytosis) mechanisms, which do not 
require a cell receptor, or receptor mediated endocytosis. 47 Gd-DTPA bis-stearylamide 
derivatives are CAs forming insoluble Gd3+-containing particles that are biodegraded after 
internalization and become soluble and trapped inside the cell.66 Gd-HPDO3A is a CA 
used for labelling stem cells via pinocytosis mechanism where the stem cells are 
incubated in a culture medium containing Gd-HPDO3A with a concentration ranging 10–
50mM.67 The relaxivity of the CA entrapped in the cell endosomic compartment can be 
seriously limited with the exception of the internalization by electroporation, where they 
are delivered to the cytoplasm.68 Other cell internalization mechanisms have used 
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membrane transporters and transmembrane carrier peptides. The latter have proven 
useful for the internalization of a number of substrates like proteins, oligonucleotides and 
plasmid DNA.  
 
Another interesting development was the synthesis of a bimodal (optical and MR) 
imaging probe consisting of a Gd3+/Eu3+-DOTA complex, a PNA (peptide nucleic acid) 
sequence and a transmembrane carrier peptide. 47 This system can enter any type of cell, 
however it accumulates only in tumour cells due to the specific binding of the PNA moiety 
to the c-myc mRNA whose production is increased in those cells.69 
 
 
Passively directed - organ-specific agents 
 
The passively directed or organ specific CAs are passively directed to a 
particular type of cell. Normally, there are organ-specific agents for the liver 
(hepatobiliary), spleen, lymph nodes, bone marrow or brain, and they are generally based 
mainly on the agent size and/or chemical structure. 47 
 
In general, tissue or organ-specific contrast agents consist of two components: a 
magnetic label capable of altering the signal intensity on MR images and a target-group 
molecule having a characteristic affinity for a specific type of cell or receptor. Some 
suitable residues have been incorporated into either the acetic side arms or the 
diethylenetriamine backbone of Gd-DTPA and Gd-DOTA to obtain the tissue or organ-
specific contrast agents. This type of CAs provides specific advantages in terms of 
sensitivity of lesion detection and characterization. Examples of these types of agents are 
the hepatobiliary CAs,70-74 the lymph nodes and bone marrow CAs,75 the brain CAs76-79 
and the gastro-intestinal CAs80,81 that can accumulate in the target sites, increasing 
contrast concentration and can produce stronger signal in the MR images. Table 2.3 
provides a summary of the properties of these CAs. 
70,71,72,73,74 7576,77,78,7980,81 
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Table 2.3. Properties of commercial organ-specific contrast agents. 
 
Short Name &   
Generic Name 
Trade Name 
Relaxivity (mM-1s-1) 
 (37 ºC) 
MR Enhancement & 
Physiochemical Properties 
Gd-EOB-DTPA – 
Gadoxetic acid 
Primovist™ 
(formerly 
Eovist®) Bayer 
Schering Pharma 
AG 
1r =5.3, 2r =6.1 0B =0.47 T 
positive – small charged linear complex 
(ionic) – Hepatobiliary  liver lesions 
Gd-BOPTA – 
Gadobenate di-
meglumine 
Multihance® 
Bracco SpA 1
r =4.6, 2r =6.2 0B =1.0 T 
positive – small charged linear complex 
(ionic) – 
Intravascular/Extracellular/Hepatobiliary  
Neuro/whole body, liver lesions 
Mn-DPDP – 
mangafodipir 
trisodium 
Teslascan® GE 
Healthvare, 1
r =2.3, 2r =4.0 0B =1.0 T 
positive – small charged – 
Pancreatic/Adrenal/Hepatobiliary     
liver lesions 
AMI-25 – 
Ferumoxides (SPIO) 
Endorem™ 
Guerbet,  1
r =40.0, 2r =160 0B =0.47 T 
negative – dextran-coated SPIO 
particles – RES-directed  liver lesions 
SH U 555 A – 
Ferucarbotran 
(SPIO) 
Resovist®  
/Cliavist® Bayer 
Schering Pharma 
AG 
1r =25.4, 2r =151 0B =0.47 T 
negative – dextran-coated SPIO 
particles – RES-directed  liver lesions  
lymph nodes 
Gadofluorine-M _ 
1r =137, 0B =1.5 T 
positive – Polymeric Gd complex – 
lymph nodes  
AMI-227 – 
Ferumoxtran-10 
Sinerem® 
Guerbet, 
Combidex® 
AMAG 
1r =22.7, 2r =53.1 0B =1.0 T 
Positive or negative – Coated USPIO 
particles – lymph nodes 
EPI-2104 R –  
EPIX 
Pharmaceuticals, 
Inc 
- 
Positive – gadolinium-based small 
peptide – lymph nodes - visualization of 
blood clots 
Gd-DTPA 
mesoporphyrin 
(gadophrin) 
Gadophrin  Bayer 
Schering Pharma 
AG 
- 
Positive -  myocardium and necrosis 
targeted 
 
 
 
2.3.2.3. NON INJECTABLE ORGAN-SPECIFIC AGENTS  
 
When ingested, non-injectable organ-specific agents (oral agents) change the 
signal intensity at the stomach and the intestine relatively to adjacent abdominal tissues. 
Depending on their magnetic properties they may change the contrast of the gastro-
intestinal (GI) tract through various mechanisms, thus allowing MR cholangiography 
(Table 2.4). 
Diamagnetic agents, such as fatty emulsions, fill the GI tract with materials with 
short 1T , enhancing its signal and producing positive contrast relatively to adjacent 
tissues. Within the same level, diamagnetic agents can also generate negative contrast 
either by decreasing the 2T  of GI water protons, such as in the presence of Ba
2+, Al3+, 
Si4+-containing suspensions, or by decreasing the proton density through the use of 
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perfluorinated compounds like perfluorooctylbromide (PFOB). 47 Paramagnetic agents, 
such as MnCl2 solutions, Magnevist® [Gd-(DTPA)] or Gadolite® Gd
3+-containing zeolite Y 
particle suspensions,80 ferric ammonium citrate (FAC) solutions, are oral positive CAs that 
decrease the 1T  of GI water protons. Large superparamagnetic particles for oral uptake,
81 
such as Abdoscan®, composed of monodisperse polymer particles of 3 mm diameter 
coated with crystals of iron oxide, or Lumirem®, a silicone-coated superparamagnetic iron 
oxide suspension, belong to the group of negative oral CAs that decrease proton 
*
22 TT . 
Their main purpose is to distinguish the loops of the bowel from other abdominal 
structures. When ingested, they flow through and darken the stomach and the small 
intestine in 30–45 minutes with a clear identification of the intestinal loops, and improving 
the visualization of adjacent abdominal tissues such as the pancreas. 47 
 
 
 
Table 2.4. Properties of commercial non-injectable organ-specific contrast 
agents. 
 
Short Name &   
Generic Name 
Trade Name Relaxivity  
MR Enhancement & 
Physiochemical Properties 
Gd-DTPA – 
gadopentetate 
dimeglumine 
Magnevist enteral® 
Bayer Schering Pharma 
AG 
1T reduction Positive - Paramagnetic 
Ferric amonium 
citrate Geritol 
Ferriseltz ® Otsuka 
Pharmaceutical 
- positive – Paramagnetic 
MnCl2 – manganese 
chloride 
LumenHance® ImaRx 
Pharmaceutical Corp. 
Bracco Spa 
1T reduction  Positive - Paramagnetic 
Gd-zeolyte Y 
particles – Gadolite 
60 gastrointestinal 
Gadolite®Pharmacyclics 
1T reduction Positive - Paramagnetic 
AMI-121 - 
ferumoxsil (USAN) 
Lumirem® / Guerbet 
Gastromark ® AMAG 
Pharmaceuticals 
*
2T enhanced Negative – Superparamagnetic 
OMP – Ferristene 
(USAN) oral 
magnetic particles 
Abdoscan® GE 
Healthcare 
*
2T enhanced Negative – Superparamagnetic 
PFOB - perfluoro-
octylbromide 
Imagent-GI® Alliance 
Pharmaceutical 
Proton density reduction, 
signal void 
Negative – Diamagnetic 
barium sulfate 
suspensions, clays 
mineral particles 
Various Mixtures Diamagnetic, - 1T -short Negative – Diamagnetic 
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2.3.2.4. RESPONSIVE, SMART OR BIOACTIVATED AGENTS 
 
The term ‘responsive’ refers to paramagnetic systems that are sensitive to a 
given biochemical or physiologic parameter that characterizes their microenvironment. 
Typical parameters to which these systems should be responsive are the pH, 
temperature, oxygen pressure, enzymatic activity, redox potential and concentration of a 
specific ion. The use of these agents induces a type of imaging, Molecular Imaging, which 
aims to noninvasively visualize the expression and function of bioactive molecules that 
often represent specific molecular signatures in disease processes. 48 So far, only very 
few of these CA have progressed to in vivo testing. The in vivo non-invasive detection of 
abnormalities in pH or temperature, in the oxygen pressure, in enzymatic activities or in 
the concentration of metal ions and radicals may serve in the future as an important 
diagnostic tool of the underlying diseases. Information on the redox status, an important 
factor governing tumour aggressiveness, can also help determine the adapted tumour 
treatment. Many of these abnormalities are observable in the extracellular media, which 
largely facilitates the chemical design of the imaging probes that have no need for 
intracellular CA delivery. 
 
 
pH-sensitive agents 
 
The potential use of pH-sensitive probes is vast, though so far pH mapping of 
tissues has been primarily intended to facilitate cancer detection and assess the tumour 
status. The pH on the surface of tumours is ~0.4 units lower than that of normal tissue, but 
in some cases it can be as low as 6.0.82 The pH-sensitive probes may also indicate 
neuronal activity because they induce a slight acidification of the extracellular medium (pH 
7.2–7.4).83 One could also imagine the use of pH-responsive probes to determine if the 
brain environment is suitable for a drug that functions in a pH-sensitive environment. 
 
The main requirements for a system to be pH-sensitive are that either the 
dynamics or structural properties determining its relaxivity are pH-dependent. The pH 
dependence of the relaxivity can reflect changes in the hydration number of the metal 
chelates and the presence of protonatable groups on the ligands can influence these 
changes.36,84 ,85,86,87,88,89 
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Designing of pH-sensing probes has become an intensive field in MR imaging 
contrast agent research.49,84-89 Some of the pH probes are useful for in vivo application. An 
example is the combination of the pH-sensitive amido-phosphonate derivative of Gd-
DOTA and a pH-insensitive analogue, which were used in a dual injection to image renal 
pH in mice.90,91 The assumption was made that both compounds have comparable 
pharmacokinetics; hence the concentration of the former can be inferred from the 
concentration of the latter. This mixture has been also used to obtain extracellular pH MR 
imaging maps in a rat glioma model, with improved spatial resolution compared with 
spectroscopic methods.92 Differences in the order of 1 pH unit could be detected; the 
absolute pH values have been calculated by using a calibration method.  
 
The key factor inducing the effectiveness of an agent is the difference between 
the relaxivity of the "on" state compared with that of the "off" state. Recently the amplitude 
of the relaxivity response to pH variation of this low-molecular-weight probe has been 
largely improved (doubled in some cases) by conjugating it to a macromolecular 
dendrimeric scaffold.93 Improving the relaxivity response to pH by increasing the molecular 
weight may also negatively impact the effectiveness of such agents. As already 
mentioned, large molecules, such as dendrimers, remain in the vasculature longer than 
discrete agents, which are better able to diffuse into all extracellular space. Large 
molecules also tend to slowly clear from the body, resulting in increased liver uptake, 
extending their retention time in the body. Further studies into the in vivo behaviour of 
dendrimer-based MR imaging contrast media will be required to establish whether this 
approach, which is successful for increasing the relaxivity response, will yield agents that 
can actually be applied in vivo. 
 
 
Temperature-sensitive agents 
 
 
Most Ln3+ chelates have temperature-dependent NMR properties, such as their 
1H NMR chemical shifts. These shifts can be monitored and used to determine 
temperature variation. For this reason some of these Ln3+ chelates are considered to be 
good temperature probes.94,95 
The encapsulation of Gd3+ chelates into liposomes is also another example of a 
temperature-dependent probe.96 The membrane transition from gel to liquid crystal occurs 
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at a specific temperature. At this precise temperature changes in the permeability of the 
membrane occurs, therefore the mobility of the water molecules through the membrane 
changes and consequently the relaxivity also changes. 47 
 
 
 
Enzymatic activity agents 
 
Among all responsive agents, enzyme targeting represents a specific 
advantage, which is particularly valid for MR imaging detection given its low sensitivity. A 
small concentration of the enzyme can catalytically convert a relatively high amount of the 
enzyme-responsive magnetic probe, which increases the detection for the enzyme 
compared with other biomolecules. In addition, the remarkable specificity of enzymatic 
reactions, which can be observed as changes in the MR imaging properties, can be 
undoubtedly attributed to the targeted enzyme. The presence of certain enzymatic 
reactions indicates the cellular state and can provide the signature of a given pathology. 
Consequently the real-time non-invasive in vivo detection of specific enzymatic activities 
would have invaluable diagnostic impact.  
 
As the enzymatic activity has been established in the processes of tumour 
formation, growth and metastasis, it is vital to monitor it. Molecular Biology studies have 
defined enzymatic steps of the apoptotic response to anticancer therapies in vitro and in 
vivo. Utilising this approach the detection of gene markers (such as β-galactosidase) could 
be another important field of application. 47 
 
The first enzymatically responsive potential MR imaging contrast agent was a 
Gd-DOTA–derivative bearing a galactopyranose residue that avoids water 
coordination.97,98 This sugar moiety is a substrate for the enzyme β-galactosidase. Its 
enzymatic cleavage by β-galactosidase opens the access of water to the first coordination 
sphere of Gd3+, resulting in an enhancement of the relaxivity, thus irreversibly activating 
the agent. This agent has been successfully used in vivo to detect by MRI β -
galactosidase mRNA expression in living Xenopus laevis embryos.  47 
 
Among other examples, Nivorozhkin et al99 reported the enzymatic 
transformation of a prodrug Gd3+ complex with poor affinity to HSA and low relaxivity to a 
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species with improved HSA affinity and enhanced relaxivity. 36 Mazooz et al100 described a 
Gd-DTPA peptide acting as a transglutaminase substrate, which was used to monitor 
transglutaminase activity. 47 Anelli et al101 functionalized Gd(DTPA)2– with sulfonamide, 
which is known as a specific carbonic anhydrase inhibitor. The agent reacts with carbonic 
anhydrase and thus targets enzyme-rich tissues. 47 Shiftan et al102 reported MR imaging 
visualization of hyaluronidase in ovarian carcinoma, related to the aggressiveness  of 
ovarian cancer metastasis. 47 Chen et al103 visualized plaque rupture in atherosclerosis 
with a Gd-DOTA–serotonin derivative, which polymerizes in the presence of neutrophil 
myeloperoxidase, resulting in a remarkable relaxivity increase. Another concept for 
enzyme detection is based on the self-immolative mechanism. 47 Duimstra et al104 reported 
a Gd3+ complex with a self-immolative moiety, designed for the detection of β-
glucuronidase. 47 
 
 
Redox potential sensitive agents 
 
Hypoxia is an important factor governing tumour aggressiveness, as hypoxic 
tissue is more resistant to conventional therapeutics. The methodology of imaging tumour 
redox status would allow the noninvasive application of  this potential biomarker of tumour 
sensitivity to existing and novel chemotherapies, as well as radiation therapy. The 
possibility of using such methods could also extend to other pathologies, such as 
cardiovascular disease, since free radical formation is associated with damaging effects 
on the coronary microcirculation during recovery from myocardial infarction.105 Hypoxia is 
mostly detected by imaging techniques including positron-emission tomography (PET) and 
blood oxygen level-dependent (BOLD) MR imaging. 
Reports on redox-sensitive MR imaging contrast agents have been rather 
scarce. The simplest design of a these agents is based on metal complexes whose metal 
ion can be reduced or oxidized depending on the biologic environment and these  two 
oxidation forms have different relaxation properties. As a result,  the two redox states 
influence the proton relaxation of the surrounding protons to a different extent, resulting in 
different image intensities. 
The partial oxygen pressure (pO2) is also an important parameter in the 
metabolic processes of the cells and its variation is related with certain pathologies.  47 The 
usual systems used as pO2 probes are based on the redox equilibrium of paramagnetic 
ions. In these systems the relaxivity depends on the oxidation state of the metal ion and 
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consequently on the oxygen pressure. It has been reported that the adducts formed 
between tpps complexes of Mn (III) and Mn (II) and poly-β-cyclodextrin have considerably 
different relaxivities depending on the redox state of the metal, itself determined  by the 
partial oxygen pressure of the solution. This technique can quantify the oxygen 
concentration in the surrounding environment.106 
More recently, DOTA-based complexes of Gd bearing a thiol moiety were 
synthesized, and they form reversible covalent linkages with HSA, which contains a 
reactive thiol at cysteine-34. This redox-sensitive reversible binding of Gd complexes to 
plasma albumin was exploited for imaging the tissue-redox state.107 
 
Metal ion and radical agents 
 
It is known that the presence of metal ions can induce changes in the structure 
of the paramagnetic complexes, consequently changing their relaxivities.  47 Considering 
the Ca2+-sensitive MR imaging probes two different approaches have been attempted. 
The first approach uses Gd-complexes with a 1T  response on
 interaction with Ca2+ ions, 
while the second approach uses a 2T  agent based on the Ca
2+-related aggregation of 
superparamagnetic iron nanoparticles and calmodulin.108 Although these strategies have 
several limitations, the main drawback of the second approach is the relatively long time 
course of the Ca2+-dependent aggregation (a few seconds) that prevents the sensing of 
fast Ca2+-concentration changes. 
The design of all Gd3+-based Ca2+ ion–sensitive probes reported so far 
involved changes in the coordination sphere of the Gd3+ ion following coordination of Ca2+. 
These probes integrate 2 coordinating units that selectively chelate Gd3+ and Ca2+ ions. In 
the absence of the sensed Ca2+ ion, one or more of the donor groups of the Ca2+ chelating 
centre, are weakly coordinated to the Gd3+ ion. Concerning the interaction with Ca2+, this 
donor group switches from Gd3+ to Ca2+ coordination, consequently liberating one 
coordination position on the Gd3+ ion. This free coordination position is immediately 
occupied by a water molecule increasing the hydration number and the relaxivity. The 
work of Li et al.109 is an example of this type of agents utilizing this approach. 
Zn2+ is the second most abundant transition metal ion in the body and its 
highest concentrations occur in the brain. Hanaoka et al.  110 used a ligand of DTPA with 
N,N,N’,N’-tetrakis (2-pyridylmethyl)ethylenediamine (TREN) as a zinc specific chelator. In 
the absence of zinc, water is bound to the gadolinium ion. In the presence of zinc, the 
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carboxylic acid and pyridine moieties coordinate to zinc thus restricting the access of 
water to the Gd3+, thereby decreasing the hydration number and respective relaxivity in 
the presence of zinc. 47 
Iron is the most abundant transition metal in the body and in  the brain. Biologic 
iron is most commonly found in the +2 (ferrous) and +3 (ferric) oxidation  states. Aime et 
al.111 synthesized an iron-sensitive contrast agent by functionalizing DTPA with salicylate 
moieties. In the presence of Fe3+ the Gd-DTPA–salicylate complexes bind to the iron ions 
via the salicylate functional groups. The relaxivity increases as this binding yields an 
increase in R . Recently another high-molecular weight tetrametallic supramolecular 
complex [(Ln-DTPA- phen)3Fe]
- (Ln=Gd, Eu, La) has been obtained upon self-assembly 
around one of the three iron(II) ions 1,10-phenantroline- based molecules substituted in 5’-
position with the polyaminocarboxylate diethylenetriamine- N,N,N’,N’,N’-pentaacetate, 
DTPA- phen4-.112 
There are reports of radical responsive CAs, consisting of Gd3+ chelates 
containing a free thiol group (Gd-HASH-DO3A) conjugated through a disulfide bond 
formed with SH-activated phospholipid molecules incorporated in a liposome. The long 
reorientational motion of the supramolecular adduct ensures a 1r  relaxivity much larger 
than that of the free complex. 47 The disulfide bonds represent a radical sensitive moiety 
and a large decrease in the relaxivity is observed upon their cleavage.113 
 
 
 
2.3.2.5. CONTRAST AGENTS BASED ON OTHER PROPERTIES 
 
New classes of MRI CAs have recently been developed, which do not fit into the 
classification mentioned above. These CAs are based on their NMR properties and can be 
grouped into two families, chemical exchange saturation transfer agents (CEST)114 and 
hyperpolarized agents.  
 
 
Chemical exchange saturation transfer agents (CEST) 
 
Basically a CEST agent is a molecule possessing exchangeable protons (-NH, -
OH, etc.) that resonate at a chemical shift different from that of the bulk water signal, 
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measurable when their exchange with the bulk water protons is slow on the NMR 
timescale. This occurs when the difference in frequency between those chemical 
environments (  ) is higher than the exchange rate of the process ( exk ). When this 
condition is fulfilled the resonance of the CEST mobile protons may be selectively 
saturated using a specific radio frequency 1B . These protons will then transfer into the 
bulk water pool and lead to a reduction of its equilibrium magnetization, resulting in a 
decrease of its signal intensity. Consequently this water saturation process is caused by 
chemical exchange (see Figure 2.16). CEST agents can be used to switch the image 
contrast ‘on’ and ‘off’ just by changing the irradiation parameters.  47 
 
 
k
ex CEST
Agent
water molecule
mobile proton of CEST agent
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Figure 2.16. a) CEST agent illustration b) Schematics of the chemical 
exchange saturation transfer (CEST) method using molecular separation of 
encoding and detection for significant signal amplification. The resonance of 
the detection molecule at high concentration (in this case, water) is observed 
after off-resonance saturation (left spectrum) and after on-resonance 
saturation (right spectrum) of a highly diluted CEST agent. 
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Several agents contain exchangeable protons and consequently can generate 
CEST contrast.115 Their signals are often very close to the bulk water signal, and broader 
than 2 ppm, due to the magnetic field inhomogeneity of many tissues.116 Within these 
conditions it is difficult to distinguish contrast due to the CEST effect and the direct 
saturation of bulk water. Large   values improve the specificity of the CEST and, as 
  increases with the magnetic field strength, the overall relationship between   and 
exk  will be a function of the field strength of the MR experiment.
 47 
Since the attainable saturation transfer (ST) value is directly related to exk , it is 
expected that paramagnetic complexes will display large   values for the exchanging 
proton resonance and thus may improve the efficacy of the CEST agents. These agents 
are called PARACEST agents and consist of particular Ln3+ complexes with a coordinated 
water molecule undergoing extremely slow exchange with the bulk water and with very 
large   values. A good ST effect was reported by Zhang et al.117 by irradiating the 
metal-bound water protons of Eu3+ chelates resonating at 50 ppm downfield from the bulk 
water. The very same effect can be obtained with slow exchanging amide protons of Ln3+ 
complexes of DOTA derivatives.118 Recent reports show that paramagnetic Ln3+ 
complexes of tetraamide derivatives of DOTA have ST properties which are markedly 
dependent on pH and lactate concentration, making them responsive CAs.119,120,121 
The main advantage of CEST agents relatively to the traditional MRI CAs is that 
the generation of contrast only occurs when the RF irradiation frequency is set to the 
same frequency as the absorption frequency of the mobile protons.  49 For this reason it is 
not necessary to register an image before the administration of the CEST agent, as the 
image visualization of CEST agents results from the comparison of the on and off 
resonance MRI scan. Co-administration of different CEST agents is also possible as the 
difference within the resonance frequencies of their mobile protons is large enough to 
avoid the overlapping of the respective CEST resonances. The detection of their 
biodistribution is possible and observable within the same image.122 
The most critical disadvantage of CEST agents is their low sensitivity. 
Theoretically, the ST process is dominated by several parameters, among which exk  and 
the number of mobile protons available are particularly relevant.  47 In the case of small 
sized CEST agents, containing less than 10 mobile protons per molecule, such as amino 
acids, heterocyclic compounds, sugars or paramagnetic chelates, they have a detection 
limit in the range of mM.114,119,123,124 Several approaches to solve this problem were 
suggested.114,125-127 ,126,127,128 
 
Magnetic Resonance Imaging Background Concepts 
 
 
66 
 
Hyperpolarized agents and molecular imaging using MRI. 
 
Undoubtedly MRI provides incomparable soft tissue contrast, however its low 
sensitivity has limited the clinical use to the imaging of water protons. A radically new 
magnetic resonance imaging (MRI) technique, using hyperpolarized 3He, 129Xe, 13C, 15N 
and 6Li is being developed to produce high-contrast images of important body tissues that 
have resisted conventional MRI techniques. A totally different approach for increasing the 
polarization of spins is to create an artificial, non-equilibrium distribution of nuclear spins 
called the hyperpolarized state49. A hyperpolarized state is defined as a state in which the 
nuclear spin populations are altered with respect to the equilibrium value described by the 
Boltzmann equation. Since the signal intensity is proportional to the spin population’s 
difference, hyperpolarization leads to an increase in the NMR signal intensity by a factor 
as high as 105. 48 Hyperpolarization can improve the detection of 3He and 129Xe by up to a 
hundred thousand times. This technology is showing dramatic results for diagnostic 
imaging of the lungs, brain, and other parts of the body.49 A wide range of organic 
substances containing 13C has been hyperpolarized by either parahydrogen-induced 
polarization (PHIP)129 or by dynamic nuclear polarization (DNP).130 The potential 
applications of hyperpolarized 13C imaging include vascular imaging, perfusion imaging131, 
catheter tracking132 and visualization and metabolic/molecular imaging.133 
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3.1. OPTICAL IMAGING 
 
 
Unlike any other imaging modality, optical imaging derives from the fact that it is 
possible to combine conventional display of tissue volumes using direct-optical, 
transillumination or tomographic techniques, with the capability of gaining information on 
molecular properties and function due to the high instrumental sensitivity for optical 
signals. Taking into account the various principles of optical imaging methods but not 
disregarding the limitation of penetration depth and spatial resolution in thick tissues, a 
number of potential applications are envisioned for clinical diagnostics. Over the past few 
years optical imaging techniques have joined the available methods for the assessment of 
tissue anatomy, physiology, metabolic and molecular function. This technology is 
attracting a lot of interest due to the fact that fluorescent dyes can be detected at low 
concentrations and non-ionizing, harmless radiation can be applied repeatedly to the 
patient. This technology has the additional advantage that it is less expensive (compared 
to other imaging techniques), small in size and, therefore, easily at hand to solve clinical 
problems. Table 3.1 summarizes the range of applications of optical imaging. The two 
leading imaging technologies are optical coherence tomography (OCT) and diffusion 
imaging. 
 
Within this perspective the design of contrast agents for optical in vivo imaging of 
diseased tissues has gained a remarkable vitality.1,2 Light is one of the most convenient 
vectors for transmitting signals that can easily reach regions of a complex molecular 
structure that are not accessible to other molecular messengers. When appropriate 
wavelengths are used, penetration depth may be substantial and light can reach regions 
of complex molecular structure which are not accessible to other molecular probes. 
Sophisticated contrast agents have been synthesized and characterized for their 
capability to monitor disease-specific anatomic, physiological and molecular parameters 
through their optical signals. 
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Table 3.1. Major application areas of optical imaging. 
In vivo optical imaging In vitro diagnostics 
Non invasive clinical imaging 
 Tissue imaging 
 Microvascular 
 Ophthalmology 
 Dermatology 
 Brain 
 Breast 
 
 
Preclinical imaging 
 Pharmacokinetic 
 Drug-efficacy testing 
 
 
 Genomics 
 Proteomics 
 Microarray readers 
 
Patient monitoring 
 Biosensor implants 
 Pulse oximetry 
 
 Biosensors 
 Pathogen detection 
 Point-of-care diagnostics 
 
Intraoperative 
 Optical imaging 
 Cancer-cell detection 
 
 
 
 
Semiconductor quantum dots (QDs) (e.g. CdSe nanocrystals with 2-10 nm 
diameter) and their bioconjugates are potential canditates as they are highly luminescent, 
tunable in the entire visible range and display a superior photostability compared to 
organic luminophores. This type of nanoparticles (NP) have been exploited for both in 
vitro analyses and in vivo imaging. Although their has been some reports regarding QDs 
with near-infrared (NIR) emission and with low toxicity Therefore, their introduction into the 
biological and medical media has been still slow.3,4,5 Alternately trivalent lanthanide ions, 
Ln3+, present another option to organic luminescent stains in view of their singular 
properties. They enable easy spectral and time discrimination of their emission bands 
which span both the visible and NIR ranges. 
The very first staining of biological cells with lanthanides dates back to 1969 
by Scaff et al.6 Bacterial smears (Escherichia coli cell walls) were treated with 
aqueous ethanolic solutions of europium chelate of 4, 4, 4-trifluoro-1-(2-thienyl)-
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1,3-butanedione (thenoyltrifluoroacetonate, TTA) and bright red spots appeared under 
mercury lamp illumination. Only in the mid-1970s that further attention was accorded to 
luminescent lanthanide bioprobes when Finnish researchers in Turku proposed Eu3+, 
Sm3+, Tb3+, and Dy3+ polyaminocarboxylates and β-diketonates as luminescent sensors in 
time-resolved luminescent (TRL) immunoassays.7,8 This technological push projected 
broader interest and subsequent developments. Examples of these developments can be 
found in homogeneous TRL assays,9 optimization of bioconjugation methods for 
lanthanide luminescent chelates10 and time-resolved luminescence microscopy (TRLM)11 
that resulted in applications of lanthanide luminescent bioprobes (LLBs)12,13 in many fields 
of biology, biotechnology and medicine, including tissue14,15 and cell imaging,16,17 analyte 
sensing18 and monitoring drug delivery.19 
In order to design optical contrast agents it is necessary to first understand the 
concept of luminescence, the optical properties of tissues as well as comprehend the 
existing technology. 
 
 
3.2. LUMINESCENCE 
 
The term “Luminescence” was defined in 1888, by the German physicist Eilhardt 
Wiedemann, as the light emission characteristics not conditioned by an increase in 
temperature.20 Within this thesis IUPAC rules21 regarding molecular luminescence 
spectroscopy will be used, where the term ‘‘fluorescence’’ is used for processes which 
occur without change in spin. These are typically 01 SS   (singlet to singlet ground state) 
or 27
2
25
2 FF   (Yb3+) transitions and ‘‘phosphorescence’’ for transitions implying a change 
in spin, most commonly 01 ST   (triplet to singlet ground state) or JFD
7
0
5   (Eu3+) 
transitions. The energy type used in the excitation of a luminescent material can be used 
to classify luminescent processes, as photoluminescence, when the excitation is by 
electromagnetic radiation; cathodoluminescence, when a beam of electrons is used; 
electroluminescence, when excitation is effected by an electric voltage; 
triboluminescence, when mechanical energy is the source of excitation; and 
chemiluminescence, when energy of a chemical reaction is employed.22  
Not all materials exhibit the luminescence phenomenon even though their molecules 
can be excited to a higher state. This is due to the existence of a non-radiative pathway in 
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the return to the ground state (GS). This transition from a vibration energy level of an 
excited state to a vibration energy level of the GS is called internal conversion. The 
population of an excited state and the energy difference between the GS and excited 
states are among the important factors that affect the luminescence of a material. Figure 
3.1 illustrates some of the typical processes involved in luminescence. The emission 
quantum yield indicates the efficiency of the luminescent material and will be defined in 
the next section.23 
 
Figure 3.1. Partial energy-level diagram for a photoluminescent system.24 
 
 
LANTHANIDE LUMINESCENCE 
 
 
The complex optical properties of the trivalent lanthanide ions, Ln3+, derives from 
special features of the electronic [Xe] 
Nf4  configuration (N=0-14)). The third ionization 
state is characterized (with the exception of lutetium, cerium and gadolinium) by the 
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removal of two electrons from the 6s orbital and one form the 4f orbital. Lanthanides (Ce–
Lu) are unique among the elements (with the exception of the actinides) in markedly 
resembling each other in their chemical properties, particularly regarding oxidation states, 
due to their electronic configuration.25,26  
 
These configurations generate a large variety of energy levels. Figure 3.2 displays 
partial energy diagrams for the lanthanide aquo ions.21 Eu3+, Gd3+, and Tb3+ are the best 
ions with respect to the energy gap requirement (as larger is that energy gap higher is the 
probability of radiative transitions) as they present a larger band gaps when compared to 
other trivalent lanthanides with E =12 300  6705 FD  , 32 200  278276 SP   and 14 800 
 0745 FD  , cm-1, respectively. Gd3+ emits in the UV and it is not very useful as a 
luminescent probe since its luminescence interferes with either the emission or absorption 
processes in the organic part of the complex molecules.23 The Russel-Saunders spin-orbit 
coupling scheme* is normally used to characterize these energy levels, that is  based on 
three quantum numbers, S , L  and J . It should be noted that this sheme does not 
characterize completely the energy levels, nevertheless, it is the commonly used.27 The 4f 
electrons are not the outermost ones and they are “shielded “ from external fields by the 
two electronic orbitals 5s2 and 5p6 with larger radial extension. Thus 4f electrons are only 
weakly perturbed by surrounding ligands charges resulting in special spectroscopic 
properties with parity-forbidden ff 44   absorptions that have characteristic narrow-line 
emission (high purity). The emission occurs mostly in the visible and near-infrared (NIR) 
ranges and with very low molar absorption coefficients, ε (or absorption cross-sections, 
σABS). These are typically < 10 mol
-1 cm-1 ( or σABS < 4 × 10
-20 cm2) when compared with 
                                                             
*
 In this notation the orbital angular momenta of the individual electrons add up to form a resultant 
orbital angular momentum L . Within the same strategy the individual spin angular momenta are 
presumed to couple to produce a resultant spin angular momentum S . Finally L and S  combine 
scattering events and form the total angular momentum J . In Russel-Saunders coupling scheme, 
the terms J  and S  define one of the )12)(12(  LS terms (or multiplets) of the configuration, 
generic represented by J
S L)12(  , where )12( S  indicates the spin multiplicity. 
 






LSSLSL
LSLSLS
J
,...,
,...,
 (3.1) 
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the molar absorbtion coefficient for dd 33   transitions values that are10 times higher, or 
for ligand-to-metal charge-transfer (LMCT) transitions that are 100 times higher.28 
 
These transitions are formally parity-forbidden, the lifetimes of the excited states are 
long, which allows the use of time-resolved detection, a definitive asset for bioassays,29-34 
and luminescence microscopy.11,35,36 2930313233343536 
 
 
 
 
Figure 3.2. Partial energy diagrams for the lanthanide aquo ions. The main 
luminescent levels are drawn in red, while the fundamental level is indicated in 
blue.23 
 
The direct Ln3+ photoexcitation is not very efficient as already mentioned. The 
design of lanthanide complexes, in which the ligands incorporate organic chromophores 
strongly bonded to the f4  metal center, improves significantly the Ln3+ luminescence 
intensity. Weissman demonstrated in 1942 that the excitation of lanthanide complexes into 
the ligand states result in metal-centered luminescence. Part of the energy absorbed by 
the organic receptor(s) is transferred onto Ln3+ excited states and sharp emission bands 
originating from the metal ion are detected after rapid internal conversion to the emitting 
level. These chromophores typically present effective absorption cross-sections 104–105 
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times higher and over a much broader spectral range than the Ln3+ corresponding ones. 
The phenomenon is termed sensitization of the metal-centered luminescence (also 
referred to as “antenna effect”) and is quite complex.37  
When the Ln3+ ions are introduced into a host, the ion experiences an 
inhomogeneous electrostatic field, the so-called crystal field, which is produced by the 
Ln3+ ligands. In addition to the splitting of the energy of the f4  orbital by spin-orbit 
coupling, individual J levels of a lanthanide ion are split further by the crystal field into a 
maximum of 2J+1 components, depending on the local symmetry of the Ln3+ ion, making 
the lanthanide emissions extremely sensitive to their environments. Figure 3.3 displays a 
schematic representation and order of magnitude of the effects of the intra-atomic and 
ligand field interactions acting on the 
Nf4  configuration, in particular of the Eu3+ ion. 
The ff 44   transitions have essentially electric-dipole (ED) and magnetic dipole 
(MD) character. ED transitions require a change of parity of the electron wavefunction 
and, then, they should be strictly forbidden within the f4  configuration (due to the Laporte 
selection rule). Contrarily, MD transitions between those levels are permitted. For Ln3+ 
ions localised in crystalline sites without inversion symmetry, however, a mixing of 
opposite-parity states into the 
Nf4  levels occur resulting in a relaxation of the Laporte 
selection rule and then in the observation of intra- f4  forced ED transitions. 
Important parameters such as radiative lifetime values, emission quantum 
efficiency and quantum yield should be determined in order to adequately 
characterize an optical material. The concepts referred in this thesis are further 
described in Carlos L.D et al. .28 The radiative lifetime ( RAD ) for a given '' Jf
N  
excited state is obtained as the reciprocal of the total transition radiative probability 
TA , which is the sum of all possible radiative decay rates from the state 'J  
towards lower levels J . The RAD  is given by:
 28 
 


J
JJT
RAD
AA '
11
  (3.2) 
where JJA ' , the radiative transition probability, or Einstein’s spontaneous 
emission rate. 
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Figure 3.3. Schematic representation and order of magnitude of the effect 
intra-atomic and ligand field interactions acting on the 
Nf4  configuration of 
the Eu3+ (Top) and Tb3+ ions (Bottom).38 
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The emission quantum efficiency of a given excited level 'J  (also refereed by some 
authors as intrinsic quantum yield39) is given by the ratio between the radiative decay rate 
and the total decay rate. This expression also includes all other processes contributing to 
the depopulation of level 'J , such as nonradiative decay paths and energy-transfer 
processes.28 
 
The emission quantum efficiency ( ) is calculated by: 
NRADRAD
RAD
RAD
EXP
AA
A




  (3.3) 
where the radiative lifetime described above and the experimental lifetime 
 NRADRADEXP    are given by the reciprocal of the total decay rate.
28 
 
The emission quantum yield ( ) is an experimentally evaluated quantity given by 
the ratio of the number of photons emitted and the absorbed photons and can be 
described by: 
 
photonsabsorvedofnumber
photonsemittedofnumber


  (3.4) 
 
Typically, the emission quantum yield includes the absorption efficiency, the 
intersystem crossing efficiency, the donor–Ln3+ energy-transfer efficiency, the intra-Ln3+ 
nonradiative decaypaths efficiency, , and the 'J -level emission quantum efficiency  . 
According to equation 3.4 we can denote that    If all the energy absorbed by the 
ligand excited states are transferred to the Ln3+ excited levels.28 
In the particular case of the Eu3+ ions the intra- f4  transitions generally occur 
between the JFD
7
0
5   ( 60J ) levels. These transitions are essentially of the induced 
ED type, with the exception of the 1
7
0
5 FD   transition that is a 100% MD transition. 
Attending to the pure MD character of the 1
7
0
5 FD   transition it is possible to determine 
intensity parameters from the emission spectrum. Since this transition does not depend on 
the local ligand field seen by Eu3+ it can become a reference for the entire spectrum. The 
1
7
0
5 FD   spontaneous decay rate, 01A , is given by 
3
0101 ' nAA  , where 
1
01 65.14'
 sA in 
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vacuum.40 Within these parameters it is possible to express the intensity of the 60
7
0
5
 FD  
transitions, JI0 , in terms of the area of their emission curves, JS0 :
28 
 
  JJJ SDNAhcI 00500    (3.5) 
 
where  05DN  is the population of the 05D  emitting level; it is possible to express 
the total radiative decay rate as: 28 
 
 
 

6
0
6
0 0
0
01
010
0
J J J
JJ
JT
hc
S
S
hcA
AA


 (3.6) 
 
It should be noted that the radiative contribution can be calculated from the relative 
intensities of the 40
7
0
5
 FD  transitions, as the branching ratio for the 6,5
7
0
5 FD   
transitions should be neglected due to their poor relative intensity. As already mentioned 
above, the emission quantum efficiency is defined by the ratio between experimental and 
radiative lifetimes. The intensity parameters  will be given by:
28 
 
    J
J
A
FUDnne
h
02
7
0
5
22324
1
2
9
64
3


 
  (3.7) 
 
with 6,4,2 J . Values for the squared reduced matrix elements are 0.0032 and 
0.0023 for 2 J  and 4 J , respectively. 28,41 As previously mentioned, the 
6
7
0
5 FD   transition has very low intensity making it very difficult for the determination of 
the rank 6 parameter. 
The sensitivity of the f4  transitions can be used to obtain further information about 
the metal ions local environment in addition to providing information on the light-emission 
properties of the Ln3+-containing materials. In the case of the Eu3+ ion this important 
feature is even more prominent, since Eu3+ is a powerful local ion probe due to its peculiar 
spectroscopic characteristics. These characteristics include:28 
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 A large energy difference (gap) between the 0
5D  first excited state and the 
high-energy 6
7F  level of the fundamental septet (ca. 12300cm-1). Given that 
for smaller gaps the desactivation through nonradiative process (e.g., O–H 
vibrations) is more likely to happen; 
 A non-degenerated first excited state that allows a simpler Stark-effect 
analysis, with the subsequent correspondence between the observed J-
splitting degeneracy and the Eu3+ local-site symmetry; 
 The presence of the ligand-field-independent 1
7
0
5 FD   magnetic-dipole 
transition, as discussed above; 
 The presence of a single 0
7
0
5 FD   line permitted for Cs,C1,2,3,4,6, and C2v,4v,6v 
point symmetry groups with a predominantly electric-dipole nature, explained 
by J-mixing effects.42,43,44 The energy of this non-degenerated transition can 
be directly related to the covalency of the chemical bonds of the first 
coordination shell in Eu3+ (the so called nephelauxetic effect);45 
 The observation of vibronic lines in a relatively large spectral region of the 
2
7
0
5 FD   excitation transition (24400–21550 cm-1) allows the identification of 
vibration modes related to the Ln3+ local environment up to ca. 3000 cm-1; 
 The presence of ligand-to-metal charge-transfer (LMCT) in the UV-vis region 
of the excitation spectra assigned to particular ligand groups. 
 
Important information about the metal-ion local coordination can be extracted from 
three distinctive parameters: i) the changes in the number of Stark components of each 
intra- f4  manifold and the variations of their relative intensity, ii) differences observed in 
the energy of particular lines, and iii) the analysis of the excited-state decay curves. 
Examples of the information extracted from these distinctive parameters are the existence 
of more than one Eu3+ local symmetry group, the number of coordinated water molecules, 
the magnitude of the ligand field, and the importance of the covalency of the Eu3+-ligands 
bonds.28 
 
The large values usually found for the full width at half maximum (fwhm) of the non-
degenerated 0
7
0
5 FD   line typically range from ca. 20 to 30 cm-1.46 They indicate that the 
matrix where the Eu3+ ions are accommodated has a large distribution of similar local 
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sites. In the case where the Eu3+ local symmetry group does not present an inversion 
centre, the Laporte’s rule is relaxed due to odd parity terms in the ligand field 
Hamiltonian,38 and the emission spectrum will be dominated by the 2
7
0
5 FD   transition. 
For Eu3+-containing materials the number of water molecules ( wn ) in the first coordination 
shell may be obtained by the difference between the decay time values measured in H2O 
and D2O as:
28 
 








 31.0
11
11.1
22 ODOH
wn

 (3.8) 
 
where OH2  and OD2  are the decay times in milliseconds in water and in D2O, 
respectively, taken in this latter case as the purely radiative decay. As mentioned above, 
the purely radiative decay may also be calculated through the experimental emission 
spectrum and therefore RAD  can be used in Equation 3.8 substituting OD2 ; while the 
value obtained experimentally for the decay EXP  is used to substitute OH2 . In conclusion 
wn  can be calculated for many different Eu
3+-containing material within different medias. 
 
 
3.3. TISSUE OPTICAL PROPERTIES 
 
The optical properties of tissues are characterized by the use of light within the 
ultraviolet (UV) and the near-infrared (NIR) spectral region. The interaction of photons with 
tissue is based on three processes: i) absorption of light, ii) scattering of light and iii) 
emission of fluorescence. Tissue optical properties can be characterized by using these 
parameters separately.47 As the penetration depth of light in living tissue strongly depends 
on the wavelength used,48 the correct wavelength range should be chosen (since the 
amount of absorption in tissue is a function of the wavelength). Normally, the extent of 
scattering in tissue decreases with increasing wavelength. For wavelengths below 600 
nm, absorption dominates scattering resulting in a small penetration depth of hundredths 
of micrometers up to a few millimetres, so that only superficial assessment of tissues is 
possible in this spectral region. 
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When direct visual inspection or characterization is used through microscopic 
techniques high spatial resolution images of tissue structures is obtained. Some examples 
are the examination of tissue surfaces using optical fibres incorporated into endoscopes 
or laparoscopes, as well as of ocular diseases through ophthalmoscopes and the direct 
assessment of skin diseases or tissues during surgical procedures.43 
 
Light absorption in tissue originates from oxy- and deoxyhemoglobin, other 
porphyrins, melanin and structures involved in cellular metabolism (such as NADH and 
flavins) as well as from several structural tissue components (such as collagen), elastin 
and lipo-pigments. Most of these compounds exhibit characteristic fluorescence spectra 
(tissue autofluorescence) throughout the visible (VIS) spectral region up to approximately 
700 nm.49,50 Fluorescence presented by these fluorescent markers provides additional 
information on tissue structure and pathophysiological states.49,51 This tissue 
autofluorescence phenomenon has already been thoroughly exploited to extract spectral 
patterns which indicate diseased tissue areas, e.g. in lymph node characterization;52 
endoscopy of the gastrointestinal tract50,53,54 or cardiovascular diagnosis.55  
 
In order to image a large tissue volume light within the spectral range (700–900 nm) 
is necessary as the tissue absorption coefficient is relatively low (resulting in penetration 
depths up to a few centimetres (figure 3.3).56 It is also possible to identify inhomogeneities 
as they exhibit a difference in absorption or fluorescence when compared to bulk tissue. 
 
Due to the scattering process photons do not follow straight paths when propagating 
through tissue and mathematical models of photon transport are needed to calculate the 
optical properties of tissue.43 This process limits the spatial resolution of the obtained 
image, where morphological and structural tissue parameters are not accessible. Tissue 
absorption is mainly determined by oxyhaemoglobin, deoxyhaemoglobin and water, which 
exhibit a well defined absorption minimum in the NIR spectral region (figure 3.3) and 
provide information that can be utilized to quantitatively calculate important physiological 
parameters, such as blood concentration (total haemoglobin) and oxygenation (ratio 
oxy/deoxy haemoglobin).57 The absorption data, together with tissue-dependent scattering 
properties, can be fitted by mathematical models to reconstruct the most probable photon 
propagation throughout the tissue in order to generate a spatial map of tissue optical 
properties for a given illumination and detection geometry. This method has predominantly 
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been applied in the detection of breast tumours and imaging brain functions. Photon 
migration and diffuse light imaging are comprehensively described in reference.58 
 
Figure 3.3. Absorption coefficients of oxyhemoglobin and deoxyhemoglobin as 
a function of wavelength. The near-infrared window of tissue is defined as the 
spectral region between approximately 700-900 nm, where the absorption 
coefficients are at minimal levels.59 
 
 
3.4. OPTICAL IMAGING TECHNOLOGY 
 
Over the past decade different types of optical imaging techniques have been 
developed for biomedical applications. These include various microscopy methods such 
as confocal microscopy, two-photon microscopy and coherent anti-Stokes Raman 
scattering (CARS) microscopy for in vitro and ex vivo applications as well as several 
methods for in vivo applications such as bioluminescence imaging, fluorescence imaging, 
diffused optical tomography and optical coherence tomography.43 Several of these 
techniques can be used in combination, either simultaneously or sequentially, to provide 
complementary information from the same cells, tissues, organs or animals.60,61 
Both bioluminescence and fluorescence imaging techniques have found wide 
applications for in vivo tumor optical imaging in mouse models, providing a non-invasive 
method with high resolution and a convenient real-time, high frequency visualization and 
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measurement of tumor biomarkers. The detection of disease progression and therapeutic 
response in the same animals is also possible. This minimizes the subject-to-subject 
variability and reduces the animal number required by a traditional method.43 Most 
importantly, these in vivo studies can bridge the gap between in vitro (cell/tissue level) and 
in vivo (the whole animal) studies, while facilitating preclinical and further translational 
studies.61 
Bioluminescence imaging (BLI) is typically based on the ATP- and O2-dependent 
enzymatic conversion of exogenous luciferin to oxyluciferin by luciferase within living cells. 
This reaction can produce photons with a broad yellow emission spectrum with a peak 
around 560 nm, detectable with a highly sensitive charge-coupled device (CCD) camera 
at 10-12 min after intraperitoneal injection of luciferin. The bioluminescence phenomena 
can last over 60 min in mice, providing multiple images of disease progression and 
therapeutic response based on the changes in the number of cells with luciferase 
expression or transcriptional activity. BLI has allowed quantitative measurements of tumor 
loadings, treatment response, immune cell trafficking and detection of gene transfer. It is 
also possible to obtain spatio-temporal information of whole biological systems in vivo 
within a short time frame that may accelerate the development of experimental therapeutic 
strategies.61,62,63 
On the other hand, fluorescence imaging has an entirely different methodology that 
consists of exciting certain fluorophores in a living system by using external light and 
detecting fluorescence emission with a sensitive CCD camera. 
There are several types of fluorophores: i) endogenous molecules (such as collagen 
or hemoglobin), ii) exogenous fluorescent molecules such as green fluorescent protein 
(GFP) or iii) small synthetic optical contrast agents. When compared to in vitro 
fluorescence microscope, in vivo fluorescence imaging is a complex process affected by 
many factors.43 One of the major limitations of in vivo fluorescence imaging is light 
attenuation and scattering due to adjacent living tissues. As previously mentioned light in 
the near infrared (NIR) range (650-900 nm) can improve the light penetration.61,62,64 It can 
also minimize the autofluorescence of some endogenous absorbers such as hemoglobin, 
water and lipids. In a full-body mouse illumination experiment, photon counts in the NIR 
range (670 nm) are about four orders of magnitude higher when compared to those in the 
green light range (530 nm) under similar conditions. Hence NIR fluorescence imaging has 
proved to be an effective solution in improving the imaging depth along with sensitivity and 
specificity. As a result NIR-fluorophores are important for successful in vivo optical 
imaging and future clinical applications. 
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3.5. OPTICAL CONTRAST AGENTS 
 
As mentioned in the previous chapter, the general definition of Contrast Agents 
(CAs) is a chemical substance introduced to the anatomical or functional region being 
imaged in order to increase the differences between different tissues, or between normal 
and abnormal tissue. 
Optical contrast agents are frequently used to stain portions of biological samples in 
order to obtain a greater understanding of the molecular, cellular and physiological 
changes at hand. Two important classes of these agents are the colorimetric and 
fluorescent markers. Colorimetric contrast agents modify the light absorption resulting in a 
contrast of observed colour; while fluorescent agents also modify light agent, fluorescent 
absorption, but subsequently re-emit a portion of the absorbed light at higher wavelengths 
(lower energy).43 This phenomenon is leveraged to achieve greater sensitivity with the use 
of fluorescent markers. Through non illumination of the sample with light at the emission 
wavelengths of the fluorophore(s) present an enhanced signal to noise ratio will be 
achieved. In recent years, the attractiveness of fluorescent microscopy in biological 
sciences has grown; however, many challenges are still to be overcome in the application 
of fluorescent markers in biological systems. For instance, organic dyes are prone to rapid 
photobleaching limiting their application to long-term bioimaging investigation.65,66 Many 
other dyes also have relatively broad emission spectra complicating their integration into 
multicolor imaging applications. In bioimaging, additional artifacts such as high light 
scattering via tissue interfaces, autofluorescence, and absorption by hemoglobin (Hb) in a 
mid-visible wavelength range are observed. The application of NIR range (650 to 900 nm) 
contrast agents can overcome many of these issues and is preferred for bio-imaging thick 
tissues. The development of NIR imaging agents such as NIR quantum dots (QDs) and 
dyes (e.g. cyanine dyes) have recently attracted significant attention.67,68 In the case of 
optical imaging CA, they are normally molecules or nanoparticles bearing one or more 
fluorophores. Typical optical imaging CAs are injected intravascularly or intraperitoneally 
and allowed to accumulate at the target site over several hours to days. Fluorophores can 
be endogenous molecules (such as collagen or hemoglobin), exogenous fluorescent 
molecules such as green fluorescent protein (GFP) or small synthetic optical CAs. 
Within the last decades multifunctional contrast agents have emerged substantially 
with the attempt to obtain the benefits of multiple imaging modalities with the use of a 
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single contrast agent.69,70 One example can be found in the fluorescent and MRI active 
probes that allow for simultaneous detection by MRI and fluorescence microscopy by 
combining the advantages of 3D anatomical resolution at cellular level from MRI with the 
high sensitivity offered by fluorescence microscopy in a single particle. 
 
 
Organic dyes 
 
Organic dyes, such as rhodamine and fluoresceins are the earliest and most 
classical luminescent materials employed in optical agents. Nevertheless, these dyes 
have some problematic limitations that are critical to the quality of optical imaging. Broad 
emission bands (which can pose a problem in multiplexing and sensitivity), short 
luminescence lifetimes ca. 10-9 s, a small Stokes shift (difficulty in separating the 
excitation and emission signals), poor photochemical stability and susceptibility to 
photobleaching (photochemical destruction of the fluorophore) on the 71,72 are the basic 
drawbacks of these type of agents. Several attempts have been made in order to create 
new fluorescent dyes that are more resistant to photobleaching and insensitive to pH 
changes. The problem of short lifetimes and Stokes shift has still not been satisfactorily 
overcome. Despite these setbacks organic dyes continue to be very popular due to their 
low cost, high availability and practicality.72 
 
 
Quantum dots 
 
Quantum dots (QDs) are crystalline semiconductors typically less than 10 nm in 
diameter and are considered to be another promising luminescent tag for optical imaging. 
They are reported to be several thousand times more stable against photobleaching, 
much brighter and have a spectral width reduced by up to one-third from conventional 
organic dyes.73,74 
One of the special features of QDs is its emission wavelengths variation that is 
strongly size dependent: They can emit different colours spanning the entire visible/NIR 
region within the same material by merely changing the size of the particles. This is a 
consequence of the so called quantum confinement effect: a confinement of the hole and 
electron wave functions in the nanocrystals when the size of the particles are reduced 
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beyond the bulk-exciton Bohr radius, and consequently, an increase in the semiconductor 
band gap.72-78 A combination of the broad absorption bands of QDs, narrow emission 
bands and their size dependent emissions offer the possibility of using them to tag 
biomolecules in ultrasensitive biological detection and in bioapplications such as gene-
expression studies, high-throughput screening and medical diagnostics based on optical-
coding technology.75 Generally QDs have longer lifetimes (20- 50 ns) than that of organic 
dyes by one order of magnitude and so QDs are highly regarded as a new generation 
materials capable of bringing immense benefits to medical diagnosis.76,79   75,76,77,7879 
On the other hand, there are a few limitations that QDs have to overcome in order to 
be the ideal candidates for optical tags. An example is the danger of releasing toxic 
elements into biological systems, especially in in vivo analyses. The most optically 
efficient QDs are engineered with one or more toxic element such as cadmium and 
selenium.80 CdSe QDs have luminescence properties from near UV to NIR regions with 
size-tunable absorption, this broad absorption band provide two advantages: i) freedom to 
select any excitation wavelength below the band gap energy and ii) minimize background 
by increasing Stokes shift. Another reported limitation of QDs is their tendency to suffer 
from optical blinking emission (continued on-off emission), a situation that is detrimental to 
real time imaging72,81-84    81,82,83,84 
As already mentioned QDs are more resistant to photobleaching than organic dyes, 
however some studies have reported various degrees of QDs fluorescence quenching 
under irradiation in ambient environment, where some of the authors85,86 conclusively 
pointed out photo-oxidation of the nanocrystals as the main/primary cause. In order to 
overcome photo-oxidation limitation researchers attempted to coat the QDs with a 
protective layer (shell) forming a core-shell type QD, where the inner core would be a 
semiconductor material, while the shell would be another semiconductor but with a wider 
band gap87. Unfortunately this attempt did not reach expectations. Within the same 
perspective emerged the coating with thiols88,89,90, polymers91,92,93 or silica94,95 serving not 
only as protective layers but as platforms for possible bioconjugations introducing 
mutimodal prespective to QD. 
In conclusion, invaluable effort is being invested by many researchers with 
uncompromised intentions to resolve the toxicity of high-quality QDs and develop non-
toxic QDs in order to offer all the advantages of QDs to biomedical imaging and 
therapeutic interventions. 
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Lanthanide Chelates (and time resolved fluorescence) 
 
Considerable interest has been allotted to the application of kinetically stable 
lanthanide complexes as probes for biological imaging and assaying.96,97 While efforts 
have been concentrated their on the development of gadolinium agents (as MRI contrast 
agents),35,98 luminescent trivatent lanthanide ions such as terbium (Tb), europium (Eu), 
ytterbium (Yb) and neodymium (Nd) also have much to offer.99,100 The large Stokes shifts 
and long-lived emission commonly associated with sensitised emission from these ions 
ensures the usage of time-gated spectroscopy to separate such long-lived signals from 
the short-lived signals that arise from scattered light and biological fluorescence.101 As a 
result considerable interest has been given the use of luminescent lanthanides in 
bioassays and more recently the possibility of using time-resolved spectroscopy and 
microscopy.103-105 
Lanthanide complexes can be tailor-made to exhibit different luminescent lifetimes 
by the exclusion of solvent molecules from the inner hydration sphere of the lanthanide 
ion. Therefore such complexes can be used in microscopy applications to gain more 
detailed information. Lanthanide complexes can be distinguished by their characteristic 
wavelengths of emission (due to the metal centre), very sharp emission bands (typically 
with a full width at half maximum of less than 10 nm) and their luminescent lifetimes (ca. 
10-3 s), which are controlled by their coordination environment.71       102103104105 
Time-resolved fluorescence (TRF), which is more or less an exclusive preserve of 
lanthanides compounds, has become by far the most effective way of eliminating 
background interferences in order to enhance sensitivity.102-105 The introduction of a time 
delay (~ 1 or 100 μs), prior to detection of the emitted light eliminates interference from 
light scattering and auto-fluorescence enhancing greatly the signal to noise ratio 
(detection limits are conservatively in the 10-12 – 10-15 M range) and hence the reliability of 
detection and monitoring.102 The principle of TRF is illustrated in figure 3.4 and involves 
sequentially an excitation of the system, cessation of the excitation allowing enough decay 
time (during which the typical fluorescence from dyes and QDs would have decayed) for 
background interferences to have disappeared and measuring the luminescence of the 
lanthanide.  
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Figure 3.4. Principle of TRF. The excitation is removed, followed by a 
sufficient time delay, and later measurement of lanthanide fluorescence and 
the cycle can continue thereafter with new excitation.106 
 
An important point in the design of an efficient lanthanide-based probe is to protect 
the lanthanide cation from solvent molecules. Particular attention should be paid in 
protecting the cation from water as the lanthanide emission is quenched by the presence 
of water molecules in the first coordination sphere of the lanthanide (non-radiative 
deactivation through O-H vibrators). NIR emitting lanthanide ions commonly have a lower 
quantum yield than those other lanthanide ions emitting in the visible range, since their 
non-radiative transitions have higher probability with regards to the lanthanide ions 
emitting in the visible range.Nevertheless, as previously mentioned, they are more 
suitable for biological applications as they can be excited at lower energy and NIR 
photons can go deeper into tissue. 
 
Several research groups have devoted great effort to designing organic ligands, a 
great variety of which are now described in the literature and reviewed by Bünzili.37 In 
general, small variations in a ligand structure can lead to remarkable changes in the 
photophysical properties. Several types of lanthanide carboxylates have been reported.107 
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Lanthanide doped nanoparticles 
 
Lanthanide doped NPs have emerged as a fast-growing platform in cell imaging due 
to the generation of low background noise for their NIR emission. To date the lanthanide 
oxide phosphor system has been the widely studied. Meiser et al. reported the synthesis 
of monodisperse fluorescent LaPO4 NPs
.108,109,110 These NPs, approximately 7 nm in size, 
have fluorescence that originates from their bulk properties - transitions between d and f 
electron states and their local symmetry - and is independent of their size. These NPs 
were biofunctionalized via biotin-avidin chemistry with good photostability and fluorescent 
properties.111 
Setua et al. produced highly monodispersed Eu3+ and Gd3+ doped Y2O3 nanocrystals 
and presented bi-modal imaging applications of both paramagnetism that enabled 
magnetic resonance imaging and bright red-fluorescence. This aided the optical imaging 
of cancer cells, targeted specifically to their molecular receptors.112 
Lanthanide up-converting NPs (UCNPs) are rare-earth doped ceramic-type 
materials such as oxides, oxysulfides, fluorides or oxyfluorides which convert infra-red 
light into the visible spectrum. They are usually synthesized as nanospheres and were 
introduced as probes for bioassays in the 1990s. Most of these UCNPs contain Er3+ ions 
as two-color (green, 540 nm; red, 654 nm) emitters and Yb3+ ions as sensitizers, but other 
Ln3+ pairs have also been proposed (e.g., Tm3+/Ho3+/Yb3+/Tm3+). These type of NPs 
present several advantages over classical bioprobes, including high sensitivity, 
multiplexing ability if several different Ln3+ ions are co-doped, low sensitivity to 
photobleaching and cheap laser diode excitation, in addition to deep penetration of the 
excitation NIR light. Initially, they were used in luminescent immunoassays. Presently their 
applications have been extended to luminescence imaging of cancerous cells.113 Novel 
imaging systems based on UCNPs have been designed114 and improved sensitivity of 
down to single molecule detection within cells is foreseen.115116117 
Lanthanide up-converting NPs (UCNPs) have been developed as a new generation 
of luminescent labels due to their superb optical features, long lifetimes and excellent 
photostability. Among various kinds of UCNPs, NaYF4 is the most well-known system that 
has been employed in both cellular and in vivo animal imaging.118,119,120 
Since the growth of this field is rapidly developing it is foreseen that lanthanide 
doped NPs will find their way into even more elaborate biotechnological applications in the 
coming future due to their relatively simple nanocomposition, deep penetration depth of 
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NIR and other advantageous physical features. Due to the potentially high toxicity of 
lanthanides, more detailed investigations will probably be required to evaluate their 
biochemical and physiological behaviours before lanthanide doped NPs are eventually 
approved for biomedical applications. 
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4.1. INTRODUCTION 
 
 
Currently, clinical diagnostics and biomedical research employ an array of 
powerful in vivo imaging techniques, including confocal and Two-Photon Microscopy, 
Magnetic Resonance Imaging (MRI),1 X-Ray Computed Tomography (CT),2 Positron 
Emission Tomography (PET),3,4 Single Photon Emission Computed Tomography 
(SPECT),5,6 and Ultrasound.7 Each of these techniques possesses unique strengths 
and weaknesses (spatial and temporal resolution and sensitivity limits), thus providing 
complementary information. Certain fused-modality instruments, such as PET/CT, have 
already appeared in the clinic.6 
MRI has an excellent spatial resolution but suffers from low sensitivity, often 
requiring the administration of millimolar concentrations of commercial Gd3+-based 
contrast agents (CAs), in order to increase the intrinsic image contrast for an efficient 
detection of pathologies.8-12 Radioactive tracers and optical imaging probes are orders 
of magnitude more sensitive and may be detected at much lower concentrations 
(picomolar or micromolar for PET or optical agents, respectively) but the corresponding 
imaging modalities have low spatial resolution.13,14      891011121314 
There has been an increasing interest in the development of multimodal imaging 
agents, integrating in a single molecular entity the requirements of MRI and a second 
imaging modality. Bimodal MRI and optical imaging probes combine the spatial 
resolution and unlimited tissue penetration of MRI with the sensitivity of optical imaging. 
The efficiency of this combined imaging technique has been demonstrated in studies 
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with animals. Modo et al. used a gadolinium-rhodamine-dextran agent to confirm by 
fluorescence microscopy that tracking of transplanted stem cells in ischemia-damaged 
rat hippocampus was possible by MRI.15 Recently, several examples of bimodal agents 
have been synthesised and evaluated, including Gd3+ complexes connected to organic 
dyes,16-18 complexes of Gd3+ and other visible19-24 or near infrared (NIR)25,26  emitting 
Ln3+ ions, or various kinds of nanoparticle (NP) based systems.17-34              
16171819202122232425262728293031323334 
Lanthanide ions are particularly well suited for the design of bimodal MRI and 
optical agents.35 Their unique electronic configuration affords exceptional magnetic and 
optical properties and similar chemical behaviour. Therefore, the replacement of one 
lanthanide by another, results in compounds with different physical properties but no 
major chemical differences. The advantage of using Gd3+ complexes as MRI contrast 
agents has been largely demonstrated.8 The Gd3+ ion possesses seven unpaired 
electrons (highest spin density) and a symmetrical 8S ground state, resulting in a slow 
electronic relaxation rate, and these are excellent features for reducing the longitudinal 
( 1T ) and transverse ( 2T ) proton relaxation times of tissue water, thus enhancing image 
contrast. For example, [Gd(DTPA)(H2O)]
2- has been approved for radiologic practice 
and medicine in 1988.36  
All Ln3+ ions, exception for La3+ and Lu3+, are photoluminescent, some more 
efficient than others. Eu3+ and Tb3+ are the most commonly ions used because they 
emit in the visible spectrum (in the red and green regions, respectively) and have long 
luminescence lifetimes, in the millisecond range).14,37,38 There are several advantages 
in using lanthanide complexes as luminescent probes versus organic dyes: i) 
resistance to photobleaching; ii) long-lived excited states, allowing the short-lived (ns 
range) biological background fluorescence to disperse before the lanthanide emission 
occurs; iii) absence of reabsorption; and iv) sharp emission bands (wavelengths are 
characteristic of the lanthanide).25 Despite these positive features of lanthanides, 
reports on the use of Ln3+ complexes in the design of combined MRI and optical probes 
are scarce.19-23 The luminescence properties of the lanthanides ions may be enhanced 
by intramolecular energy transfer from moieties attached to the central ion, the so-
called “antenna effect”. It is well known that the introduction of an aromatic ligand 
induces a considerable antenna effect, therefore enhancing the luminescence 
properties of the lanthanide ions.  
Our approach is to combine the potential of the lanthanide complexes with the 
properties of NPs since these have the ability to i) carry large payloads of active 
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magnetic centres, therefore lowering the required concentrations, ii) be target-specific 
by labelling desired cells through phagocytic pathways, and iii) be grafted by molecules 
specific to cell surface markers. Many alternative designs of efficient nanosized carriers 
for MRI probes have been proposed.39,40 Mesoporous silica nanoparticles (MSNs) have 
been shown to be very useful platforms for efficient relaxometric contrast agents 
because of their ability to carry a large payload of Gd3+ chelates with high water 
accessibility and, thus, they have been used as multimodal probes after incorporation 
of a fluorescent dye into the silica carrier.41-46 Core-shell hybrid nanoporous silica NPs 
containing a luminescent [Ru(bpy)3]Cl2 core (bpy = 2,2’bypyridine) and a paramagnetic 
monolayer coating of a silylated Gd(III) complex has also been studied.30,47,48 
41,42,43,44,45,464748 
As a proof of concept, here report on the derivatization of nanoporous silica NPs 
with aminopropyltriethoxysilane (APS), followed by reaction with diethylenetriamine 
pentaacetic acid (DTPA) and complexation of Ln3+ ions, forming the DTPA monoamide 
system SiO2@APS/DTPA:Ln (Ln = Eu
3+, Tb3+ and Gd3+). The thermodynamic stability 
constant of the Gd3+-DTPA complex is quite high, with a log K value of 22.46, which is 
very similar to the values for the Eu3+ and Tb3+ complexes.49 It has been previously 
shown that, although the thermodynamic stability constants for Gd-DTPA monoamides 
decrease by log K ~2.6 relative to the Gd-DTPA ones, their blood pH conditional 
constants differ from Gd-DTPA only by log K ~1.2.50 SiO2@APS/DTPA:Ln nanoparticles 
are not toxic51 and similar materials accumulate mostly in the liver and spleen whereas 
the lung, kidney, and heart accounted for an accumulation of less than 5%.52 The 
luminescence and water proton nuclear relaxation properties of these NPs both, in 
aqueous suspensions, and internalized in RAW 264.7 cells (mouse macrophage cell 
line), are studied in order to evaluate their usefulness as bimodal agents for MRI and 
optical imaging. 
We also report the synthesis and grafting of nanoporous silica NPs with APS and 
a Ln3+ complex with a ligand possessing an aromatic ring, which acts as an antenna for 
sensitizing Ln3+, thus improving light emission. Silica NPs are, thus, modified with 
2,2',2",2'" – [(pyridine-2,6-diyl)bis(methylenenitrilo)] tetrakis (acetic acid) (PMN), via a 
reaction with APS grafted on the NPs. Ln3+ are complexed by PMN, forming the system 
SiO2@APS/PMN:Ln (Ln = Eu, Tb and Gd). The water proton nuclear relaxation and 
luminescence properties of such derivatized NPs in aqueous suspensions and 
internalized in RAW 264.7 cells (mouse macrophage cell line) cells are studied, in 
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order to assess their efficacy as Ln3+-based bimodal agents for MRI and optical 
imaging. 
 
 
4.2. EXPERIMENTAL PROCEDURES 
 
Materials and purification methods 
 
EuCl3 (99.99%), TbCl3 (99.99%), GdCl3 (99.99%), Tetraethoxysilane (TEOS) 
(98%), 3-aminopropyltrimethoxysilane (APS) (97%), diethylenetriamine pentaacetic bis-
anhydride (DTPAA) (99.99%), 2,6-bis(bromomethyl) pyridine (98%), di(tert-butyl) 
iminobis(acetate) (98%), dry Na2CO3  (99.5%), dry acetonitrile (MeCN) (99.8%), 
trifluoroacetic acid (CF3COOH) (99%) and diethyl ether (Et2O) (99.7%); N-
hydroxysuccinimide (NHS) (98%), (1-Ethyl-3-[3-dimethyl aminopropyl]carbodiimide 
Hydrochloride (EDC) (99%) and Phosphate buffered saline (PBS) were purchased from 
Aldrich. Absolute ethanol (J.T. Baker) and ammonium hydroxide solution (5N) (Fluka) 
were used as received. All other reagents were of analytical grade. Water was 
deionized (resistivity larger than 18 MQ). 
 
Preparation of silica nanoparticles suspension 
 
The method used was derived from the so-called Stöber48,53 process, widely used 
for the synthesis of silica beads with diameters from a few tens to a few hundreds of 
nanometers54 and based on the hydrolysis/condensation of tetraethoxysilane (TEOS) 
catalyzed by ammonia in alcoholic media. Briefly, a solution of 250 mL of absolute 
ethanol and 17 mL ammonia was heated at 50 ºC and 0.035 mol TEOS was added 
allowing reflux overnight. The average particle size, determined by transmission 
electron microscopy was 67 ± 6 nm. 
 
Preparation of the grafted amino-nanoparticles 
 
To the silica NPs suspension 4.5 mmol of APS (0.8 mL) were added and stirred 
for 3 h. The suspension was then left under reflux overnight. The nanoparticles were 
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then washed and purified by centrifugation three times with ethanol and then water to 
remove unreacted APS. 
 
Preparation of the DTPA-grafted amino-nanoparticles 
 
The amino-modified NPs suspension was centrifuged and the supernatant 
discarded, the wet NPs were slowly diluted in 20 mL of an ethanol-acetic acid solution 
50/50 v/v % and 1 g of diethylene triaminepentaacetic bis-anhydride (DTPAA) was then 
slowly added to the solution (20/1 DTPAA/-NH2) at room temperature. The system was 
heated up and left to reflux overnight. The particles were filtered off and purified three 
times by centrifugation-redispersion in acetone-water 50/50 v/v % and finally three 
times in water. 
 
Preparation of the Ln3+- DTPA chelate-grafted amino-nanoparticles 
 
The DTPA-grafted NPs were redispersed in 20 mL of water. At room 
temperature, 0.3 mmol of LnCl3 (0.11g for GdCl3) were slowly added to the colloidal 
suspension. This amount corresponds approximately to the quantity of molecules 
grafted onto the particles in the 20 mL of solution, assuming a coverage rate of 6 
µmol/m². After 24 h, the excess of unreacted Ln(III) was removed by centrifugation-
redispersion three times in water. 
 
Preparation of the 2,2',2",2'"–[(Pyridine-2,6-diyl)bis methylene nitrilo)] 
tetrakis(acetic acid) compound (PMN) 
 
First the tetra(tert-butyl)2.2',2",2"'-[(Pyridine-2,6-diyl)bis(methyleneni trilo)] tetrakis 
(acetate) compound (1) was synthesized. A mixture of 2,6-bis(bromomethyl)pyridine 
(318 mg, 1.20 mmol, solid), di(tert-butyl) iminobis(acetate) (588 mg, 2.40 mmol, solid), 
dry Na2CO3 (630 mg, 6.0 mmol, solid) and dry MeCN (30 ml) was refluxed overnight 
under argon. Filtration (obtaining a yellow solution) and evaporation gave pure 
compound (yellow gel) (412 mg, 72%). 1H-NMR (CDCl3) δ (ppm):  1.44 (s, 36 H); 3.47 
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(s, 8 H); 4.00 (s, 4 H); 7.48 (d, J = 7.5, 2 H); 7.63 (T, J = 75, 1 H). A solution of 
compound (1) (412 mg, 0.86 mmol) in CF3COOH (10 ml) was stirred for 2 h at RT. 
After evaporation, the mixture was triturated with Et2O and filtered to give pure 
compound (dark yellow gel) (288 mg, 92%). 1H-NMR (DMSO) δ (ppm): 3.62 (s, 8 H); 
4.24 (s,4 H); 7.75 (d, J = 7.5, 2 H); 8.23 (t, J = 7.5, 1 H). 
 
Preparation of the PMN-grafted amino-nanoparticles 
The amino-modified NPs suspension was centrifuged and the supernatant 
discarded, the wet NPs were slowly diluted in 10 mL of PBS. While 0.5 g of PMN (1.35 
x 10-3 mol) were added to 15 mL of PBS, a yellow solution was formed. A solution of 
EDC was also prepared by adding 258.9 mg (1.35 x 10-3 mol) in 4 mL of PBS. To the 
PMN solution 15.54 mg of NHS (1.35 x 10-4 mol) was added and stirred at room 
temperature. Sequentially the EDC and NPs solutions were added, respectively. The 
system was left to react overnight. The particles were filtered off and purified three 
times by centrifugation-redispersion in water. 
 
Preparation of the Ln3+-PMN chelate-grafted amino-nano-particles 
The PMN-grafted NPs were redispersed in 20 mL of water. At room temperature, 
33.3 μmol of LnCl3 (8.78 mg for GdCl3) were slowly added to the colloidal suspension. 
This amount corresponds approximately to the quantity of molecules grafted onto the 
particles in the 10 mL of solution, assuming a coverage rate of 6 µmol/m². After 24 h, 
the excess of unreacted Ln(III) was removed by centrifugation-redispersion three times 
in water. 
 
Cell culture and in vivo imaging 
RAW 264.7 cells (mouse macrophage cell line) were maintained at 37 °C, under 
5% CO2, in Dulbecco's modified Eagle's medium-high glucose (DMEM-HG) (Sigma) 
supplemented with 10% (v/v) heat-inactivated fetal bovine serum (FBS) (Sigma), 
penicillin (100 U/mL) and streptomycin (100 μg/mL), and sodium bicarbonate (1.6 g/L). 
Cells were incubated with the respective NPs (2.5 x 1015 Part/L for both types of NPs 
SAD:Ln and SAPMN:Ln ) at 37 °C, under 5% CO2, for 1 hour. After this incubation, 
cells were washed with PBS, fixed with 4% paraformaldehyde, for 15 min at room 
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temperature, and rinsed again with PBS. Then, cells were detached from the culture 
flasks by scraping, the cell suspensions were prepared in PBS and the cell pellets were 
obtained by centrifugation at 180g during 5 min. 1T -weighted MRI images of the cellular 
pellets were acquired on a 3.0 T Siemens TimTrio scanner, using a spin--echo 
sequence (TE = 12 ms, TR = 3000 ms, FOV= 100x 100, slice thickness = 3.00 mm, 
matrix = 128 x 256 at room temperature for SAD:Ln NPs and TE = 50 ms, TR = 3000 
ms, FOV= 100x 100, slice thickness = 3.00 mm, matrix = 128 x 256 at room 
temperature for SAPMN:Ln NPs). The optical images were obtained by submitting the 
cellular pellets to a 450 W Xe arc lamp, as the excitation source and photographs were 
taken with a Canon 550D with EF-S 18-55mm. 
 
Particles Characterization 
 
TEM was performed at room temperature on a JEOL JEM-2000 FX transmission 
electron microscope using an accelerating voltage of 200 kV. Drops of diluted 
dispersions of nanoparticles were air-dried on carbon films deposited on 200-mesh 
copper grids. The excess liquid was blotted with filter paper. Diffuse Reflectance 
Infrared Fourier-Transform (DRIFT) spectra were recorded on a Bruker IFS Equinox 
55FTIR spectrometer (signal averaging 64 scans at a resolution of 4 cm-1 in KBr pellets 
containing ca. 2 mass % of material). The zeta potential of the nanoparticles was 
measured using a Zetasizer 3000HSA setup (Malvern Instruments) equipped with a 
He- Ne laser (50 mW, 532 nm). The zeta potential measurement based on laser 
Doppler interferometry was used to measure the electrophoretic mobility of 
nanoparticles. Measurements were performed for 20 s using a standard capillary 
electrophoresis cell. The dielectric constant was set to 80.4 and the Smoluchowsky 
constant f(ka) was 1.5. The silica, europium, terbium, and gadolinium contents were 
measured by inductively coupled plasma / optical emission spectrometry ICP/OES 
(ES720, Varian) equipped with a crossflow nebulizer. Solutions for each element with a 
concentration of 1 g/L were used to prepare the standard solutions (SCP Science to 
Paris) and were used as internal standard to evaluate the instrumental drift. 
The 29Si magic-angle spinning (MAS) nuclear magnetic resonance (NMR), 29Si 
cross-polarization (CP) MAS NMR and 13C CP/MAS NMR spectra were recorded on a 
Bruker Avance III 400 (9.4 T) spectrometer at 79.49 and 100.62 MHz, respectively. 29Si 
MAS NMR spectra were recorded with 2 μs (tip angle ca. 30º) rf pulses, a recycle delay 
of 60 s and 5.0 kHz spinning rate. 13C CP/MAS NMR spectra were recorded with 4 μs 
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1H 90º pulses, 2 ms contact time, a recycle delay of 4 s and at a spinning rate of 8 kHz. 
1H NMR spectra were recorded on a Bruker Avance-300 spectrometer at 300.13 MHz, 
using CDCl3 as the solvent. Chemical shifts are quoted in ppm from tetramethylsilane 
(TMS) and coupling constants J in Hz. Multiplicities are described with abbreviations as 
follow: s (singlet), d (doublet), t (triplet), q (quadruplet), m (multiplet). Spectra are 
described as δ (multiplicity, number of protons, assignment, coupling constant).  
1H longitudinal and transverse relaxation times ( 1T  and 2T  respectively) of 
aqueous suspensions of nanoparticles were measured at 20 MHz on a Bruker 
Minispec mq20 relaxometer and at 499.83 MHz (B0= 11.7 T) on a Varian Unity 500 
NMR spectrometer, at 25 and 37 ºC. 1T  values were measured using the inversion 
recovery pulse sequence, while 2T
 values were measured using a Carr-Purcell-
Meiboom-Gill (CPMG) pulse sequence. The time interval between two consecutive 
refocusing pulses (τCP) in the train of 180
o pulses applied was 1.6 ms. The values of 
*
2T , the transverse relaxation time in the presence local field inhomogeneities, were 
obtained from the water spectral line widths. All the experimental values were corrected 
for the diamagnetic contributions using aqueous suspensions of their respective NPs 
carrier SiO2@APS/DTPA (SAD) and SiO2@APS/PMN (SA/PMN) under the same 
conditions. The r2 values were also measured as a function of the CP parameter in a 
CPMG pulse sequence, for aqueous suspensions of the various NPs (CP = 0.05, 0.2, 
0.4, 0.8, 1.6, 2, 3). 
The photoluminescence spectra were recorded between 14 K and room 
temperature with a modular double grating excitation spectrofluorimeter with a TRIAX 
320 emission monochromator (Fluorolog-3, Jobin Yvon-Spex) coupled to a R928 
Hamamatsu photomultiplier, using the front face acquisition mode. The excitation 
source was a 450 W Xe arc lamp. The emission spectra were corrected for detection 
and optical spectral response of the spectrofluorimeter and the excitation spectra were 
weighed for the spectral distribution of the lamp intensity using a photodiode reference 
detector. The lifetime measurements were acquired with the setup described for the 
luminescence spectra using a pulsed Xe-Hg lamp (6 μs pulse at half width and 20–30 
μs tail). The absolute emission quantum yields were measured at room temperature 
using a Quantum Yield Measurement System C9920-02 from Hamamatsu with a 150 
W Xenon lamp coupled to a monochromator for wavelength discrimination, an 
integrating sphere as sample chamber and a multi channel analyzer for signal 
detection. 
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4.3. RESULTS AND DISCUSSION 
 
4.3.1. Characterization of Nanoparticles 
 
Aqueous suspensions of silica NPs were synthesized by basic polymerization of 
silane monomers under Stöber conditions,48 using an alcohol-water-ammonia medium 
and tetraethoxysilane (TEOS) as the silane precursor. TEM (Figure 4.1) reveals 
spherical, essentially monodispersed, particles with an average size of 67 ± 6 nm (100 
particles measured). 
 
Figure 4.1. a) TEM images of the silica NPs; b) histogram depicting the 
experimental size distribution of the NPs and the corresponding calculated 
normal cumulative distribution for the specified mean and standard 
deviation. 
 
These NPs were successively functionalized with APS, DTPA or PMN) and a 
lanthanide salt (Ln=Eu, Tb or Gd). The zeta potential titrations as a function of pH 
confirm the shift of the stability ranges of the NPs and the isoelectric points (IEPs) with 
the different modification steps (Figure 4.2). 
After APS coating the suspension exhibited an IEP of ca.10 characteristic of the 
presence of free amino groups on the NPs surface.55-57 Once the peptidic coupling 
(carboxyl groups from the DTPA or PMN with the free amino groups of the APS) was 
achieved, another clear shift of the IEP towards lower pH (IEP of ca. 6 for DTPA and 
ca. 5.5 for PMN) was observed. Upon coordination of the DTPA or PMN with Eu3+, 
Tb3+, Gd3+ (ions with similar association constants),58,59  there was no major change of 
the IEP, which does not depend on the lanthanide chemical nature.55-59       56575859 
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Figure 4.2. Zeta potential titrations as a function of pH for SiO2 (S, ●), 
SiO2@APS (●), SiO2@APS/DTPA (●), SiO2@APS/PMN (●), 
SiO2@APS/DTPA:Ln (●) and SiO2@APS/PMN:Ln (●)  
 
The amount of Ln3+ ions present in the NPs strongly depends on the amount of 
DTPA (or PMN) grafted. Therefore, the same single set of DTPA or PMN grafted NPs 
was used throughout the study, presenting a ratio of ca. 104 ions per NP. As an 
example, Table 4.1 and Table 4.2 summarize the ICP data obtained on each sample 
for the quantification of Gd, Eu, Tb and Si. 
 
 
 
Table 4.1. Elemental composition of samples SiO2@APS/DTPA:Ln 
(SAD:Ln) ascertained by ICP  
 
[Gd] (M) [Eu] (M) [Tb] (M) [Si] (M) 
[Gd] 
(Ions/NP) 
[Eu] 
(Ions/NP) 
[Tb] 
(Ions/NP) 
SAD:Eu,Gd 1.50 × 10
-3
 1.48 × 10
-3
  0.820 9.59 × 10
3
 9.46 × 10
3
  
SAD:Tb,Gd 2.66 × 10
-3
  3.15 × 10
-3
 1.840 5.73 × 10
3
  6.78 × 10
3
 
SAD:Eu,Tb  1.41 × 10
-3
 1.24 × 10
-3
 0.790  7.07 × 10
3
 6.22 × 10
3
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Table 4.2. Elemental composition of samples SiO2@APS/PMN:Ln 
(SAPMN:Ln) ascertained by ICP 
 
[Gd] (M) [Eu] (M) [Tb] (M) [Si] (M) 
[Gd] 
(Ions/NP) 
[Eu] 
(Ions/NP) 
[Tb] 
(Ions/NP) 
SA/PMN:Eu  2.85 × 10
-3
  0.162  7.0 × 10
4
  
SA/PMN:Tb   3.37 × 10
-3
 0.171   7.8 × 10
4
 
SA/PMN:Gd 3.33 × 10
-3
   0.160 8.2 × 10
4
   
SAP/MN:Eu,Gd 1.55 × 10
-3
 1.62 × 10
-3
  0.173 3.6 × 10
4
 3.7 × 10
4
  
SAP/MN:Tb,Gd 1.71 × 10
-3
  1.57 × 10
-3
 0.156 4.3 × 10
4
  4.0 × 10
4
 
SAP/MN:Eu,Tb  1.71 × 10
-3
 1.47 × 10
-3
 0.157  4.3 × 10
4
 3.7 × 10
4
 
 
 
DRIFT spectroscopy was also used to probe the effectiveness of the chemical 
modification for the SAD:Ln NPs48,51 (Figure 4.3). The absorption bands in the DRIFT 
spectrum of the SiO2@APS samples (Figure 4.3) are assigned to APS and bare silica, 
evidencing the efficient APS-silanization of the silica NPs. The modification of the 
shape of the band at 3500 cm-1 is due to the N-H vibrations. The 2983 cm-1 and 2908 
cm-1 bands, assigned to the asymmetric and symmetric stretching vibrations of CH2 
groups of the grafted alkyl chain, confirm the anchoring of the amino propyl groups, as 
well as the presence of the 1631 cm-1 and 1486 cm-1 (the free and hydrogen bonding 
NH2, respectively), 800 cm
-1 (N-H bending mode), and 1448 cm-1 (SiCH2) bands. 
 
The following step was the chemical attachment of DTPA to the aminated NPs by 
the formation of an amide linkage between the primary amine group and one of the five 
carbonyl groups of DTPA. The occurrence of this chemical grafting was confirmed by 
the DRIFT spectrum with the formation of four absorption bands: one band 
characteristic of the secondary amide C=O stretch at 1685 cm-1, two due to 
asymmetrically coupled vibration (1631 cm-1) and symmetrically coupled stretching 
(1396 cm-1) of the two C-O bonds of the carboxylate anion, and the fourth band is 
characteristic of the C-N vibration stretch at 937 cm-1 (Figure 4.3). 
 
Evidence for the chelation of Ln3+ (Ln= Gd, Eu, Tb) is also forthcoming from 
DRIFT spectroscopy.49 Band assignments of the asymmetric and symmetric stretching 
vibrations of CH2 groups of the grafted alkyl chain (2977 cm
-1, 2935 cm-1 and 2900 cm-
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1) and the 1415 cm-1 (hydrogen bonding NH2), 804 cm
-1 (N-H bending mode), and 1448 
cm-1 (SiCH2) were identified. The complexation of the Ln
3+ induced a slight 
bathochromic shift of the two CO absorption bands, from 1631 to 1579 cm-1 and 1396 
to 1415 cm-1 respectively, and the secondary amide (C=O) 1680 to 1685 cm-1. Finally, 
the C-N vibrational stretch remained unchanged at 937 cm-1. 
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Figure 4.3. Diffuse Reflectance IR Fourier-Transform spectra (DRIFT) of (a) 
silica NPs (blue line), SiO2@APS (red line) and SiO2@APS/DTPA (green 
line). The inset depicts a selected region of the spectra. 
 
Regarding SiO2@APS/PMN:Ln, DRIFT spectroscopy provided evidence for the 
grafting of APS to the SiO2 surface
60 but no confirmation for the reaction between APS 
and PMN. Information on the latter was, however, forthcoming from solid-state NMR. 
The 13C CP/MAS NMR spectra of the SiO2, SiO2@APS and SiO2@APS/DTPA 
NPs are shown in Figure 4.4 (see also Table 4.3). The spectrum of the SiO2 NPs 
reveals the presence of small amounts of ethanol (peaks at ca. 19 and 58 ppm). The 
spectrum of SiO2@APS displays three broad resonances, due to the Si-bonded propyl 
chains, at ca. 42 (C3), 22 (C2) and 9 ppm (C1).61 Finally, the spectrum of 
SiO2@APS/DTPA contains the three APS peaks as well as broad resonances in the 
ranges 165-180 (carboxylate groups) and 50-65 ppm (remaining carbons) assigned to 
DTPA. Peaks from impurities are also present at ca. 25 ppm (acetic acid), 18 ppm 
(ethanol) and 30 ppm (acetone). 
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The 29Si CP/MAS and MAS NMR spectra of the derivatized NPs are shown in 
Figure 4.4B and C, respectively. The former exhibit resonances at ca. -92, -101 and -
111 ppm, ascribed to Qn(4-n)(OH) local environments (29Si linked to n 29Si atoms via 
bridging O), respectively Q2(2OH) (such as geminal silanols), Q3(OH) (single silanols) 
and Q4 (siloxane).62 The faint and broad resonance observed at ca. -66 ppm is 
ascribed to the organosiloxane (T3) atoms R’Si(OSi)3,
51 providing evidence for the 
chemical bonding of APS to the surface of the silica NPs. The presence of T2 
environments cannot be disregarded because the peak centred at -66 ppm is 
asymmetric, and may contain an unresolved resonance at ca. -60 ppm.63 We note that 
several different T3 sites are possible in the aminosilane layer, as discussed, for 
example, in Albert et al.,63 (Sheme 4.1 is, thus, just illustrative). Further evidence for 
such coupling is forthcoming from both the 29Si CP/MAS and MAS NMR spectra 
because the number of NPs surface hydroxyl groups decreases upon derivatization 
with APS: the population ratio (Q2+Q3)/Q4 (measured from the MAS NMR spectrum) 
decreases from 0.43 to 0.37. 
Upon reaction of SiO2@APS with DTPA, the number of silanol groups rises 
again: (Q2+Q3)/Q4 increases from 0.37 to 0.62. This is evidence for strong interactions 
between the amino group and silica surface silanols, when immobilized on silica gel via 
hydrogen-bonding interactions and formation of a five-membered cyclic intermediate. 
These results confirm previous reports, which provided evidence for a cyclic structure 
of the aminosilane layer based on models of five- or six- membered rings in which the 
nitrogen atoms interact with either the Si atom or one of the SiOH groups.64,65 The 
existence of six-member ring models, containing either a SiO-….NH+H(R) or a 
SiOH….NH(R) bonding structure was also assumed using XPS results66,67 and FTIR and 
Raman spectroscopy.68  
The intensity of the T3 (+T2) CP/MAS peak decreases upon addition of DTPA 
(although this must be taken with caution because the CP/MAS spectra are not a priori 
quantitative). These results indicate that the reaction of SiO2@APS with DPTA has the 
side effect of also modifying somewhat the SiO2 NPs surface. 
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Figure 4.4. 13C CP/MAS NMR spectra of the SiO2 (blue), SiO2@APS (red), 
SiO2@APS/DTPA (green) and DTPA (black). (* Ethanol, ▲ Acetic acid and 
♦ Acetone) B) 29Si CP/MAS NMR spectra of the SiO2 (blue), SiO2@APS 
(red) and SiO2@APS/DTPA (green) C) 
29Si MAS NMR spectra of the SiO2 
(blue), SiO2@APS (red) and SiO2@APS/DTPA (green). The inset in B 
shows an expansion of the T region, exhibiting an asymmetric peak; the 
arrow depicts the region of a possible resonance from T2 environments. 
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Scheme 4.1. Representation of a SiO2-NPs functionalized with APS and 
coupled with DTPA. 
 
 
Table 4.3. 13C CP/MAS and 29Si MAS NMR chemical shifts for SiO2, 
SiO2@APS and SiO2@APS/DTPA NPs and quantification of the 
29Si Qn 
resonances. 
13
C   
29
Si SiO2 SiO2@APS SiO2@APS/DTPA 
Assignment δ/ppm   Assignment δ/ppm  δ/ppm  δ/ppm  
C 1 9  Q
2
 -92.7 (2.8%) -92.8 (3.0%) -91.0 (4.6%) 
C 1’ 9  Q
3
 -102.1 (27.1%) -100.9 (23.9%) -100.3 (33.7%) 
C 2 23  Q
4
 -111.5 (70.1%) -110.4 (73.1%) -109.6 (61.7%) 
C 2’ 22      
C 3 42      
C 3’ 42      
DTPA ~170 – 180  T
3
  -65.4 -66.4 
DTPA ~58 – 62      
DTPA ~50      
DTPA ~55      
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In the case of the SiO2@APS/PMN, the 
13C CP/MAS NMR spectra (Figure 4.5a) 
of SiO2 and SiO2@APS/PMN exhibit two main peaks at 17.3 and 57.4-57.8 ppm, 
attributed to remains of ethanol solvent. The spectrum of SiO2@APS displays three 
broad resonances, given by the APS Si-bonded propyl chains, at ca. 42 (C3), 22 (C2) 
and 9 ppm (C1).60,61 Although fainter, these resonances are also present in the 
spectrum of SiO2@APS/PMN, thus showing that the sample contains APS (albeit less). 
The 29Si CP/MAS and MAS NMR spectra of the derivatized NPs are shown in Figures 
4.5b and 4.5c, respectively. The former exhibit resonances at ca. - 92, - 101 and - 111 
ppm, ascribed to Qn(4-n)(OH) local environments (29Si linked to n 29Si atoms via 
bridging O), respectively Q2(2OH) (such as geminal silanols), Q3(OH) (single silanols) 
and Q4 (siloxane).62  
 
 
The faint resonance observed at ca. -67 ppm in the 29Si CP/MAS and MAS NMR 
spectra of SiO2@APS and SiO2@APS/PMN is ascribed to the organosiloxane (T
3) 
atoms R’Si(OSi)3, 
51 providing evidence for the chemical bonding of APS to the surface 
of the silica NPs. Since the peak centred at - 67 ppm is asymmetric and may contain 
an unresolved resonance at ca. - 61 ppm therefore a T2 environments cannot be 
disregarded.63 As already proposed,60 both the 29Si CP/MAS and MAS NMR spectra: 
when the number of NPs surface hydroxyl groups decreases upon derivatization with 
APS, the population ratio (Q2 + Q3)/Q4 (measured from the MAS NMR spectrum) 
decreases from 0.43 to 0.37 (Table 4.3). 
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Figure 4.5. (a) 13C CP/MAS NMR spectra of the SiO2 (blue), SiO2@APS 
(red) and SiO2@APS/PMN (green). (* Ethanol)
 (b) 29Si CP/MAS and (c) 29Si 
MAS NMR spectra of SiO2 (blue), SiO2@APS (red) and SiO2@APS/PMN 
(green). The inset in (b) expansion of the T region, exhibiting an asymmetric 
peak; the arrow depicts the region of a possible resonance from T2 
environments. 
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Table 4.3. 13C CP/MAS and 29Si MAS NMR chemical shifts for SiO2, 
SiO2@APS and SiO2@APS/PMN NPs and quantification of the 
29Si Qn 
resonances. 
29
Si SiO2 SiO2@APS SiO2@APS/DTPA 
Assignment δ/ppm  δ/ppm  δ/ppm  
Q
2
 -92.7 (2.8%) -92.8 (3.0%) -92.3 (3.5%) 
Q
3
 -102.1 (27.1%) -100.9 (23.9%) -100.4 (30.2%) 
Q
4
 -111.5 (70.1%) -110.4 (73.1%) -109.3 (66.3%) 
    
    
T
3
  -65.4 -66.4 
 
Upon coupling of PMN to SiO2@APS, the number of silanol groups increases 
again: (Q2 + Q3)/Q4 from 0.37 to 0.51. This suggests that some APS is removed from 
the NPs surface, in accordance with the observation that the T3 29Si CP/MAS peak 
decreases concomitantly. It may also indicate strong interactions between the amino 
groups and silica surface silanols. As already mentioned possible hydrogen-bonding 
interactions and formation of a five-membered cyclic intermediate may occur when the 
amino groups are immobilized on the silica gel.  
 
 
Scheme 4.2. Representation of a SiO2-NPs functionalized with APS and 
coupled with PMN. 
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4.3.2. Photoluminescence Properties 
 
 
SiO2@APS/DTPA:Ln NPs 
 
 
The emission (steady-state and time-resolved) and excitation properties of the 
solids and samples in suspension were investigated. Figure 4.6 a displays the 300 K 
emission spectra of SiO2@APS/DTPA:Eu in the solid state excited at three different 
wavelengths. No energy shifts are observed for any transition when the wavelength is 
varied, indicating a single local environment for the Eu3+ ions. This conclusion is also 
valid for suspensions of NPs, for which the only differences relative to the solid-state 
spectrum are the relative intensities of the intra-4f Stark components (Figure 4.7). The 
spectra comprise a series of sharp lines, assigned to the Eu3+ 5D0→
7F0–4 transitions, 
and a strong broad band between 380 and 560 nm, ascribed to the emission of the 
SiO2@APS/DTPA host. Figure 4.8 shows the emission spectra (300 K) of 
SiO2@APS/DTPA recorded with different excitation wavelengths. The spectra consist 
of two strong Gaussian-shape broad bands, at 280 - 320 nm and 320 - 600 nm, whose 
maximum shifts to the red as the excitation wavelength increases. The excitation 
spectra were monitored along with the hybrid host's emission (inset of Figure 4.8). 
They consist of two broad bands, between 240 and 300 nm and between 300 and 430 
nm whose maximum shifts to the red 69-72 69707172 
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Figure 4.6. (a) Emission spectra (300 K) of SiO2@APS/DTPA:Eu (solid state) 
excited at 280 (black), 360 (red) and 393 nm (green); (b) Excitation spectra (300 
K) of SiO2@APS/DTPA:Eu (solid state) monitored at 420 (magenta) and 614 nm 
(blue); (c) (d), and (e) show a magnification of the 5D0
7F0-2 transitions. 
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Figure 4.7. Emission spectra (300 K) of the SiO2@APS/DTPA:Eu in water 
solution (blue), solid state at 300K (red) excited at different wavelengths. 
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Figure 4.8. Emission spectra (300 K) of the SiO2@APS/DTPA excited at 
270 (black), 300 (red), 330 (green), 350 (blue), 360 (cyan), 375 (magenta) 
and 400 nm (yellow). The inset shows the excitation spectra (300 K) 
monitored at 350 (black), 405 (red), 430 (green) and 450 nm (blue). 
 
To shed more light onto the origin of this broad band, Figure 4.9 compares the 
emission spectra of the host in SiO2, SiO2@APS, SiO2@APS/DTPA and 
SiO2@APS/DTPA:Eu. In accord with previous results,
68 the Gaussian-shape broad 
band shifts to the blue with the addition of APS, from 440 (SiO2) to 430 nm 
(SiO2@APS, SiO2@APS/DTPA and SiO2@APS/DTPA:Eu). The full-width-at-half-
maximum (fwhm) decreases from 133.8 (SiO2) to 109.0 (SiO2@APS), 99.7 
(SiO2@APS/DTPA) and 84.8 nm (SiO2@APS/DTPA:Eu). The SiO2 and the SiO2@APS 
emission spectra are in agreement with spectra reported for analogous materials and 
are ascribed to oxygen defects in the silica skeleton.69,70 It should be noted that no 
calcination was used, whereas previous works report luminescence properties only 
after calcination. 69,70 
 Lanthanide-chelate Grafted Silica Nanoparticles as Bimodal-Imaging Contrast Agents 
 
 
134 
375 460 545 630 715
 
 
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
Wavelength (nm)
 SiO2                                       
ex
 360 nm
 SiO2@APS                            
ex
 360 nm
 SiO2@APS@DTPA               
ex
 360 nm
 SiO2@APS@DTPA@Eu       
ex
 355 nm
 
Figure 4.9. Emission spectra (300 K) of the SiO2 (black), SiO2@APS (red), 
SiO2@APS/DTPA (green) and SiO2@APS/DTPA:Eu (blue) excited at 360 
nm. 
 
The SiO2@APS/DTPA:Eu emission spectra exhibit a series of sharp lines 
ascribed to the Eu3+ 5D0→
7F0–4 intra-4f
6 transitions upon 280 and 360 nm excitation 
(host excited states, Figures 4.6 and 4.10) providing clear evidence for the energy 
transfer from the host to the Eu3+ ion. The comparison between the emission spectra of 
DTPA:Eu and SiO2@APS/DTPA:Eu, displayed in Figure 4.11 (in particular the energy 
and fwhm of the 5D0
7F0 line and the energy and relative intensities of the 
7F1-4 Stark 
components), indicates an effective interaction between the Eu3+ ions and the 
SiO2@APS/DTPA host, completely different from that observed for the DTPA:Eu 
complex. 
 Lanthanide-chelate Grafted Silica Nanoparticles as Bimodal-Imaging Contrast Agents 
 
 135 
250 290 330 370 410 450 490 530 570
 
 
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
Wavelength (nm)
 
em
 616 nm  Solid  (300K)
 
em
 616 nm  Solid  ( 12K)
 
 
Figure 4.10. Excitation spectra of the SiO2@APS/DTPA:Eu monitored at 
616 nm at different temperatures 300K (red) and 12K (blue). 
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Figure 4.11. Top: Emission spectra (300 K) of the DTPA:Eu (black) and 
SiO2@APS/DTPA:Eu (red) excited at 393.5 nm and 393 nm, respectively; 
Bottom: Excitation spectra (300 K) of the DTPA:Eu (black) and 
SiO2@APS/DTPA:Eu (red) monitored at 614 nm and 616 nm, respectively. 
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The excitation spectra (300 K) of the same SiO2@APS/DTPA:Eu system 
monitored at 420 nm (magenta) and 614 nm (blue), (Figure 4.6b), show two strong 
broad bands at 275 and 340 nm overlapping with a series of sharp lines ascribed to the 
Eu3+ intra- 4f6 transitions between the 7F0 and the 
5L6, 
5D4,2,1,
 5F4, 
5H3, 
5G2-5 levels. 
Lowering the temperature from 300 to 14 K, the relative intensity of the hybrid host 
bands increases and a new band appears at 330 nm (Figure 4.10). This temperature 
dependence supports the assignment of this new excitation band to a ligand-to-metal 
charge transfer (LMCT) transition, resulting from the interaction between the host and 
the Eu3+ ions.73 
 
 
In order to get further insight into the Eu3+ local coordination, the 4f6 emission 
lines were recorded at high resolution (Figure 4.6c-e). The detection of a single 
5D0
7F0 line (17289.0±1.5 cm
-1) and the J-degeneracy splitting of the 7F1,2 levels into 
three Stark components, observed over the entire range of excitation wavelengths 
used, indicate that the Eu3+ cations reside in a single low-symmetry site. The larger 
intensity of the electric-dipole 5D0
7F2 transition, relative to the intensity of the 
magnetic-dipole 5D0
7F1 transition, indicates the absence of an inversion centre for the 
Eu3+ site. 
 
The calculated value of the 5D0→
7F0 fwhm, 59 cm
-1, is much larger than the 
values (20-30 cm-1)74 reported for other organic-inorganic hybrids, suggesting for the 
Eu3+ ions a large distribution of similar local sites. The room-temperature 5D0 emission 
decay curve, monitored within the 5D0→
7F2 transition at 614 nm and excited at 393 nm, 
is well fitted by a single exponential function, yielding a 5D0 lifetime of 0.35±0.02 ms 
(Figure 4.12). The slight deviation from a mono-exponential of the decay curve is in 
agreement with the aforementioned large distribution of the Eu3+ ions in similar local 
sites. Therefore, a decrease in the lifetime relative to the non-grafted monomeric 
complex [Eu(DTPA)]2- (structure already well characterized and studied75) is observed 
due to changes in the local environment of the Eu3+ ion. 
 Lanthanide-chelate Grafted Silica Nanoparticles as Bimodal-Imaging Contrast Agents 
 
 137 
0 1 2 3 4 5
In
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
  
 
Time (ms)  
Figure 4.12. Emission decay curve of Eu3+ excited states (5D0) from the 
sample SiO2@APS/DTPA:Eu, which were monitored at 614 nm and excited 
393 nm (blue), at 300 K in the solid state. 
 
The experimental Ω2 and Ω4 intensity parameters were determined from the 
emission spectra shown in Figure 4.6 using the 5D0→
7F2 and 
5D0→
7F4 electronic 
transitions, respectively, and expressing the emission intensity (I) in terms of the 
surface (S) under the emission curve as equation 3.5. 
The branching ratio for the 5D0→
7F5,6 transitions must be neglected as they are 
not observed experimentally and their influence on the depopulation of the 5D0 excited 
state may be ignored, and the Ω6 parameter is not determined. The 
5D0  
7F1 transition 
does not depend on the local ligand field and may be used as a reference for the whole 
spectrum. An effective refractive index of 1.5 was used leading to A01 ≈ 50 s
-1.76 The 
radiative emission rate is given by as equation 3.6: 74,77,78,79 
 
The 5D0 radiative (Ar) and non–radiative (Anr) transition probabilities were 
determined for sample SiO2@APS/DTPA:Eu and are 0.3116 ms
-1 and 3.0217 ms-1, 
respectively. The quantum efficiency (η) [  nrrr AAA  ] was estimated based on 
the emission spectrum and the 5D0 lifetime ( nrrT AAA 
1 ) as η=0.09. This small 
value is essentially due to the high Anr value. The emission absolute quantum yield ( ) 
was measured and found less than 0.01. The Judd-Ofelt intensity parameters (Ω2,4) 
were 1.10 x 10-20 cm2 and 1.02 x 10-20 cm2, respectively.  
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The photoluminescence characterization of the SiO2@APS/DTPA:Tb sample was 
also carried out and gave similar results Figures 4.13, 4.14, 4.15, and 4.16). Figure 
4.13a displays the emission spectra at 300 K of the SiO2@APS/DTPA:Tb in the solid 
state excited at 285 nm (black) and 377 nm (red). The spectra consist of a large broad 
band between 380 and 520 nm, ascribed to the emission of the SiO2@APS/DTPA host, 
as for the Europium system, and of a series of straight lines assigned to the Tb3+  
5D4→
7F6–0 intra-4f
8 transitions. No energy shifts are observed for any transition when 
the wavelength is varied, indicating that the Tb3+ ion is in a single local environment. 
This conclusion is also valid in solution at 300 K, where the only difference detected 
relatively to the spectrum recorded in the solid state is in the relative intensities of the 
intra-4f Stark components (see Figure 4.14). 
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Figure 4.13. (a) Emission spectra (300 K) of the SiO2@APS/DTPA:Tb (solid 
state) excited at 285 nm (black) and 377 nm (red); (b) Excitation spectra 
(300 K) of the SiO2@APS/DTPA:Tb (solid state) monitored at 544 nm 
(blue). 
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Figure 4.14. Emission spectra (300 K) of the SiO2@APS@DTPA@Tb in the 
liquid (blue) and solid state at 300K (red): (a) excited at 285 nm; (b) excited 
at ~377 nm. 
 
The excitation spectra (300K) of the SiO2@APS/DTPA:Tb monitored at 544 nm 
(blue), Figure 4.13b, show one large broad band peaking at 275 nm overlapping a 
series of straight lines ascribed to the Tb3+ intra- 4f8 transitions between the 7F6 and the 
5L10-7,
5G6-3, 
5H7-4 
5D3-1, 
5F5,4 
5I8, levels. The broad band  is ascribed to the convolution of 
the hybrid host excited states, as observed for the SiO2@APS/DTPA:Eu NPs. 
 
 
The comparison between the emission spectra of DTPA:Tb and 
SiO2@APS/DTPA:Tb, displayed in Figure 4.15 (in particular the energy and fwhm of 
the 5D4
7F5 line and the energy and relative intensities of the 
7F6-3 Stark components), 
clearly points out to an effective interaction between Tb3+ ions and the 
SiO2@APS/DTPA host, different from that discerned in the DTPA:Tb complex. 
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Figure 4.15. Emission spectra (300 K) of the DTPA:Tb (black) and 
SiO2@APS/DTPA:Tb (red) monitored at 544 nm. 
 
The lifetime values of the Tb3+ excited states (5D4) were monitored at 546 nm and 
excited at 377 nm, at 27 ºC and solid state. The emission decay curves are well fitted 
by a single exponential function yielding τ (5D4) = 1.87 ± 0.02 ms, indicating only one 
local coordination of the Tb3+ cation (Figure 4.16). 
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Figure 4.16. Emission decay curve of Tb3+ excited states (5D4) from the 
sample SiO2@APS/DTPA:Tb, were monitored at 546 nm and excited at 272 
nm (black) and at 377 nm (blue), at 300 K solid state. 
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For certain applications, it may be of interest to introduce two different lanthanide 
centres (Ln1, Ln2) optically-active in the visible range. For example, when the colours 
of the emission of Ln1 and the cell auto-fluorescence are similar, one may resort to the 
emission of Ln2. As a proof of concept, SiO2@APS/DTPA:EuTb (1:1) NPs were 
prepared, and they display the red Eu3+ and green Tb3+ emission (Figure 4.17a). 
Bimodal, MRI and optical imaging, nanoparticles of SiO2@APS/DTPA:EuGd (1:1) and 
SiO2@APS/DTPA:TbGd (1:1) were prepared. Their emission spectra, depicted in 
Figure 4.17c,d clearly show that the Eu3+ and Tb3+ emission features described above 
are not influenced by the incorporation of Gd3+.  
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Figure 4.17. Room-temperature emission spectra of 
SiO2@APS/DTPA:EuTb (1:1) in the solid state, excited at 284 (black), 317 
(blue), 330 (cyan) and 393 nm (magenta). (b) Room-temperature excitation 
of SiO2@APS@DTPA@EuTb (1:1) in the solid state, monitored at 543.5 
(green) and 697.5 nm (red). (c) Room-temperature emission spectra of 
SiO2@APS/DTPA:EuGd (1:1) in the solid state, excited at 290 (black), 
394.5 nm (red), (d) Room-temperature emission spectra of 
SiO2@APS/DTPA:TbGd (1:1) in the solid state, excited at 285 (black), 379 
nm (green). 
a 
b 
c d 
 Lanthanide-chelate Grafted Silica Nanoparticles as Bimodal-Imaging Contrast Agents 
 
 
142 
SiO2@APS/PMN:Ln NPs 
 
Figure 4.18a displays the 300 K emission spectra of SiO2@APS/PMN: Eu in the 
solid state excited at two different wavelengths, while Figure 4.19 compares the 
emission spectra measured at three different wavelengths in solid state and water 
suspension. The spectra comprise a series of sharp lines assigned to the Eu3+ 
5D0→
7F0–4 transitions and a strong broad band centred at ca. 450 nm which, 
considering the emission spectra of SiO2, SiO2@APS and SiO2@APS/PMN (Figures 
4.20 and 4.21), is attributed to oxygen defects in the silica host (and also to the NH2 
groups of the APS layer).70,73 This broad band shifts to the blue with the addition of 
APS, from 440.0 (SiO2) to 430.0 nm (SiO2@APS, SiO2@APS/PMN), while the full-
width-at-half-maximum (fwhm) decreases from 133.8 (SiO2) to 109.0 (SiO2@APS), 
94.7 (SiO2@APS/PMN) and 82.6 nm (SiO2@APS/PMN:Eu). 
The excitation spectra of SiO2@APS/PMN:Eu (300 K), Figure 3b, display two 
strong broad bands, peaking at 275.0 and 355.0 nm, overlapping with a series of Eu3+ 
intra- 4f6 transitions between the 7F0 and the 
5L6, 
5D4,2,1,
 5F4, 
5H3, 
5G2-5 levels. When the 
temperature is decreased from 300 to 12 K a new and very broad band in the range ca. 
300-390 nm is observed (Figure 4.22). 
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Figure 4.18. Emission spectra (300 K) of SiO2@APS/PMN:Eu (solid state) 
excited at 270.5 (black) and 393.5 nm (red); b) Excitation spectra (300 K) of 
SiO2@APS/PMN:Eu (solid state) monitored at 420 (magenta) and 614 nm 
(blue); c) d), and e) show a magnification of the 5D0
7F0-2 transitions. 
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Figure 4.19. Emission spectra (300 K) of the SiO2@APS/PMN:Eu in water 
solution (blue), solid state at 300K (red) excited at different wavelengths. 
285 370 455 540 625 710
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
Wavelength (nm)
245 290 335 380 425
a
b
285 370 455 540 625 710
245 290 335 380 425
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
Wavelength (nm)
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
In
te
n
s
it
y
(a
rb
. 
u
n
it
s
)
 
Figure 4.20. (a) Emission spectra (300 K) of the SiO2@APS/PMN excited at 
270.0 (black), 300.0 (red), 330.0 (green), 360.0 (blue), 370.0 (cyan) and 
485.0 (magenta). The inset shows the excitation spectra (300 K) monitored 
at 340.0 (black), 425.0 (red), 440.0 (green) and 510.0 nm (blue); (b) 
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Emission spectra (300 K) of the SiO2@APS excited at 270.0 (black), 300.0 
(red), 330.0 (green), 360.0 (blue), 380.0 (cyan) and 400.0 (magenta). The 
inset shows the excitation spectra (300 K) monitored at 340.0 (black), 420.0 
(red), 440.0 (green) and 520.0 nm (blue). 
375 460 545 630 715
 
 
N
o
rm
a
liz
e
d
 I
n
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
Wavelength (nm)
 SiO
2
                             
ex
 360 nm
 SiO
2
@APS                  
ex
 360 nm
 SiO
2
@APS/PMN         
ex
 360 nm
 SiO
2
@APS/PMN:Eu    
ex
 360 nm
 
Figure 4.21. Emission spectra (300 K) of the SiO2 (black), SiO2@APS (red), 
SiO2@APS/PMN (green) and SiO2@APS/PMN:Eu (blue) excited at 360.0 
nm. 
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Figure 4.22. Excitation spectra of the SiO2@APS/PMN:Eu monitored at 614 
nm, 300 K (red) and 12 K (blue). 
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In order to get further insight into the Eu3+ local coordination, the 4f6 emission 
lines were recorded at high resolution (Figure 4.18c-e). The spectra excited at 270.5 
and 393.5 nm exhibit differences in the relative intensities and fwhm of the 5D0
7F0-2 
transitions. The fwhm of the non-degenerated 5D0
7F0 line, in particular, is 43.3 ± 0.3 
cm-1, at 270.5 nm, and 53.5 ± 0.5 cm-1, at 393.5 nm, which evidences the presence of 
(at least) two distinct Eu3+ local environments. A similar conclusion is reached for the 
NPs water suspensions (Figure 4.19). 
The room-temperature 5D0 emission decay curve of solid SiO2@APS/PMN:Eu, 
monitored within the 5D0→
7F2 transition at 614.0 nm and excited at 270.0 nm, is well 
fitted by a bi-exponential function, yielding lifetimes τ1 = 0.242  0.071 ms and τ2 = 
0.927  0.023 ms (Figure 4.23a), confirming the presence of two Eu3+ local 
environments. The 5D0 decay curve of the free [Eu(PMN)] monomeric complex, 
recorded in the solid state excited at 275.0 nm (Figure 4.24), is well fitted by a mono-
exponential function yielding a lifetime of 0.292  0.062 ms (in solution the reported 
lifetime is ca. 0.400 ms 61-62. 
 
0 1 2 3 4 5 6 7
0 1 2 3 4 5 6 7 8
 
 
 
 
Time (ms)
In
te
n
s
it
y
 (
a
rb
. 
u
n
it
s
)
b
 
 
 
a
 
Figure 4.23. Emission decay curve of Eu3+ excited states (5D0) from the 
sample SiO2@APS/PMN:Eu, which were monitored at 614.0 nm and 
excited at a) 270.0 nm (black); b) 370.0 nm (blue), at 300 K in the solid 
state. 
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Figure 4.24. 5D0 emission decay curve of [Eu(PMN)], monitored at 614.0 
nm and excited 275.0 nm (blue) at 300 K in the solid state. 
 
Although the free [Eu(PMN)] complex and SiO2@APS/PMN:Eu exhibit similar 
lifetimes of, respectively, 0.29 and 0.24 ms (τ 1) there are indications that the latter is 
not attributed to the [Eu(PMN)] residue, rather to a Eu3+ environment interacting 
strongly with the NPs surface, probably via silanol groups (which are far more 
abundant that the amino groups on the silica surface). The arguments are as follows. 
Figure 4.25 compares the emission and excitation spectra of the free [Eu(PMN)] 
complex and SiO2@APS/ PMN:Eu NPs. The 
5D0
7F0 line of the latter can be fitted by 
two Gaussian bands, at ca. 578 and 580 nm (inset in Figure 4.25), in accord with the 
existence of two distinct Eu3+ local environments. Whereas the low-energy-component 
(ca. 578 nm) is ascribed to a Eu3+ site with a coordination shell similar to that of the free 
[Eu(PMN)] complex, the high-energy band (ca. 580 nm), not present in the complex, 
must correspond to a Eu3+ coordination shell involving directly the SiO2@APS host. 
Therefore the excitation spectra monitored on both components provide information on 
the nature of the two distinct local sites. Figure 4.26 compares the excitation spectra of 
the SiO2@APS/PMN:Eu NPs, monitored at 578.0, 580.0 and 614.0 nm, and [Eu(PMN)] 
complex, monitored at 614.0 nm. While the spectra monitored at 580.0 nm and that of 
the free complex are similar (Figure 4.26), the spectrum monitored at 578.0 nm shows, 
in addition, a broad band (‘pedestal’) between 350.0 and 425.0. This band is, thus, 
assigned to the SiO2@APS host (Figure 4.18b and Figure 4.19). The 
5D0 emission 
decay curve excited at 370.0 nm (Figure 4.25b) is well fitted by a mono-exponential 
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function yielding a lifetime of 0.212  0.014 ms66 providing solid evidence for the 
previous assignment of the shorter lifetime to a Eu3+ environment interacting strongly 
with the NPs surface, that corresponds to the low-energy component of the 5D0
7F0 
line at ca. 578. 
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Figure 4.25. Top: Emission spectra (300 K) of [Eu(PMN)] (black) and 
SiO2@APS/PMN:Eu (red) excited at 393 nm and 393.5 nm, respectively; 
Bottom: Excitation spectra (300 K) of [Eu(PMN)] (black) and 
SiO2@APS/PMN:Eu (red) monitored at 614 nm. 
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Figure 4.26. Excitation spectra (300 K) of [Eu(PMN)] (black, monitored at 
614.0 nm) and SiO2@APS/PMN:Eu (monitored at 614.0, 578.0 and 580.0 
nm, red, green and blue curves, respectively). 
 
We assign the longer, τ 2, lifetime to Eu
3+ coordinated to the PMN ligand and 
grafted via APS to the SiO2 surface because the excitation spectra of the free 
[Eu(PMN)] complex and SiO2@APS/PMN:Eu are very similar (Figure 4.25 and Figure 
4.26) in the region of the intra-4f lines, exhibiting also the same broad band at ca. 270 
nm, assigned to the aromatic ring of PMN. The longer lifetime of SiO2@APS/PMN:Eu 
relatively to lifetime of the free [Eu(PMN)] complex may be due to differences in the 
Eu3+ coordination spheres, in particular, brought about by the peptoidic coupling of 
PMN to APS in the former. 
The maximum emission absolute quantum yields of the free [Eu(PMN)] complex 
and SiO2@APS/PMN:Eu NPs (measured at 270.5 nm) were, respectively, 0.04  0.01 
and 0.05  0.01. Importantly, a much smaller value (0.01  0.01) has been reported for 
a similar system but that did not contain an aromatic ‘antenna’, 
SiO2@APS@DTPA:Eu
.60 
SiO2@APS/ PMN:Tb NPs were also prepared an their emission spectra consist of 
(i) a broad band between 380.0 and 550.0 nm, ascribed to the emission of the 
SiO2@APS/PMN host as observed for the Eu-containing samples, and (ii) a series of 
sharp Tb3+ 5D4→
7F6–0 intra-4f
8 lines (Figure 4.27). 
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As mentioned before, it is of interest to introduce two different optically-active 
lanthanide ions (Ln1, Ln2) emitting in the visible range. As a proof of concept, 
SiO2@APS/PMN:EuTb (1:1) NPs were prepared, and they displayed the red, Eu
3+, and 
green, Tb3+, emission (Figure 4.28). 
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Figure 4.27. (a) Emission spectra (300 K) of the SiO2@APS/PMN:Tb (solid 
state) excited at 280.0 nm (black) and 377.0 nm (red); (b) Excitation spectra 
(300 K) of the SiO2@APS/PMN:Tb (solid state) monitored at 544.0 nm 
(blue). 
 
The emission spectra of bimodal SiO2@APS/PMN:EuGd (1:1) and 
SiO2@APS/PMN:TbGd (1:1) NPs for MRI and optical imaging (Figure 4.29) are very 
similar to the spectra of the Gd-free samples (Figure 4.18a and Figure 4.28), thus 
showing that the Eu3+ and Tb3+ emission is not influenced by the presence of Gd3+. 
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Figure 4.28. (a) Room-temperature emission spectra of 
SiO2@APS/PMN:EuTb (1:1) in the solid state, excited at 284.0 (black), 
317.0 (blue), 330.0 (cyan) and 393.0 nm (magenta). (b) Room-temperature 
excitation of SiO2@APS/PMN:EuTb (1:1) in the solid state, monitored at 
543.5 (green) and 697.5 nm (red). 
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Figure 4.29. Room-temperature emission spectra of a) 
SiO2@APS/PMN:EuGd (1:1), b) SiO2@APS/PMN:TbGd (1:1) NPs, excited 
at, respectively, 290 nm (black), 394.5 nm (red), and 285 (black), 379 nm 
(green). 
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4.3.3. Relaxivity Properties 
 
 
SiO2@APS/DTPA:Ln NPs 
 
 
The SiO2@APS/DTPA:Ln (Ln= Gd, Eu:Gd (1:1), Tb:Gd (1:1) NPs suspensions 
remained stable throughout the NMR measurements, allowing the collection of 
consistent relaxation data. Table 4.4 shows the proton relaxivity values (r1p and r2p), 
determined at two frequencies (20 MHz and 500 MHz) and two temperatures (25 ºC 
and 37 ºC) for the SiO2@APS/DTPA:Gd, SiO2@APS/DTPA:EuGd (1:1) and 
SiO2@APS/DTPA:TbGd (1:1) water suspensions. These relaxivities were calculated 
from the observed linear dependence of the )2,1(,/1  iTR ii  relaxation rates on the 
concentration of the Gd3+ ions present in all samples, shown in Figure 4.30 to Figure 
4.33. These values are constant over a large pH range, indicating that the 
paramagnetic NPs are stable and do not leach out Gd3+, Eu3+ or Tb3+ ions, even in 
highly basic conditions. The )2,1(  irip  values measured for the 
SiO2@APS/DTPA:Gd nanoparticles with 67 nm diameter are very similar to those 
reported for the monomeric [Gd(DTPA)]2- complex,8 reflecting the virtually free 
rotational motion of the complex at the surface of the nanoparticles, which counteracts 
the effect of the slow global motion of the nanoparticle on the relaxivities. The 
pr1 values decrease with increasing frequency, as expected for the standard inner-
sphere and outer-sphere dipolar mechanisms of proton relaxation. They are also 
almost constant with increasing temperature, reflecting that the 1T  relaxation process is 
limited by slow-to-intermediate water exchange, characteristic of DTPA-amide 
systems.8,9 These r1p values are similar to those reported for nanoporous silica 
nanoparticles coated with covalently bound Gd-Si-DTPA30 or Si-EDTA46 derivatives, but 
smaller than when a Si-DTTA30 derivative was used (H4DTTA = 
diethylenetriaminetetraacetic acid), mainly reflecting the different water accessibilities 
of the Gd3+ ion in those systems. This water accessibility is much increased in 
mesoporous silica-based nanosystems covalently labelled with Gd-DTPA, Gd-DTTA or 
Gd-DOTA derivatives,40-45 leading to r1p values 5 to 10 times larger than for the 
corresponding monomeric complexes. 
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For the SiO2@APS/DTPA:GdEu and SiO2@APS/DTPA:GdTb NPs, where 50% of 
the DTPA-coordinated Gd3+ ions are replaced by Eu3+ or Tb3+, the r1p values (referred 
to one mM Gd3+) increase relative to the SiO2@APS/DTPA:Gd NPs (Table 4.4), 
reflecting the dipolar relaxation effect of the extra ions at the particle surface. This 
increase is larger for the Tb3+ than for Eu3+ ions, as the former induces stronger 1T  
relaxation due to its slower electronic relaxation. The frequency and temperature 
dependence of r1p for the mixed cation nanoparticles is the same as for the Gd
3+ ones. 
 
The r2p values for the SiO2@APS/DTPA:Gd NPs undergo a large increase when 
the measuring frequency increases (Table 4.4). Large r2p values have also been 
observed for silica nanosystems covalently labelled with Gd3+ complexes, particularly at 
high frequencies.30,40-42,45-47 This indicates that the 2T -relaxation process, besides the 
dipolar mechanism operating for 1T -relaxation, also has a strong outer-sphere 
contribution from field inhomogeneities created by the magnetized particles that the 
water protons experience (measured by the frequency shift at the particle surface, Δ) 
as they diffuse nearby (with a diffusion correlation time τD), and which increase with the 
square of the external magnetic field strength.80 The presence of this contribution is 
confirmed by the increase of pr2  values observed for the mixed SiO2@APS/DTPA: 
EuGd NPs (Table 4.4). This magnetic susceptibility effect is particularly strong for pr2  
values at 500 MHz, and can also be observed for the 20 MHz pr2  values of the mixed 
SiO2@APS/DTPA: TbGd NPs. These effects of the nanoparticle-bound Tb
3+ ions are 
stronger than those observed for the Eu3+ ions, in agreement with the larger magnetic 
moment of Tb3+. However, their 500 MHz pr2  values decrease, rather than increase, 
when 50% of the Gd3+ ions are replaced by Tb3+ (Table 4.4). This may reflect a 
breakdown of the outer-sphere relaxation model for 2T -relaxation at high magnetic field 
due to the presence of the Tb3+ ions, when τD >> 1/ Δ. In these conditions, the static 
dephasing regime (SDR) model describes the transverse relaxation and the value of 2r  
becomes dependent on the time interval between two consecutive refocusing pulses 
(τCP) in the train of 180
o pulses applied in a Carr-Purcell-Meiboom-Gill (CPMG) pulse 
sequence.80,81 In preliminary experiments, we have observed that 2r  of suspensions of 
these particles indeed depends on τCP (data not shown). A more complete study of the 
relaxation mechanisms of these mixed NPs is beyond the scope of the present study. 
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Table 4.4. Calculated 1H relaxivity values, rip (i = 1,2), determined at 20 
MHz and 500 MHz, at 25 ºC and 37 ºC for samples SiO2@APS/DTPA:Gd, 
SiO2@APS/DTPA:EuGd (1:1) and SiO2@APS/DTPA:TbGd (1:1). 
20 MHz
 
 
r1p (s
-1
mM
-1
) r2p (s
-1
mM
-1
) 
25º  37º  25º  37º  
SiO2@APS/DTPA:Gd 5.24 ± 0.04 5.66 ± 0.03 6.36 ± 0.01 6.86 ± 0.01 
SiO2@APS/DTPA:EuGd (1:1) 8.08 ± 0.03 8.39 ± 0.02 10.09 ± 0.003 10.26 ± 0.007 
SiO2@APS/DTPA:TbGd (1:1) 17.4 ± 0.1 16.6 ± 0.1 21.59 ± 0.01 20.85 ± 0.05 
500 MHz
 
 
r1p (s
-1
mM
-1
) r2p (s
-1
mM
-1
) 
25º  37º  25º  37º  
SiO2@APS/DTPA:Gd 2.08 ± 0.04 1.93 ± 0.03 26.6 ± 0.4 34.8 ± 0.6 
SiO2@APS/DTPA:EuGd (1:1) 2.64 ± 0.08 2.50 ± 0.09 50 ± 2 55 ± 3 
SiO2@APS/DTPA:TbGd (1:1) 13.1 ± 0.6 9.5 ± 0.7 22 ± 1 22.2 ± 0.6 
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Figure 4.30. r1 values measured at 20 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/DTPA:Gd; II- SiO2@APS/DTPA:EuGd; (1:1) and     
III- SiO2@APS/DTPA:TbGd (1:1). 
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Figure 4.31. r2 values measured at 20 MHz; (a) 25ºC and (b) 37ºC and samples I- 
SiO2@APS/DTPA:Gd; II- SiO2@APS/DTPA:EuGd; (1:1) and                                                     
III- SiO2@APS/DTPA:TbGd (1:1). 
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Figure 4.32. r1 values measured at 500 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/DTPA:Gd; II- SiO2@APS/DTPA:EuGd; (1:1) and     
III- SiO2@APS/DTPA:TbGd (1:1). 
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Figure 4.33. r2 values measured at 500 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/DTPA:Gd; II- SiO2@APS/DTPA:EuGd; (1:1) and     
III- SiO2@APS/DTPA:TbGd (1:1). 
 
 
SiO2@APS/PMN:Ln NPs 
 
The SiO2@APS/PMN:Ln (Ln= Gd, Eu:Gd (1:1), Tb:Gd (1:1) NPs suspensions 
were studied by NMR. Table 4.5 shows the proton relaxivity values ( pr1  and pr2 ) 
determined at two frequencies (20 MHz and 500 MHz) and two temperatures (298 K 
and 310 K) for the SiO2@APS/PMN:Gd, SiO2@APS/PMN:EuGd (1:1) and 
SiO2@APS/PMN:TbGd (1:1) water suspensions. These relaxivities were calculated 
from the slopes of the observed linear dependence of the )2,1(,/1  iTR ii  relaxation 
rates on the concentration of the Gd3+ ions present in the samples, shown in figures 
4.34 to 4.37. These values are constant over a large pH range, indicating that the 
paramagnetic NPs are stable and do not leach out the Ln3+ ions, even in highly basic 
conditions. The )2,1( iri values measured for the SiO2@APS/PMN:Gd nanoparticles 
with 67 nm diameter are very similar to those reported for the monomeric [Gd(DTPA)]2- 
complex8 and our previous studies for SiO2@APS/DTPA:Gd NPs.
60 
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In the cases of the mixed-metal SiO2@APS/PMN:GdEu and 
SiO2@APS/PMN:GdTb NPs, where 50% of the PMN-coordinated Gd
3+ ions are 
replaced by Eu3+ or Tb3+, the r1p values (referred to one mM Gd
3+) increase relative to 
the SiO2@APS/PMN:Gd NPs (Table 4.5), and are in agreement with previous studies 
for SiO2@APS/DTPA:GdEu and SiO2@APS/DTPA:GdTb NPs.
60 
 
 
Table 4.5. Calculated 1H relaxivity values, rip (i = 1,2), determined at 20 
MHz and 500 MHz, at 25 ºC and 37 ºC for samples SiO2@APS/PMN:Gd, 
SiO2@APS/PMN:EuGd (1:1) and SiO2@APS/PMN:TbGd (1:1). 
 
20 MHz
 
 
r1p (s
-1
mM
-1
) r2p (s
-1
mM
-1
) 
25º  37º  25º  37º  
SiO2@APS/PMN:Gd 2.70± 0.01 2.83 ± 0.01 4.32 ± 0.01 4.02 ± 0.01 
SiO2@APS/PMN:EuGd  4.14 ± 0.01 4.39 ± 0.01 7.68 ± 0.01 7.50 ± 0.01 
SiO2@APS/PMN:TbGd  8.49 ± 0.01 7.95 ± 0.02 11.98 ± 0.01 12.40 ± 0.01 
500 MHz
 
 
r1p (s
-1
mM
-1
) r2p (s
-1
mM
-1
) 
25º  37º  25º  37º  
SiO2@APS/PMN:Gd 1.05 ±0.03 1.10 ± 0.02 80 ± 1 56.4 ± 0.8 
SiO2@APS/PMN:EuGd   2.13 ± 0.05 1.91 ± 0.06 227 ± 4 174  ± 2 
SiO2@APS/PMN:TbGd   2.26 ± 0.04 2.13 ± 0.05 89.9 ± 0.8 79.4 ± 0.9 
 
 
The pr2  values for the SiO2@APS/PMN:Gd NPs increase sharply at high 
frequency (Table 4.5), as also observed for other silica nanosystems covalently 
labelled with Gd3+ complexes.42-44,46,5380-]82 This results from field inhomogeneities 
created by the magnetized particles (measured by the frequency shift at the particle 
surface, Δ) that the water protons experience as they diffuse nearby (with a diffusion 
correlation time τD). This outer-sphere contribution to 2T -relaxation increases with the 
square of the external magnetic field strength.80 This contribution also causes an 
increase of pr2  values for the mixed SiO2@APS/PMN:GdEu NPs, in particular at 500 
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MHz, (Table 4.5). This effect is even stronger for the Tb3+-containing NPs, due to its 
larger magnetic moment. The decrease of their 500 MHz pr2  values when 50% of the 
Gd3+ ions are replaced by Tb3+ (Table 4.5), may result from a breakdown of the outer-
sphere relaxation model for 2T -relaxation at high magnetic fields due to the presence 
of the Tb3+ ions, when τD >> 1/Δ. In these conditions, the static dephasing regime 
(SDR) model describes the transverse relaxation and the value of r2 becomes 
dependent on the time interval between two consecutive refocusing pulses (τCP) in the 
train of 180o pulses applied in a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence.42 
In fact, preliminary experiments showed that the 2r  of suspensions of these particles 
depend on τCP (data not shown), as expected in those conditions. 
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Figure 4.34. r1 values measured at 20 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/PMN:Gd; II- SiO2@APS/PMN:EuGd; (1:1) and       
III- SiO2@APS/PMN:TbGd (1:1). 
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Figure 4.35. r2 values measured at 20 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/PMN:Gd; II- SiO2@APS/PMN:EuGd; (1:1) and       
III- SiO2@APS/PMN:TbGd (1:1). 
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Figure 4.36. r1 values measured at 500 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/PMN:Gd; II- SiO2@APS/PMN:EuGd; (1:1) and       
III- SiO2@APS/PMN:TbGd (1:1). 
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Figure 4.37. r2 values measured at 500 MHz; (a) 25ºC and (b) 37ºC and 
samples I- SiO2@APS/PMN:Gd; II- SiO2@APS/PMN:EuGd; (1:1) and       
III- SiO2@APS/PMN:TbGd (1:1). 
 
4.3.4. Cell Imaging 
 
Regarding the cellular uptake of the both NPs, the results obtained show that 
they are rapidly internalized by RAW 264.7 cells. In the case of the 
SiO2@APS/DTPA:Ln study, the 1T -weighted MRI images of cellular pellets with cells 
incubated with and without NPs, are shown in Figure 4.38a. A clear increase in the 
intensity of the pellets (positive contrast), obtained with cells incubated with 
SiO2@APS/DTPA:EuGd NPs (sample III), is observed relative to the pellets 
corresponding to unexposed cells (sample I), as opposed to the strong negative 
contrast caused by internalization of the 2T -shortening Fe2O3 NPs (sample II). The 
optical features of the NPs internalized cells were also assessed at a wavelength of 
393 nm. The results illustrated in Figure 4.38b demonstrate that the fluorescence of 
sample II is a combination of the autofluorescence of cells and the fluorescence 
exhibited by the SiO2@APS/DTPA:EuGd NPs (violet is the combination of red and 
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blue). These observations confirm the potential of the NPs as optical imaging contrast 
agents.  
 
 
Figure 4.38. (a) 1T -weighted MRI image of cellular pellets corresponding to: I- no NP 
internalization (control); II- -Fe2O3 NPs ( 2T ) NP cell internalization and III- 
SiO2@APS/DTPA:EuGd NP cell internalization; (b) Photograph of cellular pellets, 
excited at 393 nm, corresponding to: I- no NP cell internalization (control) and II-
SiO2@APS/DTPA:EuGd NP cell incorporation. 
 
In the case of the SiO2@APS/PMN:Ln study, the 1T -weighted MRI images of 
cellular pellets with cells incubated with and without NPs, are shown in Figure 4.39a. A 
clear increase in the intensity of the pellets (positive contrast), obtained with cells 
incubated with SiO2@APS/PMN:EuGd NPs (sample III), is observed relative to the 
pellets corresponding to unexposed cells (sample I), however the sample with cells 
incubated with SiO2@APS/PMN:Gd NPs (sample II), however, displays a decrease in 
intensity of the pellets confirming the r1 values obtained above. The optical features of 
the NPs internalized cells were also assessed at a wavelength of 393 nm. The results 
illustrated in Figure 4.39c demonstrate that the fluorescence of sample II and III is a 
combination of the autofluorescence of cells (sample I) and the red fluorescence 
exhibited by the Eu3+ ion (in Figure 4.39b),(violet is the combination of red and blue). 
These observations confirm the potential of the NPs as optical imaging contrast agents. 
b 
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Figure 4.39. (a) 1T -weighted MRI image of cellular pellets: I- no NP internalization 
(control); II- SiO2@APS/PMN:Gd cell internalized NPs; III- SiO2@APS/PMN:EuGd cell 
internalized NPs; (b) Photograph of SiO2@APS/PMN:Eu NPs in the solid state (top) 
and suspension (bottom), excited at 393 nm (right) and non-excited (left); (c) 
Photograph of cellular pellets, excited at 393 nm: I- no NPs cell internalization (control); 
II-SiO2@APS/PMN:Eu cell internalized NPs; III- SiO2@APS/PMN: EuGd cell 
internalized NPs. 
 
 
4.4. CONCLUSIONS 
 
Bimodal MRI - optical probes for bio-imaging, based on SiO2 nanoparticles 
derivatized with DTPA-Ln and PMN-Ln complexes (SiO2@APS/DTPA:Gd:Ln; and 
SiO2@APS/PMN:Gd:Ln; Ln= Eu
3+, Tb3+) were developed. The incorporation of Gd3+ 
ions (the MRI probe) in the nanosystems does not change the emission properties of 
the Eu3+ and Tb3+ ions, while the relaxometric features are slightly better than the 
properties of the commercially-available [Gd(DTPA)]2- complex.  
The grafting of pyridine-based aromatic ligands (efficient Ln3+ sensitizers) to the 
silica surface via APS, and their complexation with Gd3+, Eu3+/Tb3+ ions affords 
relaxometry, and photoluminescent properties. 
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Both of these bimodal probes are rapidly and efficiently uptaken by RAW 264.7 
cells (mouse macrophage cell line) and exhibit both, 1T -weighted MRI images of 
cellular pellets increased contrast and potential optical tracking by 
fluorescence.increased contrast and potential fluorescence tracking.  
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5.1. INTRODUCTION 
 
 
Nanoparticles (NPs) made of inorganic or organic materials exhibit many novel 
properties compared with the bulk materials.1 Magnetic NPs have unique properties 
such as superparamagnetism, high coercivity, low Curie temperature, high magnetic 
susceptibility, etc.2 Magnetic NPs are of great interest in a broad range of disciplines, 
from magnetic fluids to data storage, catalysis,3 and bio-applications.4 Examples of 
applications of NPs in the study of biology and biomedicine are magnetic 
bioseparation,5 cell sorting,67 detection of biological entities,8 clinical diagnosis and 
therapy (such as MRI, magnetic resonance imaging),9-18MFH (magnetic fluid 
hyperthermia)19 targeted drug delivery,20-23 immunoassays,24 and biomacromolecule 
purification.25 Magnetic iron oxide NPs play an important role in these applications and 
they have been used in in vitro diagnosis for about 50 years.26 In the last decade, 
numerous investigations have been carried out in the field of magnetic NPs,27especially 
on magnetite and maghemite due to their biocompatibility, FDA approval28 and absence 
of toxicity.29-31 
 
The control of the NPs size, shape, stability, and dispersibility in specific solvents 
is a technological challenge. Bio-applications, for example, require water-solubility and 
colloidal stability. However, most reported syntheses of high-quality NPs of metals,32,33 
semiconductors,34,35 and metal oxides36-38 involve non-aqueous solvents and coating 
with monolayers of hydrophobic surfactants. Several strategies to tackle these 
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challenges have been formulated,39 such as i) polymer coating,40,41 ii) exchanging the 
original hydrophobic stabilizer with dendrons,42,43 thiols or even oligomeric 
phosphines44 and iii) silica coatings.45-53    9,10,11,12,13,14,15,16,17,18 19,20,21,22,23242526 27 28 
29,30,3132,33 34,35 36,37,38 39 40,41 42,4344 45,46,47,48,49,50,51,52,53 
In order to expand the scope of the iron oxide NPs in biological applications, 
biomolecules have been employed as coatings, such as amino acids,54 vitamins,55,56 
proteins,57 antibodies,58,59 polypeptides,60 biotin, avidin61 and saccharides.62 However, 
silica coating remains one of the most popular and well-known techniques for NP 
surface modification, because the resulting cross-linked silica shell protects the core 
from the environment and the other way around. The silica coating also provides 
colloidal stability in biological solutions by avoiding inter-particle interactions and 
agglomeration. Furthermore, it can act as an anchor for the binding of biological 
vectors at the NPs surface.63 Although there are several publications concerning silica 
coatings, only a few methods have been reported for the preparation of water-soluble 
silica-coated NPs with a high colloidal stability and with sizes below 20 nm.45,50,53 
Particles with tunable size are important when considering biomedical 
applications. While small NPs exhibit reduced nonspecific interactions, minimal steric 
effects, and high clearance rates,64 larger NPs are subjected to internalization by 
macrophages. The thickness of the silica shell has also a strong influence on the 
physical properties of the NPs, especially in terms of contrast agent efficacy for 
magnetic resonance imaging. We describe the synthesis of γ-Fe2O3@SiO2, core-shell 
NPs with tuned shell thicknesses. These particles were characterized by Transmission 
Electron Microscopy (TEM), zeta potential determinations, Diffuse Reflectance Infrared 
Fourier-Transform and Nuclear Magnetic Resonance. The longitudinal (T1) and 
transversal (T2) relaxation times of aqueous suspensions of the prepared particles were 
measured, and their cytotoxicity was investigated. We show that the shell thickness of 
γ-Fe2O3@SiO2 NPs has a significant impact on their relaxivities. This silica layer 
exhibits two regions around the core, one, which is porous to water, and a second one, 
which is not. 
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5.2. EXPERIMENTAL PROCEDURES 
 
 
Materials and purification methods 
 
Iron (III) chloride hexahydrate (98%), iron (II) chloride tetrahydrate (99%), iron (III) 
nitrate nonahydrate (99%), tetraethoxysilane (TEOS) (98%), and citric acid (99.5%) 
were purchased from Aldrich. Absolute ethanol (J.T. Baker) and ammonia (Carlo Erba) 
were used as received. All other reagents were of analytical grade. All the experiments 
were performed in deionized Milli-Q water. 
 
 
Preparation of the maghemite ferrofluid suspension 
 
The aqueous maghemite suspension was synthesized by precipitation from iron 
chlorides.65,66 Briefly, the Fe3O4 precipitate (black dispersion of magnetite), obtained by 
alkalinization of the FeCl2 and FeCl3 (Fe
2+/Fe3+ = 1/2) aqueous mixture, was 
successively oxidized with 2M HNO3 and 0.33 M Fe(NO3)3 · 9H2O solutions at 100 ºC 
in order to obtain particles with a Fe2+/Fe3+ ratio lower than 0.05. With this oxidation 
process, magnetite is converted into maghemite. The brown dispersion was peptized in 
a 2 M HNO3 solution under vigorous stirring in order to create positive surface charges. 
The acidic precipitate was isolated by magnetic separation, washed with acetone and 
dispersed at pH ~ 2.5 in water with nitric acid. The iron concentration was determined 
by volumetric titration as well as by ICP measurements and the average particle size, 
as determined by transmission electron microscopy (TEM), was 10  2 nm  
 
Preparation of the maghemite ferrofluid core-shell suspension 
 
The selected method was derived from the so-called Stöber process67 widely 
used for the synthesis of silica beads with diameters from a few tens to a few hundreds 
of nanometers.68 It is based on the hydrolysis/condensation of tetraethoxysilane 
(TEOS) catalyzed by ammonia in alcoholic media. The surface of γ-Fe2O3 NPs was 
activated by acidic treatment: where 7.55 mL of γ-Fe2O3 colloidal suspension 
(concentration 74.4 g/L) were dispersed in 40 mL of 0.01 M citric acid. They were 
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isolated by decantation on a magnet. The particles were dispersed in 12 mL of water 
and peptization was performed by adding 20 µL of ammonia. Then, the alkaline sol of 
citrated- γ-Fe2O3 NPs was poured in 1 L of ethanol-water-ammonia solution 75/23.5/1.5 
v/v/v %, to obtained a 0.561 g/L concentration. The appropriate amounts of TEOS 
precursors were added to the dispersion under mild stirring to reach the targeted shell 
thickness. They were set to comply with the desired thickness of the silica shell 
according to equation 5.1 and added in multiple steps. 
 
  33
2
2
3
4
rer
M
M
NV shell
SiOTEOS
TEOSSiO
PartTEOS 





 


 (5.1) 
 
Where 
shelle is the shell thickness (the difference   33
3
4
rer shell   then corresponding 
to the volume of the silica shell   22 , SiOSiOV   is the density and 2SiOM  the molecular 
weight of SiO2; TEOSTEOSTEOS MV ,,   are the volume, density and molecular weight of 
TEOS; Npart. is the number of γ-Fe2O3 NPs. The very first amount of added TEOS (763 
μL) corresponds to the smallest observable silica shell thickness (roughly 1 nm). Then, 
after 12h of the reaction, 200 mL of this solution were stocked for analysis and 
replaced by the same amount of reaction medium. For the following step, the resulting 
solution was added with the necessary amount of TEOS to increase the shell 
thickness, and left to react another 12h. 200 mL of this solution were also stocked for 
analysis and replaced by the same amount of reaction medium. This procedure was 
used to get thicker shell sizes (the number of particles in each volume being 
recalculated to estimate the right amount of TEOS). Under these conditions, no 
secondary nucleation was observed, which is in agreement with the results reported by 
Chen et al.69 Two series of core shell NPs were synthesised and will be denoted series 
A and B. The difference between these two series was size of the NPs, in series B a 
better range of thinner coating was produced in order to better understand the 
influence of the silica shell. 
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Particle characterization 
 
TEM was performed at room temperature on a JEOL JEM-2000 FX transmission 
electron microscope using an accelerating voltage of 200 kV. Drops of diluted 
dispersions of core-shell were air-dried on carbon films deposited on 200-mesh copper 
grids. The excess liquid was blotted with filter paper. The Diffuse Reflectance Infrared 
Fourier-Transform (DRIFT) spectra were recorded on a Bruker IFS Equinox 55FTIR 
spectrometer (signal averaging 64 scans at a resolution of 4 cm-1 in KBr pellets 
containing ca. 2 mass % of material). The zeta potential of the NPs was assessed 
using a Zetasizer 3000HSA setup (Malvern Instruments) equipped with a He- Ne laser 
(50 mW, 532 nm). The zeta potential measurement based on laser Doppler 
interferometry was used to measure the electrophoretic mobility of NPs. Measurements 
were performed for 20s using a standard capillary electrophoresis cell. The dielectric 
constant was set to 80.4 and the Smoluchowsky constant f(ka) was 1.5. The iron 
content has been measured by inductively coupled plasma / optical emission 
spectrometry ICP/OES (ES720, Varian) equipped with a crossflow nebulizer. A 1 g/L 
iron solution was used to prepare the standard solutions (SCP Science to Paris) and 
was used as internal standard to evaluate the instrumental drift. 
 
 
Measurements of water proton longitudinal and transverse relaxation times ( 1T  
and 
2T  respectively) of aqueous suspensions of the NPs were carried out at 20 MHz 
on a Bruker Minispec mq20 relaxometer and at 499.83 MHz (B0= 11.7 T) on a Varian 
Unity 500 NMR spectrometer at 25 ºC. The 1T  relaxation times were measured using 
the inversion recovery pulse sequence, while the 2T  relaxation times were measured 
using a Carr-Purcell-Meiboom-Gill (CPMG) pulse sequence and varying the time 
interval between two consecutive refocusing pulses ( CP ) in the train of 180
o pulses 
applied. The values of *2T , the transverse relaxation time in the presence local field 
inhomogeneities, were obtained from the water spectral line widths. All the 
experimental values were corrected for the diamagnetic contribution using aqueous 
suspensions of hollow silica NPs, to obtain each paramagnetic contribution. These 
hollow shells where prepared by dilution of the core by addition of concentrated HCl. 
The magnetization measurements were performed on a known amount of 
ferrofluid using a vibrating sample magnetometer VSM-NUVO (MOLSPIN, Newcastle 
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Upon Tyne, U.K.).  Magnetometry of NPs allows the determination of the saturation 
magnetisation (Msat) and the radius of the superparamagnetic crystals (r) by fitting the 
data with a Langevin function (
x
xxL
1
)coth()(   where 
Tk
B
x
b
sat 0 ) with sat  as the 
magnetic moment at saturation, B0 as the magnetic field, bk  as the Boltzmann constant 
and T as the temperature. 
The NMRD profiles were recorded at 37 °C over a magnetic field range from 0.24 
mT to 0.24 T on a field cycling Stelar relaxometer (Mede, Italy). Additional longitudinal 
(R1) and transverse (R2) relaxation rate measurements were performed at 0.47 and 
1.41 T on Minispec mq20 and Minispec mq60 relaxometers, respectively (Bruker, 
Karlsruhe, Germany). 
 
 
Toxicity tests 
 
Cytotoxicity of the γ-Fe2O3@SiO2 NPs was tested by counting the cells in a 
Malassez chamber and using the MTT assay to evaluate the cell viability after the NPs 
preparation process. The core-shell NPs FF, 1A, 2A, 5A and 7A had diameters ranging 
between 10 and 143 nm. Briefly, microglial cell lines were seeded at the rate of ca. 16 x 
103 cells/cm2 in 35 mm diameter plates and allowed to attach for 24 h. The cells were 
then incubated for 0, 45 min, 24 h, 48 h, 72 h, 96 h, 120 h and 144 h in 1 mL of culture 
medium for control cells and supplemented with 60 µL of different NPs (0.16 mM) for 
treated cells. MTT and counting assays were performed as duplicate for each condition 
and the data were averaged. After incubation, cells were scraped from the dishes, then 
stained with trypan blue and counted with a haemocytometer. The MTT assay is a 
colorimetric assay that measures the reduction of yellow 3-(4,5-dimethythiazol-2-yl)-
2,5-diphenyl tetrazolium bromide (MTT) by dehydrogenase mostly from mitochondria. 
The MTT enters the cells and passes into the mitochondria, where it is reduced to an 
insoluble, colored (dark purple) formazan product. After cell culturing in the presence of 
NPs, 260 μL of the MTT solution in culture medium (0.5 mg/mL) was added into each 
well. The plate was then incubated at 37 ºC in 5 % CO2 for 45 min. The medium was 
removed and 1 mL of PBS solution was added, then cells were scraped and 
centrifuged at 1000 rpm for 5 min. The supernatant was removed and 1 mL of dimethyl 
sulfoxide (DMSO) was added to the pellets to dissolve the formazan crystals and then 
it was centrifuged again at 1000 rpm for 5 min. Supernatants were taken and their 
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absorbance was measured with a U-2800A (UV-VIS) spectrophotometer (Hitachi, 
Japan) at 570 nm. Since reduction of MTT can only occur in metabolically active cells, 
the level of activity is an estimation of the viability of the cells as compared to untreated 
cells. The cell viability (%) was calculated according to equation 5.2: 
 
Cell viability % = OD570(sample) / OD570(control) × 100 (5.2) 
 
where OD570(sample) represents the optical density of the wells treated with various 
iron sizes, and OD570(control) represents that of the wells treated with medium culture. 
 
 
5.3. RESULTS AND DISCUSSION 
 
5.3.1. Characterization of Nanoparticles 
 
The aqueous maghemite suspension was synthesized by basic precipitation from 
iron chlorides, followed by complete oxidation of the magnetite material. For the 
coating, a polymerization of silane monomers in the presence of the NPs under Stöber 
conditions67,70 was performed. This procedure is widely used since it provides uniform 
silica coating with a controllable thickness. Stöber’s conditions involve alcohol-water-
ammonia as the medium and tetraethoxysilane (TEOS) as the silane monomer. A pre-
activation of the surface of the NPs through acidic treatment was found to improve the 
silica coating, leading to a simple and highly reproducible method for producing 
monodispersed water-soluble stable colloidal NPs with silica shells whose thickness is 
tunable in the range 2-70 nm. 
To tune the silica shell thickness, the required amount of TEOS was calculated 
from the initial and the desired final particle size,71,72 taking into account the number of 
γ-Fe2O3 NPs, Npart., by means of equation 5.1. 
The estimated and experimental thicknesses of the silica coatings are collected in 
Table 5.1, while Figure 5.1 displays the TEM images obtained at various stages of the 
NPs synthesis for series A and B. 
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TEM showed that spherical core-shell (γ-Fe2O3@SiO2) NPs with different shell 
sizes were obtained; as clearly evidenced by these images, all the γ-Fe2O3 particles 
were surrounded by the silica layer. The scheme on the right of the lower row of the 
images defines the measured size or diameter (d) of the NPs, and their silica shell 
thickness (t). The average thickness of silica shells was determined from these images 
by measurements in four directions for each particle and at least 100 particles per γ-
Fe2O3@SiO2 sample, showing that the size dispersion of the particles is very small. 
 
Figure 5.2 shows the relationship between the obtained shell thicknesses of the 
series A NPs and the expected ones through calculations. They are proportional to the 
amount of TEOS added during the preparation. Note the deviation from a slope of 1, 
which is significant of the errors taking place at each step as well as some aggregation 
of the maghemite particles, as can be detected by TEM. 
 
The ratio of Fe/Si was determined for the series B NPs by ICP (Table 5.2). When 
the diameter of the NPs increases, the concentration of Fe with respect to Si 
decreases, as expected (Figure 5.3). 
 
 
Table 5.1. Synthesis of maghemite core-shell (γ-Fe2O3@SiO2) NPs for 
series A: comparison between estimated and experimental values of shell 
thicknesses. 
Sample 
Estimated shell 
thickness (nm)
a
 
Experimental shell 
thickness (nm) 
Experimental 
diameter (nm) 
FF@SiO2_1A 1 ± 1 2 ± 1 14 ± 2 
FF@SiO2_2A 4 ± 1 8 ± 2 27 ± 5 
FF@SiO2_3A 10 ± 1 15 ± 4 40 ± 8 
FF@SiO2_4A 18 ± 2 20 ± 4 50 ± 7 
FF@SiO2_5A 23 ± 3 28 ± 4 66 ± 8 
FF@SiO2_6A 31 ± 3 52 ± 6 114 ± 14 
FF@SiO2_7A 56 ± 6 67 ± 5 145 ± 10 
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14 nm (2 nm) 27 nm (5 nm) 40 nm (8 nm) 50 nm (7 nm)
66 nm ( nm) 114 nm (14 nm) 145 nm (10 nm)
10 nm
a-I)
FF (bare iron NPs) FF@SiO2_1A FF@SiO2_2A FF@SiO2_3A FF@SiO2_4A
FF@SiO2_5A FF@SiO2_6A FF@SiO2_7A
a-II)
FF (bare iron NPs) FF@SiO2_1B FF@SiO2_2B FF@SiO2_3B FF@SiO2_4B
FF@SiO2_5B FF@SiO2_6B FF@SiO2_7B
d
t d (  t )
9.6 nm (-- nm)
50 nm
11.2 nm (0.8 nm)
50 nm
24.7 nm (7.6 nm)
50 nm
46.4 nm (18.4 nm)
50 nm
73.8 nm (32.1 nm)
100 nm
152.9 nm (71.7 nm)
200 nm
114.2 nm (52.3 nm)
200 nm
94.9 nm (42.7 nm)
100 nm
8.5 nm ) 15 nm ) 20 )
28nm ) 5 67 
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Figure 5.1. a) TEM images showing the average size (diameter d) of 
different maghemite core-shell (γ-Fe2O3@SiO2) NPs and of their silica shell 
thickness (t): I) for series A and II) for series B; b) histograms with 
experimental size distributions and corresponding calculated normal 
cumulative distributions for the specified mean and standard deviation: I) 
samples FF@SiO2_1A (γ -Fe2O3@SiO2 14 nm) (left) and FF@SiO2_5A (γ-
Fe2O3@SiO2 66 nm) (right) II) samples FF@SiO2_1B (γ-Fe2O3@SiO2 11.2 
nm) (left) and FF@SiO2_5B (γ-Fe2O3@SiO2 94.9 nm) (right) and 
corresponding calculated normal cumulative distributions for the specified 
mean and standard deviation 
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Figure 5.2. Correlation between the experimental thickness of the silica 
shell as determined by TEM and the thickness calculated with eq. 1. 
 
 
Table 5.2 Fe/Si ratio obtained by ICP and average diameter determined by 
TEM for different NPs for series B 
Sample Fe/Si  Diameter (nm)         
FF  9.6  ±   1.3 
FF@SiO2_1B 1.1230 11.2  ±   1.7 
FF@SiO2_2B 0.2440 24.7  ±   3.2 
FF@SiO2_3B 0.0563 46.4  ±   8.0 
FF@SiO2_4B 0.0183 73.8  ±   8.1 
FF@SiO2_5B 0.0075 94.9  ±   7.0 
FF@SiO2_6B 0.0038 114.2 ±   12.7 
FF@SiO2_7B 0.0017 152.9  ±   13.1 
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Figure 5.3. Dependence of the core-shell NPs (series B) diameter on the 
Fe/Si ratio. 
 
Figure 5.4 shows the zeta potential titrations as a function of pH, and both the pH 
range of stability and the isoelectric points (IEP) of the two types of particles (2.3 for 
silica and 7.0 for γ-Fe2O3). Silica has long been used as a nonmagnetic coating 
material, in order to avoid aggregation or sedimentation of ferrofluid magnetic NPs 
because of its extraordinary stability over a wide range of polar and non-polar solvents.  
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Figure 5.4.. Zeta potential titrations as a function of pH of γ-Fe2O3 (●) and γ-
Fe2O3@SiO2 (●) aqueous suspensions. 
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In particular, aqueous dispersions of silica are known to be stable over a large pH 
range (IEP at pH 2). The shift of the IEP towards lower pH values (from ~6.5-7 to ~2.5) 
upon coating (Figure 5.4) provides an additional confirmation that the coating was 
successful. The large negative zeta potential (- 80 mV) at physiological pH of the 
coated NPs suggests that the aqueous suspensions will by highly stable under in vivo 
conditions and will not flocculate at pH 7. 
DRIFT spectroscopy was also used to probe the effectiveness of the chemical 
coating of silica on the maghemite NPs (FF) (Figure 5.5). Several absorption bands in 
the DRIFT spectrum of γ-Fe2O3@SiO2 samples (Figure 5.5) are assigned to silica; and 
clearly show that this material covers the surface of the maghemite NPs. The bound Si-
OH groups are characterized by the very broad IR absorption band in the 2800-3700 
cm-1 region whereas the so-called free Si-OH groups provide a narrow IR absorption 
band at 3630 cm-1. The stretching band at 1635 cm-1 shows the presence of residual 
physisorbed water molecules, while the large bands centered at 1864 cm-1, 1108 cm-1 
and 796 cm-1 are assigned to the Si-O and Si-O-Si stretching modes. 
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Figure 5.4. Diffuse Reflectance IR Fourier-Transform spectra (DRIFT) of 
maghemite NPs (black), silica NPs (pink) and γ -Fe2O3@SiO2 (red) 
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5.3.2. Relaxivity Properties 
 
 
In order to investigate the influence of the shell thickness of the silica coating on 
the MRI contrast agent (CA) efficiency of the γ-Fe2O3 NPs, the ri  (i = 1,2) relaxivities 
(defined as enhancement of Ri = 1/Ti, i = 1,2, the relaxation rates per mM concentration 
of CA) of the different core-shell NPs were measured at two resonance frequencies (20 
and 500 MHz) and two temperatures (25 and 37° C). Figure 5.5 shows typical values of 
the r1 and r2 relaxivities for the aqueous suspensions of γ-Fe2O3@SiO2 NPs (series A) 
as a function of the diameter d of the NPs with a 10.0 nm diameter γ-Fe2O3 core and an 
increasing thickness of its silica layer, giving d values of 14 nm (sample 1A) to 145 nm 
(sample 7A) (Table 5.2). 
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Figure 5.5. Dependence of water relaxivities of aqueous suspensions of the 
γ-Fe2O3@SiO2 NPs on their diameter, as a result of increased silica layer 
thickness: a) inset: r1 at 20 MHz (25 ºC); b) main plot: ri (i =1, 2) at 500 MHz 
(25 ºC and 37 ºC). r2 relaxivities were measured at τCP = 1.6 ms. 
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Table 5.3. Parameters obtained from analysis of r2 (CP = 1.6 ms) and r2* 
values of aqueous suspensions of core-shell (γ-Fe2O3@SiO2) NPs at B0 = 
11.7 T and 25 oC. 
 
Sample 
Diameter 
(nm)
a
 
r2           
(s
-1
mM
-1
) 
r2*           
(s
-1
mM
-1
) 
2ri   (nm) 2rdif   (nm) 
FF 10 ± 2 228 ± 2 230 ± 1 13 ± 1 13 ± 1 
FF@SiO2_1A 14 ± 2 100 ± 1 103± 1 29 ± 1 30 ± 1 
FF@SiO2_2A 27 ± 5 64± 2 68 ± 1 44 ± 1 46 ± 2 
FF@SiO2_3A 40 ± 8 47 ± 2 58 ± 1 52 ± 1 63 ± 3 
FF@SiO2_4A 50 ± 7 38 ± 2 57 ± 1 53 ± 1 77 ± 5 
FF@SiO2_5A 66 ± 8 23 ± 3 52 ± 1 58 ± 2 126 ± 18 
FF@SiO2_6A 114 ± 14 15 ± 2 35 ± 1 86 ± 2 192 ± 30 
FF@SiO2_7A 145 ± 10 13 ± 2 33 ± 1 90 ± 2 225 ± 33 
 
 
 
The r1 values obtained at 20 MHz decrease with the increase of the silica shell 
thickness. This decrease is initially quite sharp, from 32.0 s-1mM-1 for NPs without silica 
coating (d = 10.0 nm) to 11.2 s-1mM-1 for d = 14 nm, while the r1 values become very 
small (< 2 s-1 mM-1) for d > 25 nm (Figure 5.5, inset). At 500 MHz, r1 values are very 
small in all cases, even in the absence of silica shell (Figure 5.5). 
 
For superparamagnetic NPs, the relaxivities ri (i = 1, 2) are dominated by the 
outer-sphere relaxation mechanism, which is due to the effect of local magnetic field 
gradients generated by the NPs on the water protons diffusing near their surface.73 74 
Taking into account the effect of water diffusion through the non-fluctuating magnetic 
field (B0) inhomogeneities created by the time-averaged value of the magnetic moment 
(<μz>) of the NPs aligned onto B0, and the effect of the fluctuation of the magnetic 
moment itself (Δμz), a theoretical model was developed, where the r1 and r2 relaxivities 
contain terms proportional to <μz>
2, which define the Curie relaxation75 and dominate at 
high field, and fluctuating terms proportional to Δμz
2 (Néel relaxation) that dominate at 
low field.74,76 This model accounts quite well for the magnetic field dependence of r1 for 
ultra small particles of iron oxide (USPIO) (diameters of 10-40 nm) at high fields (B0 > 
0.02 T, corresponding to ~ 0.8 MHz Larmor frequency), where Curie relaxation 
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dominates, but does not account for the small r1 dispersion observed at low field (below 
1 MHz), which depends on the crystal anisotropy energy.77 Above 1 MHz, r1 depends 
on the translational diffusion correlation time τD and decreases with increase of the 
proton Larmor frequency I, with an inflection point defined by the condition I.τD ~ 1. τD 
= rp
2/D, where D is the relative diffusion coefficient of the paramagnetic center and the 
water molecule and rp is the radius of the particle, which determines their distance of 
closest approach. 
 
The decrease of the r1 values at 20 MHz with the increase of the silica shell 
thickness reflects the decrease of the outer-sphere contribution of the core to r1 due to 
the increase of the distance of closest approach of the diffusing bulk water molecules 
to the superparamagnetic core of the particle. This induces an increase of the 
translational diffusion correlation time, D. At least a large part of the silica layer is 
expected to be impermeable to water. The relative diffusion coefficient D is expected to 
be nearly constant for all NPs. Being the sum of the diffusion constants of water (DH2O) 
and of the NP (DNP), it is dominated by DH2O due to the large size of the NPs and the 
slow diffusion of water in the putative silica surface layer. The very small r1 values 
obtained at 500 MHz result from the expected field dependence of outer-sphere 
relaxation. 
 
The effective transverse relaxation rates (R2*) for the aqueous suspensions of the 
γ-Fe2O3@SiO2 NPs were obtained from the spectral line widths of their proton water 
resonance. Values of R2p* (the paramagnetic contribution to R2*) were calculated by 
subtraction of the diamagnetic contribution of aqueous suspensions of diamagnetic iron 
oxide-free silica NPs from each paramagnetic contribution, using the spectral line 
widths for the various samples. Finally, the corresponding relaxivities, r2*, were 
obtained (see Table 5.2). The line broadening effects reflect the dephasing of the water 
proton magnetic moments diffusing past the magnetic field gradients in the vicinity of 
the small superparamagnetic NPs, causing their T2-shortening. 
 
The transverse relaxation times are characterized by the correlation times D, 
()-1, and CP. The uncoated particles have a radius of 5 nm, from which it can be 
calculated that for these particles D is 10
-8 s. From simulations reported by Gillis et 
al.,78 the transverse relaxivity may be predicted by the outer sphere theory (eq. 5.3), 
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where Δω is the difference in the Larmor frequency at the particle surface and the 
infinity and v is the volume fraction of the particles. 
 
Dvrr 
2*
22
9
4
  (5.3) 
 
Upon coating, both D and ()
-1 will decrease and we assume that the outer 
sphere regime remains valid. 
The r2 values were measured as a function of the time interval between two 
consecutive 180o pulses (CP) in a CPMG pulse sequence, for aqueous suspensions of 
the various NPs of increasing diameter. Figure 5.6 shows that the transverse 
relaxivities of these NPs are virtually independent of CP for all silica shell sizes. This 
observation is not surprising, since the D values of the systems measured are all much 
smaller that the applied CP values and, consequently the refocusing pulses are fully 
effective. 
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Figure 5.6. Dependence of r2 water proton relaxivities (500 MHz, 25 ºC) of 
aqueous suspensions of the γ-Fe2O3@SiO2 NPs (series A) on cp as a 
function of their diameter, as a result of increased silica layer thickness. 
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Figure 5.5 and Table 5.3 show that the r2 relaxivity (measured at CP = 1.6 ms) 
sharply decreases when the thickness of the coating of the NPs increases. As 
discussed above for r1 effects, this results from the decrease of the outer-sphere 
contribution of the core to r2 due to the increase of the distance of closest approach of 
the diffusing bulk water molecules to the superparamagnetic core of the particle. 
Data show that r2  r2* for the smallest particles (γ -Fe2O3 NPs (core), 1A and 2A), 
but r2 < r2
* for particles with thicker coatings. It is possible that for the thicker coatings 
the silica layer is only impermeable to water up to a certain silica shell thickness. The 
diffusion of the water molecules in the permeable silica layer may be relatively slow. If 
in this layer the diffusion is so slow that the condition D >> ()
-1 holds, the diffusion 
correlation time is not effective when refocusing pulses are applied and, consequently, 
the phase incoherence of the water protons is fully refocused in that part of the system, 
resulting in zero contribution to r2. As far as r2 and r2
* are concerned, it will be assumed 
that the particles consist of three spheres79 with radii rc, ri, and rdiff (Figure 5.7). 
 
a) 
 
 
 
 
 
Figure 5.7. a) Schematic representation of a γ-Fe2O3@SiO2 NP. Here, rc is 
the radius of the core and ri and rdiff are the radii of imaginary spheres, as 
defined in the text. b) Variation of the silica permeability to water molecules 
with the shell thickness. 
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Here, rc is the radius of the core (5 nm), ri is the radius of the sphere around the 
core, that seems to be impermeable to water, and rdiff is the radius of a sphere, in which 
any water molecule that is inside diffuses very slowly and does not contribute to r2. 
Water molecules outside the latter sphere are assumed to contribute fully to r2, 
whereas all water (including that inside the latter sphere) contributes to r2
*.  
Taking into account the distance dependence of , v and D, the following 
scaling may be applied:80 81 
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Combination of eqs (5.4-5.6) gives: 
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Similarly, it can be derived that: 
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Using the two latter equations and the experimental values of r2 and r2
*, the 
values of ri and rdiff were calculated for the various samples (see Table 5.2 and Figure 
5.7b). These calculated rdiff values are in relatively fair agreement with the particle 
diameters obtained from the TEM measurements. The results also suggest that the 
water impermeable part of the silica coating tends to a maximum value of 40 nm, while 
the water permeable part increases with the coating thickness. 
 
 
The core-shell NPs (series B) were studied by relaxometry and magnetometry. 
As expected for particles with the same magnetic core, the size and the saturation 
magnetization obtained by magnetometry remain almost constant (Table 5.4 and 
Figure 5.8). 
 
 
Table 5.4. Magnetization values of the NPs (series B) obtained by 
magnetometry. 
Sample r (nm)
a
 Msat (Am
2
/kg) 
FF 5.5 62.1 
FF@SiO2_1B 5.7 55.7 
FF@SiO2_2B 5.5 58.4 
FF@SiO2_3B 5.6 57.4 
FF@SiO2_4B 5.6 56.2 
FF@SiO2_5B 5.6 55.4 
FF@SiO2_6B 5.6 55.9 
FF@SiO2_7B 5.6 57.8 
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Figure 5.8. Magnetometry curves of the NPs:FF (magenta, ); 
FF@SiO2_1B; (olive, ); FF@SiO2_2B (wine, ); FF@SiO2_3B (blue, ); 
FF@SiO2_4B (red, ); FF@SiO2_5B (pink, ); FF@SiO2_6B (cyan,) and 
FF@SiO2_7B (green, ). 
 
 
In order to investigate the influence of the shell thickness of the silica coating on 
the MRI contrast agent (CA) efficiency of the γ-Fe2O3 NPs, the ri  (i = 1,2) relaxivities 
(defined as enhancement of Ri = 1/Ti, i = 1,2, the relaxation rates per mM concentration 
of CA) of the different core-shell NPs were measured at two resonance frequencies (20 
and 60 MHz) and 37 °C (Table 5.5). Their relaxometric behavior shows a decrease of 
the relaxation rates on increasing the size of the NPs, in agreement with preliminary 
data.82 
 
The 1H NMRD profiles recorded at 37 °C confirm the decrease of r1 when the 
coating is thicker (Figure 5.9). All NMRD profiles (Figure 5.8) have been fitted using the 
phenomenological model developed by Roch et al.77 
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Table 5.5: Relaxivity values of the NPs aqueous solutions at 20 and 60 
MHz (37 °C) 
 
Sample 
r1 (20 MHz, s
-1
 
mM
-1
) 
r2 (20 MHz, s
-1
 
mM
-1
) 
r1 (60 MHz, s
-1
 
mM
-1
) 
r2 (60 MHz, s
-1
 
mM
-1
) 
FF 
35.17 129.25 15.96 130.28 
FF@SiO2_1B 
21.82 114.18 7.66 117.03 
FF@SiO2_2B 
8.14 96.16 2.05 102.08 
FF@SiO2_3B 
2.38 85.89 0.72 92.91 
FF@SiO2_4B 
0.84 50.25 0.40 55.02 
FF@SiO2_5B 
0.55 39.78 0.32 43.63 
FF@SiO2_6B 
0.57 40.57 0.34 43.06 
FF@SiO2_7B 
0.55 39.18 0.34 43.06 
 
 
For each sample, the anisotropy energy is high enough to neglect the precession 
at the electronic frequency of the magnetization of the particle. This results in the 
absence of dispersion at low field in the NMRD curve. Accordingly, the fitting equation 
may be reduced to the “high anisotropy approximation”: 
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where R1 is the water proton longitudinal relaxation rate. The constant C is equal 
to (in cgs units)  





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


Dd
C
C
p
spi .
405000
32 22 

,  where  i  is the gyromagnetic ratio of 
proton (2.67519. 104 rad.G-1.s-1), μsp is the magnetic moment of the NP (e.m.u) s
-1, Cp  
is the number of particles per liter,  d is the diameter of the NP (cm), D is the solvent 
media self diffusion coefficient (cm2s-1) and L(x) is the Langevin function, with 
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Tk
B
x
b
sat 0 , where 0B  is the magnetic field, kb the Boltzmann constant and T the 
temperature. 
The JF(I,D,N)  function is the Freed expression of the spectral density expressed 
as:83  
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where I is the proton Larmor angular frequency (rad.s
-1), N  is the Néel relaxation rate 
(s-1) and
D
d
D
4
2
 is the translational correlation time (s-1). 
 
 
The JA(I,D)  function is the Ayant expression of the spectral density expressed 
as:84 
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Figure 5.9: 1H NMRD profiles for the NPs aqueous solutions and their 
theoretical fittings. NPs: FF (magenta, ); FF@SiO2_1; (olive, ); 
FF@SiO2_2 (wine, ); FF@SiO2_3 (blue, ); FF@SiO2_4 (red, ); 
FF@SiO2_5 (pink, ); FF@SiO2_6 (cyan,) and FF@SiO2_7 (green, ). 
 
This equation provides a good fitting of the NMRD curves for NPs covered with 
the thinnest silica layers. However, when the coating becomes very thick, the 
diamagnetic contribution of the silica cannot be neglected in the fitting of the NMRD 
profile. This contribution must be added to that of the magnetic particles alone. As 
shown by Roose et al.,85 the NMRD profile of such large diamagnetic particles is 
characterized by dispersion at very low fields. 
For this reason the central region of the NMRD profiles of the particles covered 
with the thickest layers of silica (see samples FF@SiO2_4B, FF@SiO2_5B, 
FF@SiO2_6B, FF@SiO2_7B) are fitted “by eye” with the superparamagnetic relaxation 
(between 0.5 and 10MHz). A better fit could be obtained after subtraction of the 
diamagnetic contribution of the silica. The values of the parameters obtained by fitting 
the NMRD profiles are presented in Table 5.5 together with those obtained by TEM and 
magnetometry. 
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A good linear relationship is obtained between the NPs sizes measured by 
electron microscopy and those obtained by fitting the NMRD profiles (Figure 5.9 and 
Table 5.5). Importantly, the sizes obtained by NMRD for particles coated with a thick 
layer of silica are significantly lower than those measured by transmission electron 
microscopy, indicating that a significant part of the silica coating is permeable to water. 
Indeed, the effective distance of closest approach of the water protons to the 
superparamagnetic core, as determined by equation 1, is shorter than the NPs 
thickness as given by TEM, in agreement with what was proposed before for these 
systems.82 
Interestingly, the magnetization Msat expressed relatively to the global weight of 
the particles, and obtained from the relaxometric data decreases significantly for the 
larger particles (Table 5.5). A correlation can be drawn between the values of Msat 
obtained by both magnetometry (which gives the value of the magnetization of the 
crystal itself) and relaxometry (which gives the value of the magnetization of “the” 
particle, i.e. the crystal plus the coating). Assuming a waterproof coating, such a 
correlation is achieved by multiplying the former one by the factor in eq. 5.12: 
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  (5.12) 
 
where 
coat
sM  is the average saturation magnetization per kilo of coated particle 
material,
bp
sM  is the saturation magnetization of the bare maghemite particle, dbp is the 
diameter of the bare particle, dcoat is the diameter of the coated particle, and 4.90 and 
2.2 are, respectively, the specific mass of maghemite and silica. The Msat values of 
Table 5.5 show that, by covering the magnetic crystal and “expelling” the water further 
and further away from it creates bigger and bigger particles of the same “magnetic 
content”, so behaving like larger but less magnetized particles. However, the fact that 
the magnetization dilution of the core-shell NPs measured by NMRD is significantly 
smaller than that predicted from eq.5.12 clearly indicates again that the silica shell is 
not waterproof, but is partly water permeable. This observation is of paramount 
importance in the context of the development of contrastophores for molecular imaging. 
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Figure 5.19: Comparison between the NPs diameter obtained by NMRD 
fitting and TEM. 
 
Table 5.5: Parameters obtained for the NPs samples by different 
techniques. 
Sample number TEM 
diameter  
(nm) 
Magnetome
tric 
diameter 
(nm) 
NMRD 
diameter 
(nm) 
Msat Crystal 
Magnetometry 
(Am
2
/kg of iron 
oxide) 
Measured Msat 
NMRD 
(Am
2
/kg          
of particle) 
Calculated Msat 
NMRD 
(Am
2
/kg           
of particle)
a
 
Calculated Msat 
TEM 
(Am
2
/kg           
of particle)
b
 
FF 9.6 11.0 13.6 62.1 51.1 51.1 51.1 
FF@SiO2_1B 11.2   11.4 16.2 55.7 47.9 39.0 40.4 
FF@SiO2_2B 24.7  11.0 21.4 58.4 39.0 22.2 6.2 
FF@SiO2_3B 46.4 11.2 27.6 57.4 23.9 11.9 1.00 
FF@SiO2_4B 73.8 11.2 40.0 56.2 12.3 4.3 0.25 
FF@SiO2_5B 94.9  11.2 43.4 55.4 8.2 3.4 0.12 
FF@SiO2_6B 114.2 11.2 43.0  55.9 6.4 3.5 0.07 
FF@SiO2_7B 152.9 11.2 61.6  57.8 5.1 1.2 0.03 
a,b Calculated from equation [5.12] using aNMRD diameters and bTEM diameters. 
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The conditions under which the equations for outer sphere relaxation are valid 
still have to be discussed. This formalism is based on a small perturbation theory. By 
simulation, Gillis and al.78 have shown that for magnetite particles without diamagnetic 
coating, the results of the outer sphere theory are valid when τD is shorter than 10
-7s. If 
the measurement is made at 37 °C (D = 3.10-9 m2s-1), the diameter should, thus, be 
smaller than 30 nm. In the same work, the authors also showed that the conditions of 
application of the outer sphere theory are fixed by the condition ()r.D <1, where ()r  
is the chemical shift between the proton in the equatorial plane of the particle and the 
bulk proton.  For bare particles, the value of this product is 0.45. The variation of the 
value of ()r.D with the thickness of the coating is related to the equatorial magnetic 
field of the particle which is given by: 
 
3
3
coat
bpbp
eq
coat
eq
d
d
BB   (5.13) 
where 
coat
eqB  is the equatorial magnetic field of the coated particle and 
bp
eqB  is the 
equatorial magnetic field of the bare particle. 
 
As   eqr B 
5
4
 (Beq being the equatorial field of the crystal and γ the 
proton gyromagnetic ratio), the ratio between the product [()r.D ]coat of coated particle 
and the product [()r.D ]bp for bare particle is given by 
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Thus, although the overall size of the NPs increases, the conditions for 
application of the outer sphere theory become more and more favorable for thicker 
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coatings because the dependence on the diameter is cubic for () and of power one 
for D. 
 
 
5.3.3. Cytotoxicity 
 
The cytotoxicity of the γ-Fe2O3@SiO2 NPs (series A) was assessed after 
incubations with microglial cell lines for ¾ h, 24 h, 48 h, 72 h, 96 h, 120 h, and 144 h. 
For each time point, cells were incubated or not with the NPs (0.16 mM). Then, the 
cells were separated in two sets, one used as control and the other one being 
submitted to the MTT assay. This test was performed to characterize the viability of the 
cells and evaluate the residual toxicity after the internalization of the NPs.86 The cell 
viability tests (Figure 5.20), show that with and without NPs as well as for all NPs sizes 
except for [7A], cells can survive internalization and the cell growth process is 
maintained up to 144 h. Additionally, cells internalized with both γ -Fe2O3 or γ -
Fe2O3@SiO2 particles exhibit the same lag phase of 48 h as the control ones. 
 
 
Figure 5.20. Cell viability after exposure to different core-shell NPs sizes 
incubated at different times. 
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The MTT test characteristic of the mitochondrial dehydrogenase activity was 
performed after NPs cell internalization. This metabolic test is illustrated in Figure 5.21 
by the measurement of the 570 nm absorbance of incubated cells at different time 
course with different sizes of core-shell NPs. 
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Figure 5.21. Variation of total activity, and b) activity per million of cells of 
mitochondrial dehydrogenase of microglial cells as given by the variation of 
the solubilized formazan optical density of the medium with incubation times 
for different sizes of NPs after incubation without (control cells) and with 
both coated and uncoated particles of different sizes (cells + NPs). 
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Both coated and uncoated particles induce an optical density of the cells, which 
varies with the incubation time with a maximum value for 120 h, following the same 
behaviour as that of the control cells. Like the cell growth in the preceding experiment, 
the dehydrogenase activity is not affected by NPs internalization in the cells from FF to 
5A. In these experiments, the crude analysis of the dehydrogenase activity is relevant 
for the cell viability, but is not enough to give information about modifications of the cell 
phenotype. However, the dehydrogenase activity is drastically modified for the larger 
particles (e.g. 7A). Such NPs are known to be internalized and stored in lysosome-like 
vesicles. In case of NPs 7A, the consequences of their accumulation inside such cells 
able to phagocytise particles larger than 100 nm are still unknown. Their impact on the 
local changes in the overall redox potential due to the high load of iron in the vesicles is 
still an open question. We also normalized the activity per cell as a variation of the 
optical density per million cells as shown in Figure 5.21b. This allows all along the time 
of culture, the characterization of the cell growth on the dehydrogenase expression and 
the possible contribution of the NPs uptake during the growth time. The growth of 
control cells shows a basal level decreasing until 24 h that correlates with the lag 
phase of growth. Then the expression of the dehydrogenase per cell increases in two 
major steps, the first one between 48 h and 72 h, and the second one between 96 h 
and 144 h. After this period of time, the cells are nearly confluent. When the cells are 
incubated with NPs, the activity per cell is not significantly affected except for sample 
7A after 144 h of exposure. Therefore, one can safely assume that in these conditions, 
the dehydrogenase expression does not appear to be sensitive to the vesicular load 
with these core-shell NPs. 
 
 
5.4.  CONCLUSIONS 
 
The understanding of the relationship between the coating properties and the 
changes in relaxivity is vital for designing magnetic NP probes for MRI. This is 
important for medical applications, as a higher contrast typically leads to a higher 
sensitivity and reduces the amount of contrast agent required for imaging. Our choice 
of a silica coating was motivated by the increased stability of the resulting NP 
suspensions and the ensuing ease of conjugation of targeting molecules to the surface 
of the contrast agents for sensing and imaging. We have shown that in γ -Fe2O3@SiO2 
core-shell NPs, the coating thickness has a significant impact on their r2 and r2* 
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relaxivities at medium and high fields and on r1 relaxivities at medium fields, as a result 
of decreased outer-sphere relaxation effects. Comparing the r2 and r2* values for the 
different sizes of particles we were able to divide the silica coating in two regions, one 
impermeable close to the γ -Fe2O3 core and one permeable to water and at the 
interface with the bulk water. We have shown that by controlling this coating we are 
able to tune the size of these two regions. The impermeable one seems to increase up 
to a maximum value of 40 nm, while the permeable region goes on increasing with the 
coating thickness. The diffusion of the water molecules in the permeable silica region is 
relatively slow resulting in zero contribution to r2. The effect of silica coating of 
increasing thickness on the r2/r1 ratio is different from that reported for nanocrystalline 
superparamagnetic iron oxide NPs (MIONs) coated with a polyethylene glycol (PEG)-
modified, phospholipid micelle coating with increasing molecular weights which 
increase the particle diameter, where this increase causes a r2 decrease and a r1 
increase.79 
The magnetometric curves γ -Fe2O3@SiO2 have been fitted with a Langevin 
function and the NMRD profiles with the model developed by Roch et al. The latter 
provides a good fitting of the NMRD curves for the particles covered with the thinnest 
silica layers. However, with increasing coating thickness, the silica diamagnetic 
contribution cannot be neglected in the fitting of the NMRD profile and must be added 
to the contribution of the magnetic particles. A linear relationship between the NP sizes 
measured by TEM and by fitting the NMRD profiles is obtained, but the sizes obtained 
by NMRD are significantly lower than those measured by TEM. A correlation also 
exists between the values of Msat obtained by magnetometry and relaxometry, whereby 
the Msat value of the superparamagnetic core strongly decreases with the increasing 
thickness of the diamagnetic silica shell. However such a Msat dilution as measured by 
NMRD is lower than expected for water-impermeable silica layers. Both results reflect 
the fact that a significant part of the silica coating is permeable to water, in agreement 
with what was proposed before for these systems.40 The depth of this water-permeable 
layer is uncertain, as the exchange of the more deeply penetrating water molecules 
could become too slow to influence the measured relaxivity. This observation is of 
paramount importance in the context of the development of contrastophores for 
molecular imaging. The adequate silica shell thickness may, thus, be tuned to allow for 
both, a sufficiently high response as contrast agent, and an adequate grafting of 
targeted biomolecules. 
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Additionally, preliminary cytotoxicity studies confirmed that these contrast agents 
do not appear detrimental to microglial cells. However, as the naked NPs have the 
highest relaxivities, and the coating thickness does not play a role in their cytotoxicity, a 
preliminary conclusion is that overall optimal particles should have a minimal coating 
thickness to provide solution stability and a basis for surface conjugation without 
compromising their relaxivities. 
Therefore, our results provide clues for the design of magnetic NP based contrast 
agents and their optimization for specific applications in medical diagnosis. This is up to 
now the only technique to provide clear evidence that a silica layer used as a coating in 
a core-shell system, exhibits regions that are porous to water and regions that are not. 
The knowledge of theses systems may be extended to other systems and applications. 
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The objective of this thesis was to design and prepare bio-imaging probes, in 
particular exhibiting MRI and photoluminescence bimodality. Two different types of 
nanoparticles performing as T1 and T2 MRI contrast agents were synthesised and their 
physical and chemical properties characterised, namely texture, structure, 1H dynamics 
and relaxometry and photoluminescence properties. The combination of the properties 
of trivalent lanthanide complexes and nanoparticles offered an excellent solution for 
bimodal imaging. The following relevant observations and conclusions may prompt 
future studies on related systems. 
 
 T1-type contrast agents 
 
ͽ Bimodal MRI-photoluminescence probes for bio-imaging consisting on 
SiO2 nanoparticles derivatized with DTPA-Ln
3+ and PMN-Ln3+  complexes 
(SiO2@APS/DTPA:Gd:Ln; and SiO2@APS/PMN:Gd:Ln; Ln
3+ = Eu3+, Tb3+) 
were developed. These systems bear an active magnetic centre (Gd3+) 
and photoluminescent ions (Eu3+ or Tb3+) on the surface of silica 
nanoparticles. 
ͽ The number of Ln3+ (Eu3+, Tb3+ and Gd3+) ions on the surface the 
SiO2@APS/DTPA nanoparticles (up to ca. 10
4 ions per nanoparticle) is 
determined by the amount of DTPA grafted. Because the 
SiO2@APS/PMN nanoparticles exhibit a second type of local coordination 
for the Ln3+ ion it is difficult to quantify the amount of PMN complex 
grafted, although it is possible to estimate the amount of Ln3+ per 
nanoparticle (up to ca. 105 ions per nanoparticle).  
ͽ The tandem use of 13C and 29Si solid-state NMR and DRIFT spectroscopy 
was shown to be very powerful approach to study the modification of the 
surface of the nanoparticles. Upon APS derivatization the number of 
surface hydroxyl groups decreases and the 29Si (Q2+Q3)/Q4 population 
ratio is reduced from 0.43 to 0.37. For the SiO2@APS/DTPA system, clear 
evidence of the covalent bonding between APS and DTPA is provided by 
the secondary amide C=O stretch at 1685 cm-1. Since the number of 
silanol groups increases (the ratio (Q2+Q3)/Q4 increases from 0.37 to 0.62) 
reaction of SiO2@APS with DPTA has the side effect of modifying the 
surface of the SiO2 nanoparticles. Although the APS to PMN covalent 
 213 
bonding could not be ascertained by DRIFT or NMR evidence for it was 
forthcoming from photoluminescence spectroscopy. As observed in the 
DTPA system, the reaction between APS and PMN modified the 
nanoparticles surface, increasing the number of silanol groups, with 
(Q2+Q3)/Q4 raising from 0.37 to 0.51. 
ͽ Complexation of DTPA and PMN to Ln3+ ions emitting in the visible region 
afforded long-life excited states, resistance to photo-bleaching, and sharp 
emission bands. The photoluminescence properties of the systems were 
not changed by the incorporation of Gd3+ ions. Evidence was obtained for 
the energy transfer from the DTPA/PMN ligand to Ln3+. The grafting of 
PMN, a pyridine-based aromatic antenna ligand enhanced this energy 
transfer. While in the SiO2@APS/DTPA:Eu system the Eu
3+ ions reside in 
a single low-symmetry site, with a large local distribution, in the 
SiO2@APS/PMN:Eu system there are two local Eu
3+ environments. We 
conjectured that in one site the Eu3+ coordinates to the PMN chelate, 
while in a second site it interacts strongly with the NPs surface via the 
silanol groups, which are far more abundant than the amino groups on the 
silica surface. 
ͽ The incorporation of Gd3+ ions, the MRI probe, in the nanosystems does 
not change the emission properties of the Eu3+ and Tb3+ ions. The 
relaxometric features of these nanoparticles are slightly better than the 
properties of the commercially-available [Gd(DTPA)]2- complex. 
ͽ The bimodal probes are rapidly and efficiently uptaken by RAW 264.7 
cells (mouse macrophage cell line) exhibiting the 1T -weighted MRI images 
of cellular pellets increased contrast and potential optical tracking by 
fluorescence. 
ͽ In future studies an alternative and more efficient procedure should be 
devised for grafting the PMN complex, ensuring that a single Eu3+ local 
environment is present. 
 
 
 T2-type contrast agents 
 
ͽ Iron oxide nanoparticles coated with silica layers of different thickness 
were prepared. The stability of the resulting nanoparticles suspensions is 
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increased by this silica shell, which also allows the straightforward grafting 
of targeting molecules. 
ͽ The thickness of this silica shell changed considerably the r2 and r2* 
relaxivities at medium and high B0 fields (0.47 T and 11.7 T), and the r1 
relaxivity at medium B0 fields (0.47 T) as a result of decreased outer-
sphere relaxation effects. 
ͽ A model was proposed to explain the impact of the silica shell on the r2 
and r2* relaxivities. This model partitions the silica coating in two regions, 
one impermeable to water and close to the γ-Fe2O3 core, the other porous 
to water and at the interface with the bulk water. 
ͽ The magnetometry curves of the γ-Fe2O3@SiO2 nanoparticles were fitted 
with a Langevin function and the NMRD profiles with the model of Roch et 
al. A good fit of the NMRD curves was obtained for particles covered with 
the thinnest silica layers. For particles with relatively thick silica layers it 
was necessary to introduce a contribution from the diamagnetic silica. 
ͽ The cell viability and mitochondrial dehydrogenase expression given by 
the microglial cells were evaluated and confirmed that these contrast 
agents are not detrimental to the microglial cells. 
ͽ The knowledge obtained with these systems may now be extended to 
other systems and applications. The results provide clues for the design of 
contrast agents based on superparamagnetic nanoparticles and their 
optimisation for specific medical diagnosis applications. 
ͽ In future work this system should be extended to bimodal, by grafting a 
photoluminescence probe. 
 
 
 
 
